AMENDMENTS
1184 - 1537

Draft report
Véronique Trillet-Lenoir
(PE693.752v01-00)

on Strengthening Europe in the fight against cancer - towards a comprehensive and coordinated strategy
(2020/2267(INI))
Amendment 1184
Nicolás González Casares, Alessandra Moretti, Maria Arena, Romana Jerković, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 83 a (new)

83a. Underlines the essential role of labour inspectorates to secure compliance with health and safety legislation and prevention of work-related cancer; calls on Member States to enhance labour inspectorates and to secure their adequate funding; emphasises that monitoring and control is of particular importance for mobile workers; calls for the fastest possible implementation and operation of the European Labour Authority (ELA), and calls for the ELA to provide for real labour inspection power in cross-border cases and to monitor compliance with health and safety legislation; calls on the Commission and Member States to involve the ELA in cross-border situations to secure proper enforcement of health and safety legislation;

Amendment 1185
Nicolás González Casares, Alessandra Moretti, Maria Arena, Romana Jerković, Sara Cerdas, Marc Angel, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 83 b (new)

83b. Calls on the Commission to introduce a legislative proposal for a European Social Security Number (ESSN) and a European Personal Labour Card (EPLC) for mobile workers to provide national authorities and trade unions with an instrument to effectively
enforce health and safety regulation, compliance with cancer-prevention and to combat unsafe working environments;

Amendment 1186
Nicolás González Casares, Maria Arena, Romana Jerković, Cyrus Engerer, Sara Cerdas, Patrizia Toia, Marc Angel, Johan Danielsson, Estrella Durà Ferrandis

Motion for a resolution
Paragraph 83 c (new)

83c. Urges the Commission to pay attention to shifts in the EU labour market, securing sufficient funding for proper data collection; believes that extensive and thorough information and data collection must be of absolute importance and a continued priority for the Commission in order to respond with necessary legislative and non-legislative initiatives in regard to work-related cancer prevention; stresses the need to establish comprehensive national registers for all Member States, enabling Europe-wide data collection on carcinogen exposure and that these registers should cover all relevant carcinogens; calls for a close cooperation between EU institutions, Member States, the European Agency for Safety and Health at work (EU-OSHA) and relevant stakeholders, strongly involving social partners in actively using the data collection to follow up with necessary legislative and non-legislative measures to combat work-related cancers;

Amendment 1187
Michèle Rivasi
Motion for a resolution
Paragraph 84

84. Supports the upcoming roll-out of a Cancer Survivor Smart Card, as announced in Europe’s Beating Cancer Plan, to all European cancer survivors, especially survivors of childhood and adolescent cancers, which will summarise their clinical history, including patients’ own experience, and facilitate and monitor follow-up care;

Or. en

Amendment 1188
Peter Liese
on behalf of the EPP Group
Tomislav Sokol, Nathalie Colin-Oesterlé, Liudas Mažylis, Maria Spyraki, Dolors Montserrat, Cindy Franssen, Adam Jarubas, Deirdre Clune, Sunčana Glavak, Bartosz Arlukowicz

Motion for a resolution
Paragraph 84

84. Supports the upcoming roll-out of a Cancer Survivor Smart Card, as announced in Europe’s Beating Cancer Plan, to all European cancer survivors, especially survivors of childhood and adolescent cancers, which will summarise their clinical history, including patients’ own experience, and facilitate and monitor follow-up care; stresses the sensitive nature of individual health data and need for the Smart Card to be fully protected under the GDPR;

Amendment
84. Supports the upcoming roll-out of a Cancer Survivor Smart Card, as announced in Europe’s Beating Cancer Plan, to all European cancer survivors, especially survivors of childhood and adolescent cancers, which will summarise their clinical history, including patients’ own experience, and facilitate and monitor follow-up care; stresses the sensitive nature of individual health data and need for the Smart Card to be fully protected under the GDPR;

Or. en
Amendment 1189
Giorgos Georgiou, Alexis Georgoulis

Motion for a resolution
Paragraph 84

Motion for a resolution

84. Supports the upcoming roll-out of a Cancer Survivor Smart Card, as announced in Europe’s Beating Cancer Plan, to all European cancer survivors, especially survivors of childhood and adolescent cancers, which will summarise their clinical history, including patients’ own experience, and facilitate and monitor follow-up care;

Amendment

84. Supports the upcoming roll-out of a Cancer Survivor Smart Card, as announced in Europe’s Beating Cancer Plan, to all European cancer survivors, especially survivors of childhood and adolescent cancers for whom the Survivorship Passport model exists as a basis, which will summarise their clinical history, including patients’ own experience, and facilitate and monitor follow-up care;

Or. en

Amendment 1190
Margarita de la Pisa Carrión

Motion for a resolution
Paragraph 85

Motion for a resolution

85. Considers that insurers and banks should not take into account the medical history of people who have been affected by cancer; calls for national legislation to ensure that cancer survivors are not discriminated against compared to other consumers; notes the Commission’s intention to engage with businesses to develop a code of conduct to ensure that developments in cancer treatments and their improved effectiveness are reflected in the business practices of financial service providers; supports, in parallel, the promotion of advances made in France, Belgium, Luxembourg and the Netherlands, where cancer survivors enjoy the ‘Right to be Forgotten’; requests that by 2025, at the latest, all Member States

Amendment

85. Considers that insurers and banks should be supported by Member States so that people who have been affected by cancer are treated fairly and are not punished twice for their disease; notes the Commission’s intention to engage with businesses to develop a code of conduct to ensure that developments in cancer treatments and their improved effectiveness are reflected in the business practices of financial service providers; supports, in parallel, the promotion of advances made in France, Belgium, Luxembourg and the Netherlands, where cancer survivors enjoy the ‘Right to be Forgotten’; requests that by 2025, at the latest, all Member States should guarantee the Right to be Forgotten to all European
should guarantee the Right to be Forgotten to all European patients ten years after the end of their treatment, and five years after the end of treatment for patients whose diagnosis was made before the age of 18; calls for the introduction of common standards for the Right to be Forgotten under the relevant provisions on consumer protection policy of the Treaty on the Functioning of the European Union, in order to remedy the fragmented national practices in the area of creditworthiness assessment and ensure equal access to credit for cancer survivors;

patients ten years after the end of their treatment, and five years after the end of treatment for patients whose diagnosis was made before the age of 18; calls for the introduction of common standards for the Right to be Forgotten to inspire national practices in the area of creditworthiness assessment and ensure equal access to credit for cancer survivors;

Amendment 1191
Peter Liese
on behalf of the EPP Group
Tomislav Sokol, Nathalie Colin-Oesterlé, Liudas Mažylis, Marian-Jean Marinescu, Maria Spyraki, Dolors Montserrat, Cindy Franssen, Adam Jarubas, Deirdre Clune, Sunčana Glavak, Bartosz Arłukowicz

Motion for a resolution
Paragraph 85

85. Considers that insurers and banks should not take into account the medical history of people who have been affected by cancer; calls for national legislation to ensure that cancer survivors are not discriminated against compared to other consumers; notes the Commission’s intention to engage with businesses to develop a code of conduct to ensure that developments in cancer treatments and their improved effectiveness are reflected in the business practices of financial service providers; supports, in parallel, the promotion of advances made in France, Belgium, Luxembourg and the Netherlands, where cancer survivors enjoy the ‘Right to be Forgotten’; requests that by 2025, at the latest, all Member States

85. Considers that insurers and banks should not take into account the medical history of people who have been affected by cancer; calls for embedding the Right to be Forgotten for cancer-survivors in EU legislation to prevent discrimination and improve the access of cancer survivors to financial services; notes the Commission’s intention to engage with businesses to develop a code of conduct to ensure that developments in cancer treatments and their improved effectiveness are reflected in the business practices of financial service providers; supports, in parallel, the promotion of advances made in France, Belgium, Luxembourg and the Netherlands, where cancer survivors enjoy the ‘Right to be Forgotten’; requests that
should guarantee the Right to be Forgotten to all European patients ten years after the end of their treatment, and five years after the end of treatment for patients whose diagnosis was made before the age of 18; calls for the introduction of common standards for the Right to be Forgotten under the relevant provisions on consumer protection policy of the Treaty on the Functioning of the European Union, in order to remedy the fragmented national practices in the area of creditworthiness assessment and ensure equal access to credit for cancer survivors;

85. Considers that insurers and banks should not take into account the medical history of people who have been affected by cancer; calls for national legislation to ensure that cancer survivors are not discriminated against compared to other consumers; notes the Commission’s intention to engage with businesses to develop a code of conduct to ensure that developments in cancer treatments and their improved effectiveness are reflected in the business practices of financial service providers; supports, in parallel, the promotion of advances made in France, Belgium, Luxembourg and the Netherlands, where cancer survivors enjoy the ‘Right to be Forgotten’; requests that by 2025, at the latest, all Member States should guarantee the Right to be Forgotten to all European patients ten years after the end of their treatment, and five years after
the end of treatment for patients whose diagnosis was made before the age of 18; calls for the introduction of common standards for the Right to be Forgotten under the relevant provisions on consumer protection policy of the Treaty on the Functioning of the European Union, in order to remedy the fragmented national practices in the area of creditworthiness assessment and ensure equal access to credit for cancer survivors;

Amendment 1193
Loucas Fourlas

Motion for a resolution
Paragraph 85

85. Considers that insurers and banks should not take into account the medical history of people who have been affected by cancer; calls for national legislation to ensure that cancer survivors are not discriminated against compared to other consumers; notes the Commission’s intention to engage with businesses to develop a code of conduct to ensure that developments in cancer treatments and their improved effectiveness are reflected in the business practices of financial service providers; supports, in parallel, the promotion of advances made in France, Belgium, Luxembourg and the Netherlands, where cancer survivors enjoy the ‘Right to be Forgotten’; requests that by 2025, at the latest, all Member States should guarantee the Right to be Forgotten
to all European patients ten years after the end of their treatment, and up to five years after the end of treatment for patients whose diagnosis was made before the age of 18; calls for the introduction of common standards for the Right to be Forgotten under the relevant provisions on consumer protection policy of the Treaty on the Functioning of the European Union, in order to remedy the fragmented national practices in the area of creditworthiness assessment and ensure equal access to credit for cancer survivors;
calls for the introduction of common standards for the Right to be Forgotten under the relevant provisions on consumer protection policy of the Treaty on the Functioning of the European Union, in order to remedy the fragmented national practices in the area of creditworthiness assessment and ensure equal access to credit for cancer survivors;

Or. en

Amendment 1195
Michèle Rivasi

Motion for a resolution
Paragraph 86

86. Calls on the Commission to support the European Code of Cancer Care launched by the European Cancer Organisation (ECO), which is an empowering and informative tool to ensure that the best available care is provided to European citizens and patients;

deleted

Or. en

Amendment 1196
Pietro Fiocchi

Motion for a resolution
Paragraph 86

86. Calls on the Commission to support the European Code of Cancer Care launched by the European Cancer Organisation (ECO), which is an empowering and informative tool to ensure that the best available care is

86. Calls on the Commission to support the European Code of Cancer Care launched by the European Cancer Organisation (ECO), which is an empowering planning and support tool to ensure that the best available care is
provided to European citizens and patients; provided to European patients as well as informing citizens and their family members about healthy lifestyle choices they can take to reduce cancer risk;

Amendment 1197
Alexis Georgoulis

Motion for a resolution
Paragraph 86

Motion for a resolution

86. Calls on the Commission to support the European Code of Cancer Care launched by the European Cancer Organisation (ECO), which is an empowering and informative tool to ensure that the best available care is provided to European citizens and patients;

Amendment

86. Calls on the Commission to support the European Code of Cancer Care Practice launched by the European Cancer Organisation (ECO), which is an empowering and informative tool to ensure that the best available care is provided to European citizens and patients; stresses that this support should include assistance in awareness raising and promotion;

Amendment 1198
Hilde Vautmans, Irena Joveva

Motion for a resolution
Paragraph 86

Motion for a resolution

86. Calls on the Commission to support the European Code of Cancer Care launched by the European Cancer Organisation (ECO), which is an empowering and informative tool to ensure that the best available care is provided to European citizens and patients;

Amendment

86. Calls on the Commission to support the European Code of Cancer Care Practice launched by the European Cancer Organisation (ECO), which is an empowering and informative tool to ensure that the best available care is provided to European citizens and patients; underscores that this support should include assistance in awareness raising
and promotion;

Amendment 1199
Alessandra Moretti

Motion for a resolution
Paragraph 86

Motion for a resolution

86. Calls on the Commission to support the European Code of Cancer Care launched by the European Cancer Organisation (ECO), which is an empowering and informative tool to ensure that the best available care is provided to European citizens and patients;

Amendment

86. Calls on the Commission to support the European Code of Cancer Practice launched by the European Cancer Organisation (ECO), which is an empowering and informative tool to ensure that the best available care is provided to European citizens and patients;

Amendment 1200
Nicolás González Casares, Alessandra Moretti, Maria Arena, Romana Jerković, Sara Cerdas, Marc Angel, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 86

Motion for a resolution

86. Calls on the Commission to support the European Code of Cancer Care launched by the European Cancer Organisation (ECO), which is an empowering and informative tool to ensure that the best available care is provided to European citizens and patients;

Amendment

86. Calls on the Commission to support the European Code of Cancer Practice launched by the European Cancer Organisation (ECO), which is an empowering and informative tool to ensure that the best available care is provided to European citizens and patients;

Amendment 1201
Margarita de la Pisa Carrión
Motion for a resolution
Paragraph 87

87. Sees an urgent need for a European charter of the rights of cancer patients; calls for this charter to define the rights of cancer patients at every stage of their care pathway, i.e. access to prevention, initial diagnosis and throughout their treatment, and for it to apply equally to all EU citizens, regardless of the country or region in which they live;

Amendment

87. Sees an urgent need for a European Code of best practices against cancer; calls for this code to take into account every stage of the cancer care pathway, i.e. access to prevention, initial diagnosis and throughout their treatment, and for it to apply equally to all EU citizens, regardless of the country or region in which they live;

Or. en

Amendment 1202
Joëlle Mélin

Motion for a resolution
Paragraph 87

87. Sees an urgent need for a European charter of the rights of cancer patients; calls for this charter to define the rights of cancer patients at every stage of their care pathway, i.e. access to prevention, initial diagnosis and throughout their treatment, and for it to apply equally to all EU citizens, regardless of the country or region in which they live;

Amendment

87. Sees that, out of pure compassion, a European charter of the rights of cancer patients should be drawn up; calls for this charter to define the rights of cancer patients at every stage of their care pathway, i.e. access to prevention, initial diagnosis and throughout their treatment, and for it to apply equally to all EU citizens, regardless of the country or region in which they live;

Or. fr

Amendment 1203
Bartosz Arłukowicz

Motion for a resolution
Paragraph 87
Motion for a resolution

87. Sees an urgent need for a European charter of the rights of cancer patients; calls for this charter to define the rights of cancer patients at every stage of their care pathway, i.e. access to prevention, initial diagnosis and throughout their treatment, and for it to apply equally to all EU citizens, regardless of the country or region in which they live;

Amendment

87. Sees an urgent need for a European charter of the rights of cancer patients and to develop a set of indicators for quality assessment based on patient experience (PROMs/PREMs); calls for this charter to define the rights of cancer patients at every stage of their care pathway, i.e. access to prevention, initial diagnosis and throughout their treatment, and for it to apply equally to all EU citizens, regardless of the country or region in which they live;

Or. pl

Amendment 1204
Peter Liese
on behalf of the EPP Group
Tomislav Sokol, Nathalie Colin-Oesterlé, Liudas Mažylis, Maria Spyraki, Dolors Montserrat, Cindy Franssen, Adam Jarubas, Deirdre Clune, Sunčana Glavak, Bartosz Arłużowicz

Motion for a resolution
Paragraph 87

Motion for a resolution

87. Sees an urgent need for a European charter of the rights of cancer patients; calls for this charter to define the rights of cancer patients at every stage of their care pathway, i.e. access to prevention, initial diagnosis and throughout their treatment, and for it to apply equally to all EU citizens, regardless of the country or region in which they live;

Amendment

87. Sees an urgent need for a European charter of the rights of cancer patients; and to create a set of quality assessment indicators based on patients’ experience (PROMs and PREMs); calls for this charter to define the rights of cancer patients at every stage of their care pathway, i.e. access to prevention, initial diagnosis and throughout their treatment, and for it to apply equally to all EU citizens, regardless of the country or region in which they live;

Or. en
Amendment 1205
Alexis Georgoulis, Giorgos Georgiou

Motion for a resolution
Paragraph 87 a (new)

Motion for a resolution

87a. Urges that, during the implementation period of Europe’s Beating Cancer Plan, additional attention be provided to the means by which EU cancer policy can support needs connected to the physical and psychological impacts of cancer treatment; underlines that this should, as a minimum, include attention to matters such as pain management and patient access to psycho-oncology, palliative and supportive care within announced initiatives such as the Cancer Inequalities Registry and the EU Network of Comprehensive Cancer Centres;

Or. en

Amendment 1206
Hilde Vautmans, Irena Joveva

Motion for a resolution
Paragraph 87 a (new)

Motion for a resolution

87a. Urges that, during the implementation period of Europe’s Beating Cancer Plan, additional attention be provided to the means by which EU cancer policy can support needs connected to the physical and psychological impacts of cancer treatment; underlines that this should, as a minimum, include attention to matters such as pain management and patient access to psycho-oncology, palliative and supportive care within announced initiatives such as the Cancer Inequalities Registry and the EU Network of Comprehensive Cancer Centres;
Amendment 1207
Pietro Fiocchi

Motion for a resolution
Paragraph 87 a (new)

Motion for a resolution

87a. Urges that, during the implementation period of Europe’s Beating Cancer Plan, additional attention be provided to the means by which EU cancer policy can support needs connected the physical and psychological impacts of cancer treatment; underlines that this should, as a minimum, include attention to matters such as pain management and patient access to psycho-oncology, palliative and supportive care within announced initiatives such as the Cancer Inequalities Registry and the EU Network of Comprehensive Cancer Centres;

Amendment

Amendment 1208
Michèle Rivasi

Motion for a resolution
Paragraph 87 b (new)

Motion for a resolution

87b. Calls on the Member States to pay enhanced attention, within their national cancer plans, to addressing the physical and psychological impacts of cancer and its treatment, including pain management, patient access to psycho-
Amendment 1209
Alexis Georgoulis, Giorgos Georgiou

Motion for a resolution
Paragraph 87 c (new)

87c. Strongly suggests the necessity for specific policies to safeguard patients’ rights according to a European Charter of Cancer Patient’s Rights; understands the need for resource-efficient management, yet strongly argues that it should not hamper patients’ rights[1], and particularly their right to choose their treatment; stresses the need for policies to ensure that treatments are chosen according to the will and needs of well-informed patients, and not misled by resource management criteria such as the fastest or cheapest treatment;


Amendment 1210
Alexis Georgoulis, Giorgos Georgiou

Motion for a resolution
Paragraph 87 d (new)

87d. Regrets that there are important variations among Member States regarding the possibilities and access to
diagnosis and treatment for cancer patients; notes that PET scan for example is offered by the public health systems of certain countries and not by others; calls on the Commission and the Member States to strengthen their efforts with specific measures ensuring equal access to cancer prevention, diagnosis, treatment and follow up for all European citizens, leaving no one behind;

Or. en

Amendment 1211
Alessandra Moretti, Sara Cerdas, Patrizia Toia, Maria Arena, Estrella Durá Ferrandis

Motion for a resolution
Subheading V

Motion for a resolution
Amendment

V. Challenges in cancer among children, adolescents and young adults
V. Challenges in cancer among children, adolescents and young adults and other specific population groups

Or. en

Amendment 1212
Peter Liese
on behalf of the EPP Group
Tomislav Sokol, Nathalie Colin-Oesterlé, Liudas Mažylis, Maria Spyrraki, Dolors Montserrat, Cindy Franssen, Adam Jarubas, Deirdre Clune, Sunčana Glavak, Bartosz Arłukowicz

Motion for a resolution
Paragraph 87 e (new)

Motion for a resolution
Amendment

87e. Welcomes the childhood cancer spotlight initiatives announced by the Commission;

Or. en
Amendment 1213
Loucas Fourlas

Motion for a resolution
Paragraph 87 e (new)

Motion for a resolution

87e. Welcomes the childhood cancer spotlight initiatives announced by the Commission;

Amendment

Or. en

Amendment 1214
Nicolás González Casares, Maria Arena, Romana Jerković, Cyrus Engerer, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 88

Motion for a resolution

88. Calls for clear policy requirements on paediatric cancer research needs; calls on Member States and the Commission to redress the unequal allocation of investment to paediatric cancers; considers that a clear and specific EU funding stream should be dedicated to paediatric cancer research and budget allocations earmarked across all relevant EU programmes;

Amendment

88. Reiterates the need for dedicated policies and programmes in the field of paediatric cancers; welcomes the childhood cancer spotlight initiatives announced by the Commission; calls for clear policy requirements on paediatric cancer research needs; calls on Member States and the Commission to redress the unequal allocation of investment to paediatric cancers; considers that a clear and specific EU funding stream should be dedicated to paediatric cancer research and budget allocations earmarked across all relevant EU programmes;

Or. en

Amendment 1215
Peter Liese
on behalf of the EPP Group
Motion for a resolution
Paragraph 88

**Motion for a resolution**

88. Calls for clear policy requirements on paediatric cancer research needs; calls on Member States and the Commission to redress the unequal allocation of investment to paediatric cancers; considers that a clear and specific EU funding stream should be dedicated to paediatric cancer research and budget allocations earmarked across all relevant EU programmes;

**Amendment**

88. Calls for clear policy requirements on paediatric cancer research needs; calls on Member States and the Commission to redress the unequal allocation of investment to paediatric cancers; considers that a clear and specific EU funding stream should be dedicated to paediatric cancer research and budget allocations earmarked across all relevant EU programmes; **highlights the importance of sustaining international academic research platforms in paediatric cancers, cross-linked and informed by industry-driven research;**

Or. en

**Amendment 1216**

Tudor Ciuhodaru

Motion for a resolution
Paragraph 88

**Motion for a resolution**

88. Calls for clear policy requirements on paediatric cancer research needs; calls on Member States and the Commission to redress the unequal allocation of investment to paediatric cancers; considers that a clear and specific EU funding stream should be dedicated to paediatric cancer research and budget allocations earmarked across all relevant EU programmes;

**Amendment**

88. Calls for clear policy requirements on paediatric cancer research needs; calls on Member States and the Commission to **prioritise programmes dedicated to research in this field and** to redress the unequal allocation of investment to paediatric cancers; considers that a clear and specific EU funding stream should be dedicated to paediatric cancer research and budget allocations earmarked across all relevant EU programmes;

Or. ro
Amendment 1217
Ondřej Knotek, Irena Joveva

Motion for a resolution
Paragraph 88

Motion for a resolution

88. Calls for clear policy requirements on paediatric cancer research needs; calls on Member States and the Commission to redress the unequal allocation of investment to paediatric cancers; considers that a clear and specific EU funding stream should be dedicated to paediatric cancer research and budget allocations earmarked across all relevant EU programmes;

Amendment

88. Calls for clear policy requirements on paediatric cancer research needs; calls on Member States and the Commission to redress the unequal allocation of investment to paediatric cancers; considers that a clear and specific EU funding stream should be dedicated to paediatric cancer research and budget allocations earmarked across all relevant EU programmes including in the Horizon Europe cancer mission;

Or. en

Amendment 1218
Vlad Gheorghe

Motion for a resolution
Paragraph 88

Motion for a resolution

88. Calls for clear policy requirements on paediatric cancer research needs; calls on Member States and the Commission to redress the unequal allocation of investment to paediatric cancers; considers that a clear and specific EU funding stream should be dedicated to paediatric cancer research and budget allocations earmarked across all relevant EU programmes;

Amendment

88. Calls for clear policy requirements on paediatric cancer research needs; calls on Member States and the Commission to redress the unequal allocation of investment to paediatric cancers; considers that a clear and specific EU funding stream should be dedicated to paediatric cancer treatment and research and budget allocations earmarked across all relevant EU programmes;

Or. en
Amendment 1219
Kateřina Konečná, Alexis Georgoulis, João Pimenta Lopes, Giorgos Georgiou

Motion for a resolution
Paragraph 88 a (new)

Motion for a resolution Amendment

88a. Calls for dedicating research funding to rare cancers, which represent 24% of all new cancer cases, including rare adult solid cancers, haematological cancers and paediatric cancers (which are the leading cause of death by disease among children and adolescents in Europe); calls for the establishment of European strategic initiatives for rare cancers, such as a new Joint Action on Rare Cancers, including rare adult cancers and paediatric cancers;

Or. en

Amendment 1220
Giorgos Georgiou, Alexis Georgoulis, João Pimenta Lopes

Motion for a resolution
Paragraph 88 b (new)

Motion for a resolution Amendment

88b. Re-iterates the need for dedicated policies and programmes in the field of paediatric cancers in accordance with the actions and recommendations of the Joint Action on Rare Cancers (JARC), which include a specific section on paediatric cancers in each chapter, the EU Strategy on the Rights of the Child, and the WHO Global Initiative for Childhood Cancer;

Or. en

Amendment 1221
Nicolae Ștefănuță, Alin Mituța, Ivars Ijabs, Vlad Gheorghe
Motion for a resolution
Paragraph 88 b (new)

Motion for a resolution
Amendment

88b. Re-iterates the need for dedicated policies and programmes in the field of paediatric cancers in accordance with the actions and recommendations of the Joint Action on Rare Cancers (JARC), which include a specific section on paediatric cancers in each chapter, the EU Strategy on the Rights of the Child, and the WHO Global Initiative for Childhood Cancer;

Or. en

Amendment 1222
Loucas Fourlas

Motion for a resolution
Paragraph 88 b (new)

Motion for a resolution
Amendment

88b. Reiterates the need for dedicated policies and programmes in the field of paediatric cancers in accordance with the actions and recommendations of the Joint Action on Rare Cancers (JARC), which include a specific section on paediatric cancers in each chapter, the EU Strategy on the Rights of the Child, and the WHO Global Initiative for Childhood Cancer;

Or. en

Amendment 1223
Joëlle Mélin

Motion for a resolution
Paragraph 88 c (new)
Motion for a resolution

88c. Strongly recommends, therefore, that the Paediatric Regulation finally be revised to kick-start the process of supporting research in paediatric oncology (Paediatric Medicines Regulation (2016/2902(RSP)));

Amendment 1224
Margarita de la Pisa Carrión

Motion for a resolution
Paragraph 88 d (new)

Motion for a resolution

88d. Sees an urgent need to include paediatric and teenage cancer patients as a group requiring special treatment and protection;

Amendment 1225
Bartosz Arłukowicz

Motion for a resolution
Paragraph 89

Motion for a resolution

89. Calls on the Commission and the Member States to focus on ensuring equal access to the best specialist diagnostics and multi-disciplinary treatment for children with cancer, and to improve cancer treatment outcomes in all Member States; considers that the professional figure of the paediatric oncologist should be recognised in all Member States; believes that every patient who has experienced cancer as a
child or adolescent should receive ongoing medical care and monitoring even after reaching adulthood, and therefore calls for measures to make cooperation between paediatric and adult doctors more flexible; encourages the exchange of knowledge on the course of cancers among children and adolescents;

Amendment 1226
Vlad Gheorghe

Motion for a resolution
Paragraph 89

89. Calls on the Commission and the Member States to focus on ensuring equal access to the best specialist diagnostics and multi-disciplinary treatment for children with cancer, and to improve cancer treatment outcomes in all Member States; considers that the professional figure of the paediatric oncologist should be recognised in all Member States;

Amendment

89. Calls on the Commission and the Member States to focus on ensuring equal and geographically balanced access to the best specialist diagnostics and multi-disciplinary treatment for children with cancer, and to improve cancer treatment outcomes in all Member States; considers that the professional figure of the paediatric oncologist should be recognised in all Member States;

Amendment 1227
Nicolás González Casares, Maria Arena, Romana Jerković, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 89

89. Calls on the Commission and the Member States to focus on ensuring equal access to the best specialist diagnostics and multi-disciplinary treatment for children

Amendment

89. Calls on the Commission and the Member States to focus on ensuring equal access to the best specialist diagnostics and multi-disciplinary treatment for children
with cancer, and to improve cancer treatment outcomes in all Member States; considers that the professional figure of the paediatric oncologist should be recognised in all Member States;

Amendment 1228
Nicolae Ştefănuţă, Alin Mituţa, Ivars Ijabs, Vlad Gheorghe

Motion for a resolution
Paragraph 89 a (new)

Motion for a resolution

89a. Stresses the need for comprehensive population-based childhood cancer registries based on internationally agreed childhood cancer classification systems, ensuring high-quality comparable data across Europe; reinforces the need for publishing annually the number of cancer cases in children and adolescents in Europe and in each Member State, respectively, as already available yearly for cancer occurring in adults; recognises the important role of the Commission’s Joint Research Centre in this regard and welcomes its endeavour to release statistics on childhood tumours by the end of 2022; highlights the importance of publishing such statistics in line with the International Classification of Childhood Cancer (ICCC);
Motion for a resolution

89b. Calls for comprehensive population-based childhood cancer registries based on internationally agreed upon childhood cancer classification systems to ensure high-quality comparable data across Europe; reinforces the need for publishing annually the number of cancer cases in children and adolescents in each Member State;

Or. en

Amendment 1230
Loucas Fourlas

Motion for a resolution
Paragraph 89 c (new)

Motion for a resolution

89c. Recognises that the European childhood cancer sector is based on long-term cooperation and established cross-border structures uniting national paediatric haemato-oncology units and European clinical trial groups; calls on the Commission and Member States to support the objectives of the SIOP Strategic Plan ‘A European Cancer Plan for Children and Adolescents’ published in 2015 by the European Society for Paediatric Oncology (SIOP Europe) in cooperation with the broader paediatric cancer community; highlights the importance of including a dedicated paediatric cancer component in all National Cancer Control Plans;

Or. en
Amendment 1231
Giorgos Georgiou, Alexis Georgoulis, João Pimenta Lopes

Motion for a resolution
Paragraph 89 d (new)

Motion for a resolution  

Amendment

89d. Calls on the Commission and Member States to support the objectives of the SIOP Europe Strategic Plan ‘A European Cancer Plan for Children and Adolescents’ published in 2015 by the European Society for Paediatric Oncology (SIOP Europe) in cooperation with the broader paediatric cancer community;

Or. en

Amendment 1232
Margarita de la Pisa Carrión

Motion for a resolution
Paragraph 89 e (new)

Motion for a resolution  

Amendment

89e. Calls on the need to consider paediatric palliative care as a specific unit within the framework of childhood cancer treatment and develop these services in paediatric hospitals with hemato-oncology services;

Or. en

Amendment 1233
Nicolás González Casares, Maria Arena, Romana Jerković, Cyrus Engerer, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 89 f (new)
Motion for a resolution

Amendment

89f. Underlines the importance of developing comprehensive population-based childhood cancer registries, including a breakdown of all new childhood cancer cases in Europe and in every Member State;

Or. en

Amendment 1234  
Margarita de la Pisa Carrión, Pietro Fiocchi

Motion for a resolution  
Paragraph 89 g (new)

Motion for a resolution

Amendment

89g. Underlines the key role of nurse case managers in collaboration with the doctors to accompany patients and their families through the different organisation structures to support them and minimise the uncertainty during the process of an integrated care pathway;

Or. en

Amendment 1235  
Tudor Ciuhodaru

Motion for a resolution  
Paragraph 90

Motion for a resolution

Amendment

90. Calls for adolescents and young adults (AYAs) with cancer to be recognised at EU level as a particular group with specific medical and psychosocial needs;

90. Calls for adolescents and young adults (AYAs) with cancer to be recognised at EU level as a particular group with specific medical and psychosocial needs, and for the creation of schools programmes dedicated to them;
Amendment 1236
Margarita de la Pisa Carrión, Pietro Fiocchi

Motion for a resolution
Paragraph 90 a (new)

Motion for a resolution

90a. Calls on the Commission to encourage Member States to carry out specific studies on the incidence of nutrition and physical activity during hospitalisation in paediatric and teenage patients; considers the importance of designing specific programs allowing paediatric cancer patients and AYAs to have access to physical exercise and nutrition programs at all times;

Amendment 1237
Giorgos Georgiou, Alexis Georgoulis, João Pimenta Lopes

Motion for a resolution
Paragraph 90 b (new)

Motion for a resolution

90b. Highlights the importance of including a dedicated paediatric cancer component in all National Cancer Control Plans;

Amendment 1238
Joëlle Mélin

Motion for a resolution
Paragraph 91
Motion for a resolution

91. Stresses the need to strengthen the right to cross-border care for children and AYA cancer patients when the best treatment is not available in their country of residence;

Amendment

91. Stresses the pressing need for the Member States to cooperate in medicine and research; urges the implementation of international conventions on treating third-country nationals;

Or. fr

Amendment 1239
Peter Liese
on behalf of the EPP Group
Tomislav Sokol, Nathalie Colin-Oesterlé, Liudas Mažylis, Marian-Jean Marinescu, Maria Spyraki, Dolors Montserrat, Cindy Franssen, Adam Jarubas, Deirdre Clune, Sunčana Glavak, Bartosz Arłukowicz

Motion for a resolution
Paragraph 91

Motion for a resolution  

91. Stresses the need to strengthen the right to cross-border care for children and AYA cancer patients when the best treatment is not available in their country of residence;

Amendment

91. Stresses the need to strengthen the right to cross-border care for children and AYA cancer patients when the best treatment is not available in their country of residence, and ensure that access to innovation in early clinical trials for relapsed or difficult-to-treat malignancies is covered by the relevant provisions; emphasizes the need for clarification regarding access to cross-border clinical trials, which is not clear in the Cross-Border Healthcare Directive;\(^{1a}\)


Or. en
Amendment 1240
Nicolae Ștefănuță, Alin Mituța, Ivars Ijabs, Vlad Gheorghe

Motion for a resolution
Paragraph 91

91. Stresses the need to strengthen the right to cross-border care for children and AYA cancer patients when the best treatment is not available in their country of residence;  
91. Stresses the need to strengthen the right to cross-border care for children and AYA cancer patients when the best treatment is not available in their country of residence; **stresses the need to ensure that access to innovation in early clinical trials for difficult-to-treat malignancies in children adolescents and young adults (AYAs) is covered by the relevant provisions**;

Or. en

Amendment 1241
Giorgos Georgiou, Alexis Georgoulis, João Pimenta Lopes

Motion for a resolution
Paragraph 91

91. Stresses the need to strengthen the right to cross-border care for children and AYA cancer patients when the best treatment is not available in their country of residence;  
91. Stresses the need to strengthen the right to cross-border care for children and AYA cancer patients when the best treatment is not available in their country of residence and ensure that access to innovation in early clinical trials for relapsed or difficult-to-treat malignancies is covered by the relevant provisions;

Or. en

Amendment 1242
Kateřina Konečná, Alexis Georgoulis, Giorgos Georgiou

Motion for a resolution
Paragraph 91
Motion for a resolution

91. Stresses the need to strengthen the right to cross-border care for children and AYA cancer patients when the best treatment is not available in their country of residence;

Amendment

91. Stresses the need to strengthen the right to cross-border care for children and AYA cancer patients, when the best treatment is not available in their country of residence, by enhancing the sustainability of existing cross-border collaborations including the European Reference Networks, in particular the ERN PaedCan;

Or. en

Amendment 1243
Ondřej Knotek, Irena Joveva

Motion for a resolution
Paragraph 91

Motion for a resolution

91. Stresses the need to strengthen the right to cross-border care for children and AYA cancer patients when the best treatment is not available in their country of residence;

Amendment

91. Stresses the need to strengthen the right to cross-border care, including access to innovation in early clinical trials, for children and AYA cancer patients when the best treatment is not available in their country of residence;

Or. en

Amendment 1244
Bartosz Arłukowicz

Motion for a resolution
Paragraph 91

Motion for a resolution

91. Stresses the need to strengthen the right to cross-border care for children and AYA cancer patients when the best treatment is not available in their country of residence;

Amendment

91. Stresses the need to strengthen the right to cross-border care for children and AYA cancer patients, particularly when the best treatment is not available in their country of residence;
Amendment 1245
Giorgos Georgiou, Alexis Georgoulis, João Pimenta Lopes

Motion for a resolution
Paragraph 91 a (new)

Motion for a resolution

91a. Highlights the need for exploring innovative models for incentivising research and development especially in the area of paediatric cancers;

Or. en

Amendment 1246
Margarita de la Pisa Carrión

Motion for a resolution
Paragraph 92

Motion for a resolution

92. Calls for an ambitious revision of the regulations on paediatric and orphan medicinal products in order to ensure access to innovative cancer drugs, identify the most important drugs to meet the needs of children with poor prognostic cancers, reduce delays so that children can have faster access to paediatric drugs, and address limited access to certain essential medicines due to drug shortages and the high price of innovative medicines; recommends an increase of 20% in the available new paediatric cancer drugs by 2027;

92. Calls for the introduction of significant changes in the regulations on paediatric and orphan medicinal products and other effective financing provisions in order to ensure access to innovative cancer drugs, identify the most important drugs to meet the needs of children with poor prognostic cancers, reduce delays so that children can have faster access to paediatric drugs and innovative clinical trials for paediatric cancer, and address limited access to certain essential medicines due to drug shortages and the high price of innovative medicines; recommends a substantial increase in the available new paediatric cancer drugs by 2027;

33 Regulation (EC) No 1901/2006 of the


Amendment 1247
Nicolás González Casares, María Arena, Romana Jerković, Cyrus Engerer, Sara Cerdas, Marc Angel, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 92

92. Calls for an ambitious revision of the regulations on paediatric33 and orphan34 medicinal products in order to ensure access to innovative cancer drugs, identify the most important drugs to meet the needs of children with poor prognostic cancers, reduce delays so that children can have faster access to paediatric drugs, and address limited access to certain essential medicines due to drug shortages and the high price of innovative medicines; recommends an increase of 20 % in the available new paediatric cancer drugs by 2027;

92. Notes with satisfaction that both regulations on paediatric and orphan medicinal products have fostered the development and availability of medicines for patients with rare diseases and for children, redirecting private and public investments towards previously neglected areas; calls for an ambitious revision of the regulations on paediatric33 and orphan34 medicinal products in order to ensure the development of and access to innovative cancer drugs, identify the most important drugs to meet the needs of children with poor prognostic cancers, as well as incentivise the First-in-Child development of new paediatric anticancer medicines, reduce delays so that children can have faster access to paediatric drugs, and address limited access to certain essential medicines due to drug shortages and the high price of innovative medicines; recommends an increase of 20 % in the available new paediatric cancer drugs by 2027; recalls the need for the ad hoc funding for paediatric research to be included in the Horizon Europe Call for
Grants;


Amendment 1248
Peter Liese
on behalf of the EPP Group
Tomislav Sokol, Nathalie Colin-Oesterlé, Liudas Mažylis, Marian-Jean Marinescu, Maria Spyraki, Dolors Montserrat, Cindy Franssen, Adam Jarubas, Deirdre Clune, Sunčana Glavak, Bartosz Arłukowicz

Motion for a resolution
Paragraph 92

Motion for a resolution

92. Calls for an ambitious revision of the regulations on paediatric and orphan medicinal products in order to ensure access to innovative cancer drugs, identify the most important drugs to meet the needs of children with poor prognostic cancers, reduce delays so that children can have faster access to paediatric drugs, and address limited access to certain essential medicines due to drug shortages and the high price of innovative medicines; recommends an increase of 20 % in the available new paediatric cancer drugs by 2027;

Amendment

92. Calls for an ambitious revision of the regulations on paediatric and orphan medicinal products in order to ensure access to innovative cancer drugs, identify the most important drugs to meet the needs of children with poor prognostic cancers, reduce delays so that children can have faster access to paediatric drugs, and address limited access to certain essential medicines due to drug shortages and the high price of innovative medicines; recommends an increase of 20 % in the available new paediatric cancer drugs by 2027 and to increase the accessibility of personalised medicine; calls on the Commission to incentivise child specific and first-in-child innovation and to facilitate the repositioning of medicines failing in adults when there is scientific
and preclinical rationale, as well as to provide more effective, tailored and flexible incentives to foster the development of medicines for cancer in children, encourage timely paediatric development and reduce delays, such as by means of transferable vouchers, tax credits, and early proportionate rewards allocated incrementally and not exclusively at the end of the Supplementary Protection Certificate (SPC); calls on the Commission to remove Article 11b of the Paediatric regulation in the upcoming review to allow paediatric cancer medicine development to be driven by science and the medicine’s mechanism of action;


Amendment 1249
Loucas Fourlas

Motion for a resolution
Paragraph 92

92. Calls for an ambitious revision of the regulations on paediatric\(^{33}\) and orphan\(^{34}\) medicinal products in order to ensure access to innovative cancer drugs, identify the most important drugs to meet the needs of children with poor prognostic cancers, reduce delays so that children can have


faster access to paediatric drugs, and address limited access to certain essential medicines due to drug shortages and the high price of innovative medicines; recommends an increase of 20% in the available new paediatric cancer drugs by 2027;

---


Amendment 1250
Giorgos Georgiou, Kateřina Konečná, Alexis Georgoulis, João Pimenta Lopes

Motion for a resolution
Paragraph 92

92. Calls for an ambitious revision of the regulations on paediatric\textsuperscript{33} and orphan\textsuperscript{34} medicinal products in order to ensure access to innovative cancer drugs, identify the most important drugs to meet the needs of children with poor prognostic cancers, reduce delays so that children can have faster access to paediatric drugs, and address limited access to certain essential medicines due to drug shortages and the high price of innovative medicines; recommends an increase of 20% in the available new paediatric cancer drugs by 2027;

---

92. Calls for an ambitious revision of the regulations on paediatric\textsuperscript{33} and orphan\textsuperscript{34} medicinal products in order to ensure access to innovative cancer drugs, identify the most important drugs to meet the needs of children with poor prognostic cancers as well as incentivise the First-in-Child development of new paediatric anticancer medicines, reduce delays so that children can have faster access to paediatric drugs, and address limited access to certain essential medicines due to drug shortages and the high price of innovative medicines; recommends an increase of 20% in the available new paediatric cancer drugs by 2027;
Motion for a resolution
Paragraph 92

92. Calls for an ambitious revision of the regulations on paediatric\textsuperscript{33} and orphan\textsuperscript{34} medicinal products in order to ensure access to innovative cancer drugs, identify the most important drugs to meet the needs of children with poor prognostic cancers, reduce delays so that children can have faster access to paediatric drugs, and address limited access to certain essential medicines due to drug shortages and the high price of innovative medicines; recommends an increase of 20\% in the available new paediatric cancer drugs by 2027;


Amendment 1252
Hilde Vautmans, Irena Joveva

Motion for a resolution
Paragraph 92

Motion for a resolution

92. Calls for an ambitious revision of the regulations on paediatric and orphan medicinal products in order to ensure access to innovative cancer drugs, identify the most important drugs to meet the needs of children with poor prognostic cancers, reduce delays so that children can have faster access to paediatric drugs, and address limited access to certain essential medicines due to drug shortages and the high price of innovative medicines; recommends an increase of 20 % in the available new paediatric cancer drugs by 2027;

Amendment

92. Calls for an ambitious revision of the regulations on paediatric and orphan medicinal products in order to ensure access to innovative cancer drugs, identify the most important drugs to meet the needs of children with poor prognostic cancers, reduce delays so that children can have faster access to paediatric drugs, and address limited access to certain essential medicines due to drug shortages and the high price of innovative medicines; recommends an increase of 20 % in the available new paediatric cancer drugs by 2027; considers, consequently, that ad hoc funding for paediatric research should be included in the Horizon Europe Call for Grants, and that a clear obligation to include paediatric research should be considered as a condition for application;


 Amendment 1253
Loucas Fourlas

Motion for a resolution
Paragraph 92

Motion for a resolution

92. Calls for an ambitious revision of the regulations on paediatric\textsuperscript{33} and orphan\textsuperscript{34} medicinal products in order to ensure access to innovative cancer drugs, identify the most important drugs to meet the needs of children with poor prognostic cancers, reduce delays so that children can have faster access to paediatric drugs, and address limited access to certain essential medicines due to drug shortages and the high price of innovative medicines; recommends an increase of 20\% in the available new paediatric cancer drugs by 2027; calls on the Commission, where appropriate in dialogue with the Member States, to work on a reimbursement system that favours a real breakthrough accessible innovation for paediatric cancer patients;


Amendment 1254
Pietro Fiocchi

PE697.582v02-00 42/190 AM\239642EN.docx
Motion for a resolution
Paragraph 92

92. Calls for an ambitious revision of the regulations on paediatric and orphan medicinal products in order to ensure access to innovative cancer drugs, identify the most important drugs to meet the needs of children with poor prognostic cancers, reduce delays so that children can have faster access to paediatric drugs, and address limited access to certain essential medicines due to drug shortages and the high price of innovative medicines; recommends an increase of 20% in the available new paediatric cancer drugs by 2027;


Amendment 1255
Ondřej Knotek, Irena Joveva

Motion for a resolution
Paragraph 92

92. Calls for an ambitious revision of the regulations on paediatric and orphan medicinal products in order to ensure access to innovative cancer drugs, identify the most important drugs to meet the needs of children with poor prognostic cancers, reduce delays so that children can have faster access to paediatric drugs, stimulate competition by adapting a regulatory framework and stimulating investments in off-patent orphan and paediatric medicines, and address limited access to certain essential medicines due to drug shortages and the high price of innovative medicines; recommends an increase of 20% in the available new paediatric cancer drugs by 2027;


medicinal products in order to ensure access to innovative cancer drugs, identify the most important drugs to meet the needs of children with poor prognostic cancers, reduce delays so that children can have faster access to paediatric drugs, and address limited access to certain essential medicines due to drug shortages and the high price of innovative medicines; recommends an increase of 20 % in the available new paediatric cancer drugs by 2027;


Amendment 1256
Bartosz Arłukowicz

Motion for a resolution
Paragraph 92

Motion for a resolution

92. Calls for an ambitious revision of the regulations on paediatric and orphan medicinal products in order to ensure access to innovative cancer drugs, identify the most important drugs to meet the needs of children with poor prognostic cancers, reduce delays so that children can have faster access to paediatric drugs, and address limited access to certain essential medicines due to drug shortages and the high price of innovative medicines, including transformative therapies such as cell and gene therapies, and address limited access to certain essential medicines due to drug shortages and the high price of innovative medicines; recommends an increase of 20 % in the available new paediatric cancer drugs by 2027;

Amendment

92. Calls for an ambitious revision of the regulations on paediatric and orphan medicinal products in order to ensure access to innovative cancer drugs, identify the most important drugs to meet the needs of children with poor prognostic cancers, reduce delays so that children can have faster access to paediatric drugs, and address limited access to certain essential medicines due to drug shortages and the high price of innovative medicines, including transformative therapies such as cell and gene therapies, and address limited access to certain essential medicines due to drug shortages and the high price of innovative medicines; recommends an increase of 20 % in the available new paediatric cancer drugs by 2027;
high price of innovative medicines; recommends an increase of 20 % in the available new paediatric cancer drugs by 2027; high price of innovative medicines; recommends an increase of 20 % in the available new paediatric cancer drugs by 2027, as well as an increase in the accessibility of personalised medicine;


Amendment 1257
Michèle Rivasi

Motion for a resolution
Paragraph 92

92. Calls for an ambitious revision of the regulations on paediatric\(^\text{33}\) and orphan\(^\text{34}\) medicinal products in order to ensure affordable access to innovative cancer drugs, identify the most important drugs to meet the needs of children with poor prognostic cancers, reduce delays so that children can have faster access to paediatric drugs, and address limited access to certain essential medicines due to drug shortages and the high price of innovative medicines; recommends an increase of 20 % in the available new paediatric cancer drugs with proven added therapeutic value by 2027;

92. Calls for an ambitious revision of the regulations on paediatric\(^\text{33}\) and orphan\(^\text{34}\) medicinal products in order to ensure affordable access to innovative cancer drugs, identify the most important drugs to meet the needs of children with poor prognostic cancers, reduce delays so that children can have faster access to paediatric drugs, and address limited access to certain essential medicines due to drug shortages and the high price of innovative medicines; recommends an increase of 20 % in the available new paediatric cancer drugs with proven added therapeutic value by 2027;


Amendment 1258
Giorgos Georgiou, Kateřina Konečná, Alexis Georgoulis, João Pimenta Lopes

Motion for a resolution
Paragraph 92 a (new)

Motion for a resolution

Amendment

92a. **Highlights the importance of allocating appropriate funding to science and social humanities research in order to evaluate inequalities in access to standards of care and innovation in childhood cancer across Europe, which account for differences in survival rates of paediatric cancer patients of up to 20% among Member States, and formulate mitigating measures in order to guarantee equitable rights and access to treatment for all children and young people with cancer in Europe; regrets in this regard the disparities in terms of access to high quality healthcare services among Member States and also between different regions within Member States, and asks the Commission to address those disparities with the appropriate legislative measures in order to ensure equal rights in the EU;**

Amendment 1259
Marian-Jean Marinescu
Motion for a resolution
Paragraph 93

93. Calls for the creation of an EU-level advisory group of stakeholders dedicated to childhood and AYA cancers, which could support the goal-driven and coherent implementation of relevant actions across Europe’s Beating Cancer Plan, Horizon Europe and the Pharmaceutical Strategy;

Amendment

93. Calls for the creation of an EU-level advisory group of stakeholders dedicated to childhood and AYA cancers, which could support the goal-driven and coherent implementation of relevant actions across Europe’s Beating Cancer Plan, Horizon Europe and the Pharmaceutical Strategy and EU4Health Programme;

Amendment 1260
Giorgos Georgiou, Kateřina Konečná, Alexis Georgoulis, João Pimenta Lopes

Motion for a resolution
Paragraph 93 a (new)

93a. Stresses the need for comprehensive population-based childhood cancer registries based on internationally agreed upon childhood cancer classification systems to ensure high-quality comparable data across Europe; reiterates the need for publishing annually the number of cancer cases in children and adolescents in the EU and in each Member State, respectively, as already available yearly for cancer occurring in adults; recognises the important role of the Commission’s Joint Research Centre in this regard and welcomes its endeavour to release statistics on childhood tumours by the end of 2022; highlights the importance of publishing such statistics in line with the International Classification of Childhood Cancer (ICCC);
Amendment 1261
Loucas Fourlas

Motion for a resolution
Paragraph 93 b (new)

Motion for a resolution

93b. Stresses the need for comprehensive population-based childhood cancer registries based on internationally agreed upon childhood cancer classification systems to ensure high-quality comparable data across Europe; reiterates the need for publishing annually the number of cancer cases in children and adolescents in the EU and in each Member State, respectively, as already available yearly for cancer occurring in adults; recognises the important role of the Commission’s Joint Research Centre in this regard and welcomes its endeavour to release statistics on childhood tumours by the end of 2022; highlights the importance of publishing such statistics in line with the International Classification of Childhood Cancer (ICCC);

Or. en

Amendment 1262
Loucas Fourlas

Motion for a resolution
Paragraph 93 c (new)

Motion for a resolution

93c. Highlights the importance of allocating appropriate funding to science and social humanities research in order to evaluate inequalities in access to standards of care and innovation in childhood cancer across Europe and
formulate mitigating measures;

Or. en

Amendment 1263
Joëlle Mélin

Motion for a resolution
Paragraph 94

Motion for a resolution
Amendment

94. **Calls on** the Member States to **fully transpose Directive (EU) 2019/1158 of 20 June 2019 on work-life balance for parents and carers**, which introduces leave for carers and the possibility to request flexible working time arrangements;

**94. Urges** the Member States to **introduce specific instruments, tailored to national needs, to pay daily childcare allowances for sick children, given that ensuring a work-life balance is not the responsibility of employers**;

---


---

Amendment 1264
Peter Liese
on behalf of the EPP Group
Tomislav Sokol, Nathalie Colin-Oesterlé, Liudas Mažylis, Marian-Jean Marinescu, Maria Spyraki, Dolors Montserrat, Cindy Franssen, Adam Jarubas, Deirdre Clune, Sunčana Glavak, Bartosz Arłukowicz

Motion for a resolution
Paragraph 94

Motion for a resolution
Amendment

94. **Calls on** the Member States to fully transpose Directive (EU) 2019/1158 of 20 June 2019 on work-life balance for parents and carers, which introduces leave for

94. **Stresses the importance of the implementation and monitoring of the European Pillar of Social Rights and calls** on the Member States to fully transpose
carers and the possibility to request flexible working time arrangements;

Directive (EU) 2019/1158 of 20 June 2019 on work-life balance for parents and carers\(^\text{35}\), which introduces leave for carers and the possibility to request flexible working time arrangements so that workers have the right to carers’ leave of five working days per year in order to provide personal care or support to a relative, or to a person who lives in the same household as the worker, and who is in need of significant care or support for a serious medical reason, as defined by each Member State;


Amendment 1265
Bartosz Arlukowski

Motion for a resolution
Paragraph 94

Motion for a resolution

94. Calls on the Member States to fully transpose Directive (EU) 2019/1158 of 20 June 2019 on work-life balance for parents and carers\(^\text{35}\), which introduces leave for carers and the possibility to request flexible working time arrangements;


Amendment

94. Calls on the Member States to fully transpose Directive (EU) 2019/1158 of 20 June 2019 on work-life balance for parents and carers\(^\text{35}\), which introduces leave for carers and the possibility to request flexible working time arrangements, and to support employers in this regard;

Amendment 1266
Joëlle Mélin

Motion for a resolution
Paragraph 96

Amendment

96. Supports the recommendation of the Joint Action on Rare Cancers for the roll-out of a European unique patient identifier, in order to ensure the monitoring of long-term outcomes in childhood cancer survivors in a cross-border setting;

Motion for a resolution

96. Is extremely concerned about the recommendation of the Joint Action on Rare Cancers which calls for the roll-out of a European unique patient identifier, and aims to ensure the monitoring of long-term outcomes in childhood cancer survivors in a cross-border setting;

Or. fr

Amendment 1267
Giorgos Georgiou, Kateřina Konečná, Alexis Georgoulis

Motion for a resolution
Paragraph 96

Amendment

96. Supports the recommendation of the Joint Action on Rare Cancers for the roll-out of a European unique patient identifier, in order to ensure the monitoring of long-term outcomes in childhood cancer survivors in a cross-border setting;

Motion for a resolution

96. Supports the recommendation of the Joint Action on Rare Cancers for the roll-out of a European unique patient identifier, the Survivorship Passport and guidelines on long-term surveillance and transition from paediatric to adult care in order to ensure the monitoring of long-term outcomes in childhood cancer survivors in a cross-border setting; stresses the need for the ‘Right to be Forgotten’ to be fit for purpose for this population;

Or. en

Amendment 1268
Peter Liese
on behalf of the EPP Group
Motion for a resolution
Paragraph 96

96. Supports the recommendation of the Joint Action on Rare Cancers for the roll-out of a European unique patient identifier, in order to ensure the monitoring of long-term outcomes in childhood cancer survivors in a cross-border setting;

96. Supports the recommendation of the Joint Action on Rare Cancers for the roll-out of a European unique patient identifier, the Survivorship Passport and guidelines on long-term surveillance and transition from paediatric to adult care in order to ensure the monitoring of long-term outcomes in childhood cancer survivors in a cross-border setting; stresses the need for the ‘Right to be Forgotten’ to be fit for purpose for this population;

Or. en

Amendment 1269
Loucas Fourlas

Motion for a resolution
Paragraph 96

96. Supports the recommendation of the Joint Action on Rare Cancers for the roll-out of a European unique patient identifier, in order to ensure the monitoring of long-term outcomes in childhood cancer survivors in a cross-border setting;

Amendment

96. Supports the recommendation of the Joint Action on Rare Cancers for the roll-out of a European unique patient identifier, in order to ensure the monitoring of long-term outcomes in childhood cancer survivors in a cross-border setting; stresses the need for the ‘Right to be Forgotten’ to be fit for purpose for this population;

Or. en

Amendment 1270
Nicolae Ștefănuță, Alin Mituța, Ivars Ijabs, Vlad Gheorghe
Motion for a resolution
Paragraph 96

Motion for a resolution

96. Supports the recommendation of the Joint Action on Rare Cancers for the roll-out of a European unique patient identifier, in order to ensure the monitoring of long-term outcomes in childhood cancer survivors in a cross-border setting;

Amendment

96. Supports the recommendation of the Joint Action on Rare Cancers for the roll-out of a European unique patient identifier, and guidelines on long-term surveillance and transition from paediatric to adult care in order to ensure the monitoring of long-term outcomes in childhood cancer survivors in a cross-border setting;

Or. en

Amendment 1271
Tomislav Sokol

Motion for a resolution
Paragraph 96 a (new)

Motion for a resolution

96a. Acknowledges that rare adult cancers are a public health challenge, as altogether rare cancers amount to about 24% of new cancer cases; recalls that a rare cancer is defined as a cancer affecting less than 6 per 100,000 individuals a year, and that however three quarters of rare cancers have an annual incidence rate of less than 0.5 per 100,000; notes that there are an estimated 5.1 million people living with a rare cancer across Europe and that, in 2017, 5-year relative survival for all rare cancers was 48% compared with 63% for all common cancers; recalls that patients affected by rare adult cancers share the challenges linked to the rarity and uncommon nature of their disease: long delays to diagnosis, and sometimes misdiagnosis, difficult access to timely and adequate care and treatments; notes that patients often feel alone, isolated and...
suffer greatly reduced quality of life, whereas their carers are also significantly and negatively impacted;

Amendment 1272
Peter Liese
on behalf of the EPP Group
Tomislav Sokol, Nathalie Colin-Oesterlé, Liudas Mažylis, Marian-Jean Marinescu, Maria Spyraκi, Dolors Montserrat, Cindy Franssen, Adam Jarubas, Deirdre Clune, Sunčana Glavak, Bartosz Arłukowicz

Motion for a resolution
Paragraph 96 b (new)

Motion for a resolution
Amendment

96b. Notes that the current bureaucratic workload of trial activation in Europe is too high for many rare diseases including childhood cancer because investigator-led trials suffer from lack of commercial sponsorship and many non-commercial organisations are still unwilling to undertake the role of sponsor at a pan-European level for multinational trials in children; calls on the Commission to review the existing legislation in this regard and to facilitate multinational trials for children;

Amendment 1273
Margarita de la Pisa Carrión

Motion for a resolution
Paragraph 96 c (new)

Motion for a resolution
Amendment

96c. Calls for the promotion of bone marrow donation in the Member States so that the lives of thousands of people
diagnosed with leukemia can be saved, a number that is constantly increasing and of which many are children, since it is the most common childhood cancer; highlights that bone marrow transplantation is the only hope for many affected by leukemia and other blood diseases, whereas 3 out of 4 patients will not have a compatible family member, so they will need a donor;

Amendment 1274
Nicolae Ștefănuță, Alin Mituța, Ivars Ijabs, Vlad Gheorghe

Motion for a resolution
Paragraph 96 d (new)

Motion for a resolution

Amendment

96d. Underlines the need for effectively addressing mental health issues in children, adolescents and young adults (AYAs) with cancer and survivors; calls on the Commission and the Member States to ensure equal access to and availability of appropriate psycho-social support measures for this group of patients;

Amendment 1275
Giorgos Georgiou, Alexis Georgoulis, João Pimenta Lopes

Motion for a resolution
Paragraph 96 d (new)

Motion for a resolution

Amendment

96d. Underlines the need for effectively addressing mental health issues in children and adolescents with cancer and survivors; calls on the Commission and
the Member States to ensure equal access to and availability of appropriate psycho-social support measures for this population across Europe;

Amendment 1276
Loucas Fourlas

Motion for a resolution
Paragraph 96 d (new)

96d. Underlines the need for effectively addressing mental health issues in children and adolescents with cancer and survivors; calls on the Commission and the Member States to ensure equal access and availability to appropriate psycho-social support measures for this population across Europe;

Amendment 1277
Nicolás González Casares, Alessandra Moretti, Maria Arena, Romana Jerković, Cyrus Engerer, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 96 e (new)

96e. Calls on Member States to develop measures to address mental health issues in children and adolescents with cancer as well as childhood cancer survivors, and facilitating access to appropriate psycho-social support measures across Europe;
Amendment 1278
Alin Mituţa, Nicolae Ştefănuţă, Hilde Vautmans, Ondřej Knotek, Vlad Gheorghe

Motion for a resolution
Paragraph 96 f (new)

Motion for a resolution Amendment
96f. Recommends that all National Cancer Control Plans have a designated section on paediatric oncology;

Or. en

Amendment 1279
Alessandra Moretti, Sara Cerdas, Patrizia Toia, Maria Arena, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 96 g (new)

Motion for a resolution Amendment
96g. Recalls the importance of addressing the specific issues related to geriatric oncology and the unique approach needed to address cancer in such a delicate age group;

Or. en

Amendment 1280
Alessandra Moretti, Sara Cerdas, Patrizia Toia, Maria Arena, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 96 h (new)

Motion for a resolution Amendment
96h. Recalls that in Europe over 60% of new cancer cases and over 70% of cancer deaths occur in people aged 65 and older; underlines that, as the population in Europe ages, this proportion will increase representing a crucial challenge for public authorities and healthcare systems
in the years to come, primary as a public health issue, but also in terms of resources; expects the Commission and Member States to urgently address this situation with concrete actions in order to be prepared to face this evolution in cancer care; notes that standard cancer care strategies have been mostly validated in younger adults; regrets that elderly patients are currently underrepresented in cancer clinical trials with the consequence of making it more difficult for clinicians to elaborate evidence-based recommendations in everyday clinical practice and at the same time creating potential discrimination for the access of elderly people to innovative and potentially life-saving new treatments on the sole base of their age; asks the Commission and Member States to act in order to facilitate clinical trials in this segment of population and to address urgently the emerging issue of cancer in elderly patients; asks the Commission and Member States to facilitate the implementation of multi-disciplinary and comprehensive oncogeriatric care models in routine clinical pathways and the creation of centres of excellence in geriatric oncology to meet the complex needs of the expanding older cancer patient population; asks the Commission and member states to foster opportunities for the training and upskilling of the oncology workforce (including medical, nursing and allied healthcare professional staff) in the principles of geriatrics;

Amendment 1281
Alessandra Moretti, Sara Cerdas, Patrizia Toia, Maria Arena, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 96 i (new)
96i. Recalls that in the context of personalised medicine, gender based medicine and therapies are considered to be an effective treatment strategy also for the cure of cancer, taking into consideration differences at the biological, genetic and musculoskeletal level between men and women; calls on the Commission and Member States to facilitate the development of gender based treatment for cancer, in line with the indications coming from medical practitioners and physicians;

Or. en

Amendment 1282
Tomislav Sokol

Motion for a resolution
Paragraph 96 j (new)

96j. Welcomes the “Genomic for Public Health” project and the establishment of a “roadmap to personalised prevention” in Europe’s Beating Cancer Plan, to identify gaps in research and innovation, and support an “approach to map all known biological anomalies leading to cancer susceptibility, including hereditary cancers”, which amount to 5-10% of cancer cases;

Or. en

Amendment 1283
Tomislav Sokol

Motion for a resolution
Paragraph 96 k (new)
Motion for a resolution

Amendment

96k. Supports the introduction of a dedicated flagship initiative on rare adult cancers within the Europe’s Beating Cancer Plan to tackle the specific challenges faced by this patient community as described above and make the best use of there commendations set out in the Rare Cancer Agenda 2030 to foster research and improve care in each step of the rare cancer patient journey; ensures that rare adult cancers are included in all initiatives across the four pillars of the Europe’s Beating Cancer Plan;

Or. en

Amendment 1284
Nicolás González Casares, Alessandra Moretti, Maria Arena, Romana Jerković, Cyrus Engerer, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 96 l (new)

Motion for a resolution

Amendment

96l. Stresses the need to create a dedicated Flagship initiative on rare cancers within Europe’s Beating Cancer Plan, to support the implementation of the 10 recommendations from the EU Joint Action on Rare Cancers - the Rare Cancer Agenda 2030, and tackle the specific challenges faced by the community representing almost one quarter of all new cancer cases;

Or. en

Amendment 1285
Tomislav Sokol
Motion for a resolution
Paragraph 96 m (new)

Motion for a resolution
Amendment

96m. Calls for dedicated funding for rare adult cancer research projects under Horizon Europe, including under the Mission on Cancer (for instance under UNCAN.eu – the European Initiative to Understand Cancer) to develop targeted therapies, and support the development of databases, registries and biobanks relevant to rare adult cancers;

Or. en

Amendment 1286
Nicolás González Casares, María Arena, Romana Jerković, Cyrus Engerer, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 96 n (new)

Motion for a resolution
Amendment

96n. Underlines the importance of ensuring dedicated funding under Horizon Europe for the creation of a European Partnership on Rare Cancers;

Or. en

Amendment 1287
Alessandra Moretti

Motion for a resolution
Paragraph 96 o (new)

Motion for a resolution
Amendment

96o. Calls on the Commission and the Member States to dedicate research funding to rare cancers, which represent 24% of all new cancer cases, including
rare adult solid cancers, haematological cancers and paediatric cancers under the Mission on Cancer, including UNCAN.eu – the European Initiative to Understand Cancer, among others; underlines the importance of establishing European strategic initiatives for rare cancers, such as a new Joint Action on Rare Cancers;

Amendment 1288
Nicolás González Casares, Maria Arena, Romana Jerković, Cyrus Engerer, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 96 p (new)

96p. Encourages the creation of user-friendly, interoperable and harmonised IT solutions within the framework of the European Reference Networks (ERNs) and national rare cancer networks to allow for easy exchange of cases, knowledge and discussion on complex cancer cases and treatment pathways;

Amendment 1289
Tomislav Sokol

Motion for a resolution
Paragraph 96 q (new)

96q. Encourages Member States to establish national networks for rare adult cancers to optimise the referral of patients to specialised centres in a timely fashion and facilitate interaction with ERNs to maximise the exchanges of
multidisciplinary knowledge and high-quality care as well as foster clinical research;

Amendment 1290
Tomislav Sokol

Motion for a resolution
Paragraph 96 r (new)

Motion for a resolution

Amendment

96r. Stresses the difficulty in diagnosing rare adult cancers more timely, and thus recommends easier and timely access to molecular testing that can help patients receive an accurate diagnosis and targeted therapy, and even access relevant clinical trials where appropriate; stresses, further, that research on biomarkers is critical in that area;

Amendment 1291
Alessandra Moretti

Motion for a resolution
Paragraph 96 s (new)

Motion for a resolution

Amendment

96s. Encourages the creation of national networks linked to the rare cancer ERNs on rare adult solid cancers and haematological neoplasms;

Or. en
Amendment 1292
Tomislav Sokol

Motion for a resolution
Paragraph 96 t (new)

Motion for a resolution

Amendment

96t. Calls for increasing awareness of rare adult cancers amongst primary and secondary healthcare professionals and implementing adequate referrals to specialised multidisciplinary expert centres at both national and European level;

Or. en

Amendment 1293
Alessandra Moretti

Motion for a resolution
Paragraph 96 u (new)

Motion for a resolution

Amendment

96u. Underlines the importance of ensuring dedicated funding under Horizon Europe for the creation of a European Partnership on Rare Cancers;

Or. en

Amendment 1294
Tomislav Sokol

Motion for a resolution
Paragraph 96 v (new)

Motion for a resolution

Amendment

96v. Calls for improving access to clinical trials and Expanded Access Programmes (EAPs) for rare adult cancer patients; regrets that it continues to be
very difficult for rare adult cancer patients from many countries to access EAPs and trials abroad; calls for a better implementation of EU schemes to access healthcare abroad, whereas national healthcare systems should facilitate access to trials and EAPs for patients with rare adult cancers who have few treatment options;

Amendment 1295
Tomislav Sokol

Motion for a resolution
Paragraph 96 w (new)

Motion for a resolution
Amendment

96w. Encourages novel regulatory approaches such as adaptive licensing, to enable rare adult cancer patients to access new/innovative therapies under safe monitoring, while facilitating the collection of real-world data;

Or. en

Amendment 1296
Tomislav Sokol

Motion for a resolution
Paragraph 96 x (new)

Motion for a resolution
Amendment

96x. Emphasises the need to include rare adult cancers in the “inter-specialty cancer training programme” including specialised nursing training, in conjunction with ERNs for rare adult cancers; additionally, emphasises the need to support educational programmes targeting rare adult cancer patients,
carers and patient representatives in conjunction with ERNs, to increase levels of health literacy and ultimately help patients and their families to make informed choices about treatment options and follow-up care;

Amendment 1297
Tomislav Sokol

Motion for a resolution
Paragraph 96 y (new)

Motion for a resolution

96y. Acknowledges the specificities of rare adult cancers in programmes dedicated to improving the quality of life of cancer patients, survivors and carers; calls on the Commission and Member States to implement specific training for professionals, other than healthcare providers (e.g. social workers, case managers), taking care of rare adult cancer patients; stresses that rare adult cancer patients need to receive adequate psychological support, rehabilitation and monitoring of long-term side effects of treatments by professionals who understand their rare disease and the specificities linked to it; recommends that all patients with rare adult cancers also be provided with a survivorship care plan; considers that carers for rare adult cancer patients (often family members) also need access to specific psychosocial support to cope with the severity and complexity of the disease, and the significant burden of care which they take on;

Or. en
Amendment 1298
Tomislav Sokol

Motion for a resolution
Paragraph 96 z (new)

Motion for a resolution

96z. Calls on Member States to include a specific section on the management of rare adult cancers in their National Cancer Control Programme (NCCP) (along with a distinct section on cancers in children) as recommended in the Rare Cancer Agenda 2030; considers that the specificities should be acknowledged in specific distinct sections in all the NCCPs, with relevant synergies with rare disease national plans, to foster research as well as improve care management and care pathways for these patients, from primary care up to highly specialised multidisciplinary healthcare centres, notably belonging to, or in close contact with a relevant ERN; notes that, to date, rare cancers in adults and paediatric cancers are hardly included in many NCCPs of Member States;

Or. en

Amendment 1299
Tomislav Sokol

Motion for a resolution
Paragraph 96 aa (new)

Motion for a resolution

96aa. Urges relevant national authorities to involve rare adult cancer patient organisations as partners in NCCPs to voice rare adult cancer patients’ needs and expectations, as well as actively participate in the implementation of dedicated measures for rare adult
Motion for a resolution
Subheading I

I. Holistic research

Amendment

I. Holistic research and implementation of its results

Amendment 1300
Bartosz Arłukowicz

Amendment 1301
Peter Liese
on behalf of the EPP Group
Tomislav Sokol, Nathalie Colin-Oesterlè, Liudas Mažylis, Maria Spyraki, Dolors Montserrat, Cindy Franssen, Adam Jarubas, Deirdre Clune, Sunčana Glavak, Bartosz Arłukowicz

Amendment 1302
Nicolás González Casares, María Arena, Romana Jerkovič, Cyrus Engerer, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 97
Motion for a resolution

97. Stresses that Europe’s Beating Cancer Plan should be implemented in close cooperation with the Cancer Mission under Horizon Europe and its objectives of promoting EU investment in cancer research and innovation;

Amendment

97. Stresses that Europe’s Beating Cancer Plan should be implemented in close cooperation with the Cancer Mission under Horizon Europe and its objectives of promoting EU investment in cancer research and innovation; welcomes that Horizon Europe will fund research infrastructures, cloud computing and European Innovation Council actions; recalls the need to address the existing gap with regard to paediatric cancers and recommends to dedicate not less than 20% of cancer research funds in Horizon Europe to new paediatric cancer drugs;

Or. en

Amendment 1303
Hilde Vautmans, Irena Joveva

Motion for a resolution
Paragraph 97

97. Stresses that Europe’s Beating Cancer Plan should be implemented in close cooperation with the Cancer Mission under Horizon Europe and its objectives of promoting EU investment in cancer research and innovation;

Amendment

97. Stresses that Europe’s Beating Cancer Plan should be implemented in close cooperation with the Cancer Mission under Horizon Europe and its objectives of promoting EU investment in cancer research and innovation; recommends that no less than 20 % of cancer research funds in Horizon Europe be dedicated to new paediatric cancer medicines in order to fill the existing gap in paediatric medicines;

Or. en

Amendment 1304
Nicolae Ștefănuță, Alin Mituța, Ivars Ijabs, Vlad Gheorghe
Paragraph 97

97. Stresses that Europe’s Beating Cancer Plan should be implemented in close cooperation with the Cancer Mission under Horizon Europe and its objectives of promoting EU investment in cancer research and innovation;

97. Stresses that Europe’s Beating Cancer Plan should be implemented in close cooperation with the Cancer Mission under Horizon Europe and its objectives of promoting EU investment in cancer research and innovation; **calls for paediatric cancer research to have a dedicated partnership in "Cluster 1: Health" of the Horizon Europe Pillar II funding programme;**

Amendment 1305
Antoni Comín i Oliveres

97. Stresses that Europe’s Beating Cancer Plan should be implemented in close cooperation with the Cancer Mission under Horizon Europe and its objectives of promoting EU investment in cancer research and innovation;

97. Stresses that Europe’s Beating Cancer Plan should be implemented in close cooperation with the Cancer Mission under Horizon Europe and its objectives of promoting EU investment in **anticipatory and responsive** cancer research and innovation;

Amendment 1306
João Pimenta Lopes, Giorgos Georgiou, Alexis Georgoulis

97. Stresses that Europe’s Beating Cancer Plan should be implemented in close cooperation with the Cancer Mission under Horizon Europe and its objectives of promoting EU investment in cancer research and innovation;

97. Stresses that Europe’s Beating Cancer Plan should be implemented in close cooperation with the Cancer Mission under Horizon Europe and its objectives of promoting EU investment in **anticipatory and responsive** cancer research and innovation;
Cancer Plan should be implemented in close cooperation with the Cancer Mission under Horizon Europe and its objectives of promoting EU investment in cancer research and innovation;

Cancer Plan should be implemented in close cooperation with the Cancer Mission under Horizon Europe and its objectives of promoting EU investment in cancer research and innovation; public production and innovation;

Or. pt

Amendment 1307
Pietro Fiocchi

Motion for a resolution
Paragraph 97

Motion for a resolution

97. Stresses that Europe’s Beating Cancer Plan should be implemented in close cooperation with the Cancer Mission under Horizon Europe and its objectives of promoting EU investment in cancer research and innovation;

Amendment

97. Stresses that Europe’s Beating Cancer Plan should be implemented in close cooperation with the Mission on Cancer under Horizon Europe and its objectives of promoting EU investment in cancer research and innovation;

Or. en

Amendment 1308
Bronis Ropé

Motion for a resolution
Paragraph 97 a (new)

Motion for a resolution

97a. Calls for increased national funding for applied oncology research through the earmarking of national financial resources and the setting of political priorities; believes that ‘from lab to clinic’ research activity should be promoted by strengthening the legal and financial framework to encourage the faster translation of scientific discoveries and advances into practical treatment

Amendment

97a. Calls for increased national funding for applied oncology research through the earmarking of national financial resources and the setting of political priorities; believes that ‘from lab to clinic’ research activity should be promoted by strengthening the legal and financial framework to encourage the faster translation of scientific discoveries and advances into practical treatment
Amendment 1309
Margarita de la Pisa Carrión

Motion for a resolution
Paragraph 97 b (new)

97b. Calls for the promotion of oncogeriatrics as a branch that deserves a special consideration and needs to be enriched by scientific research in order to ascertain best treatment and diagnostic methods for patients at this stage of their lives;

Amendment 1310
Bronis Ropè

Motion for a resolution
Paragraph 97 c (new)

97c. Considers it necessary to take into account the fact that the disparities between the EU Member States in terms of timely diagnosis and treatment of cancer are largely due to the disparities that exist between countries in the area of research funding, since in the competition for EU research funds, some Member States are at an ex ante competitive disadvantage as a result of unequal starting positions, underdeveloped infrastructure and lower national research allocations, as well as lower citation rates and the lack of clout of their scientific publications; calls on the
Commission and the Member States to take appropriate action to address this discriminatory situation;

Or. It

Amendment 1311
Marian-Jean Marinescu

Motion for a resolution
Paragraph 98

98. Recalls that cancer research, and its translation into everyday clinical practice, is fundamental to ensuring continuous improvements in cancer prevention, diagnosis, treatment and follow-up care for survivors; welcomes, therefore, the launch of Horizon Europe partnerships to translate scientific knowledge into innovations;

Or. en

Amendment 1312
Alexis Georgoulis

Motion for a resolution
Paragraph 98

98. Recalls that cancer research, and its translation into everyday clinical practice, is fundamental to ensuring continuous improvements in cancer prevention, diagnosis, treatment and follow-up care for survivors; welcomes, therefore, the launch of Horizon Europe partnerships to translate scientific knowledge into innovations; asks the Commission to follow closely the Horizon Europe partnerships activity and the concretization of the research in real added value support for current medical practice;

Or. en
scientific knowledge into innovations; highlights that promotion and development of translational research should be considered as an important core objective of the EU Network of Comprehensive Cancer Centres;

Amendment 1313
Tomislav Sokol, Sunčana Glavak, Cindy Franssen

Motion for a resolution
Paragraph 98

98. Recalls that cancer research, and its translation into everyday clinical practice, is fundamental to ensuring continuous improvements in cancer prevention, diagnosis, treatment and follow-up care for survivors; welcomes, therefore, the launch of Horizon Europe partnerships to translate scientific knowledge into innovations;

Amendment
98. Recalls that cancer research, and its translation into everyday clinical practice, is fundamental to ensuring continuous improvements in cancer prevention, diagnosis, treatment and follow-up care for survivors; welcomes, therefore, the launch of Horizon Europe partnerships to translate scientific knowledge into innovations; urges that promotion and development of translational research be understood as an important core objective of the EU Network of Comprehensive Cancer Centres;

Amendment 1314
Bartosz Arłukowicz

Motion for a resolution
Paragraph 98

98. Recalls that cancer research, and its translation into everyday clinical practice, is fundamental to ensuring continuous improvements in cancer prevention,

Amendment
98. Recalls that cancer research, as well as research on optimising the organisation of cancer treatment, the financing of healthcare providers and the
diagnosis, treatment and follow-up care for survivors; welcomes, therefore, the launch of Horizon Europe partnerships to translate scientific knowledge into innovations; functioning of management institutions, and its translation into everyday clinical practice, is fundamental to ensuring continuous improvements in cancer prevention, diagnosis, treatment and follow-up care for survivors; welcomes, therefore, the launch of Horizon Europe partnerships to translate scientific knowledge into innovations;

Amendment 1315
Hilde Vautmans, Irena Joveva

Motion for a resolution
Paragraph 98

Motion for a resolution  
Amendment

98. Recalls that cancer research, and its translation into everyday clinical practice, is fundamental to ensuring continuous improvements in cancer prevention, diagnosis, treatment and follow-up care for survivors; welcomes, therefore, the launch of Horizon Europe partnerships to translate scientific knowledge into innovations; underlines that these partnerships should include paediatric competences and issues;

Or. pl

Amendment 1316
Nicolae Ștefănuță, Alin Mituța, Ivars Ijabs, Vlad Gheorghe

Motion for a resolution
Paragraph 98

Motion for a resolution  
Amendment

98. Recalls that cancer research, and its translation into everyday clinical practice, is fundamental to ensuring continuous improvements in cancer prevention, diagnosis, treatment and follow-up care for survivors; welcomes, therefore, the launch of Horizon Europe partnerships to translate scientific knowledge into innovations; underlines that these partnerships should include paediatric competences and issues;

Or. en
improvements in cancer prevention, diagnosis, treatment and follow-up care for survivors; welcomes, therefore, the launch of Horizon Europe partnerships to translate scientific knowledge into innovations; 

improvements in cancer prevention, diagnosis, treatment and follow-up care for survivors; welcomes, therefore, the launch of Horizon Europe partnerships to translate scientific knowledge into innovations; 

recommends that the cited partnerships include paediatric competences and issues; 

Or. en

Amendment 1317
Michèle Rivasi

Motion for a resolution
Paragraph 98

98. Recalls that cancer research, and its translation into everyday clinical practice, is fundamental to ensuring continuous improvements in cancer prevention, diagnosis, treatment and follow-up care for survivors; welcomes, therefore, the launch of Horizon Europe partnerships to translate scientific knowledge into innovations; 

98. Recalls that cancer research, and its translation into everyday clinical practice, is fundamental to ensuring continuous improvements in cancer prevention, diagnosis, treatment and follow-up care for survivors; welcomes, therefore, the launch of Horizon Europe partnerships to translate scientific knowledge into innovations that reach patients; 

Or. en

Amendment 1318
Loucas Fourlas

Motion for a resolution
Paragraph 98

98. Recalls that cancer research, and its translation into everyday clinical practice, is fundamental to ensuring continuous improvements in cancer prevention, diagnosis, treatment and follow-up care for survivors; welcomes, therefore, the launch of Horizon Europe partnerships to translate scientific knowledge into innovations; 

98. Recalls that multidisciplinary cancer research, and its translation into everyday clinical practice, is fundamental to ensuring continuous improvements in cancer prevention, diagnosis, treatment and follow-up care for survivors; welcomes,
of Horizon Europe partnerships to translate scientific knowledge into innovations; therefore, the launch of Horizon Europe partnerships to translate scientific knowledge into innovations;

Amendment 1319
Nicolás González Casares, Maria Arena, Romana Jerković, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 98 a (new)

Motion for a resolution
Amendment

98a. Welcomes that the Marie Skłodowska-Curie Actions will continue educating and training researchers in cancer prevention, prediction, detection, diagnosis and treatments;

Amendment 1320
Nicolás González Casares, Maria Arena, Romana Jerković, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 98 b (new)

Motion for a resolution
Amendment

98b. Welcomes the Commission's communication on a new ERA for Research and Innovation, which sets out the strategic objectives and actions to be implemented in close cooperation with the Member States; supports the target of investing 3% of EU GDP in research and development which will help to promote excellence research across the EU and enable research results to reach the scientific community, society and the real economy; deplores the significant inequalities in research funding across
the EU; calls on the Member States to adopt a pact for Research and Innovation in Europe that includes the commitment to increase public spending on R&I to 1.25% of the GDP, by 2030, in a coordinated manner across the EU;

Amendment 1321
Nicolás González Casares, Maria Arena, Romana Jerković, Cyrus Engerer, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 98 c (new)

Motion for a resolution

Amendment

98c. Calls on the Member States to promote and ensure attractive scientific careers for researchers in Europe, with special attention to women; calls on the Member States to establish a well-structured scientific workforce and infrastructure, as well as continuous funding for their research centres; welcomes that the proposed Innovative Health Initiative will help create an EU-wide research and innovation ecosystem, promoting cooperation between the health industry, academia and other stakeholders to translate scientific knowledge into innovations that address prevention, diagnosis, treatment and management of diseases, including cancer;

Amendment 1322
Andrey Slabakov, Angel Dzhambazki, Pietro Fiocchi

Motion for a resolution
Paragraph 99
99. Reiterates its call for **sustainable and** adequate funding for competitive European research on cancer; calls for at least a 20 % increase in the mobilisation of public and private research on therapeutic and diagnostic cancer innovations;

**Amendment**

99. Reiterates its call for adequate funding for competitive European research on cancer; calls for at least a 20 % increase in the mobilisation of public and private research on therapeutic and diagnostic cancer innovations;

Or. en

Amendment 1323
Joëlle Mélin

Motion for a resolution
Paragraph 99

99. Reiterates its call for sustainable and adequate funding for competitive European research on cancer; **calls for** at least a 20 % increase in the mobilisation of public and private research on therapeutic and diagnostic cancer innovations;

**Amendment**

99. Reiterates its call for sustainable and adequate funding for competitive European research on cancer; **considers that** at least a 20 % increase in the mobilisation of public and private research on therapeutic and diagnostic cancer innovations **would be effective**;

Or. fr

Amendment 1324
Michèle Rivasi

Motion for a resolution
Paragraph 99

99. Reiterates its call for sustainable and adequate funding for competitive European research on cancer; **calls for** at least a 20 % increase in the mobilisation of public and private research on therapeutic and diagnostic cancer innovations;

**Amendment**

99. Reiterates its call for sustainable and adequate funding for competitive European research on cancer; **stresses that such research should aim to address areas of high unmet need, neglected tumour types including those with poor prognosis, and be conducted across all parts of the**
cancer care continuum, including for all treatment modalities; calls for at least a 20 % increase in the mobilisation of public and private research on therapeutic and diagnostic cancer innovations; calls for the Framework Programme and national research programmes to support research into paediatric and orphan medicines through innovation prize funds that include conditionalities on product availability and affordability;

Amendment 1325
Katěřina Konečná, Alexis Georgoulis, Giorgos Georgiou

Motion for a resolution
Paragraph 99

Motion for a resolution

99. Reiterates its call for sustainable and adequate funding for competitive European research on cancer; calls for at least a 20 % increase in the mobilisation of public and private research on therapeutic and diagnostic cancer innovations;

Amendment

99. Reiterates its call for sustainable and adequate funding for competitive European research on cancer; stresses that such research should aim to address areas of high unmet need, neglected tumour types including those with poor prognosis, and be conducted across all parts of the cancer care continuum, including for all treatment modalities; calls for at least a 20 % increase in the mobilisation of public and private research on therapeutic and diagnostic cancer innovations upon clear conditionalities and transparency of the contracts stipulated between public and private entities;

Amendment 1326
Alexis Georgoulis

Motion for a resolution
Paragraph 99

PE697.582v02-00 80/190 AM\1239642EN.docx
Motion for a resolution

99. Reiterates its call for sustainable and adequate funding for competitive European research on cancer; calls for at least a 20 % increase in the mobilisation of public and private research on therapeutic and diagnostic cancer innovations;

Amendment

99. Reiterates its call for sustainable and adequate funding for competitive European research on cancer; stresses that such research should aim to address areas of high unmet need, neglected tumour types including those with poor prognosis, and be conducted across all parts of the cancer care continuum, including for all treatment modalities; calls for at least a 20 % increase in the mobilisation of public and private research on therapeutic and diagnostic cancer innovations;

Or. en

Amendment 1327
Alessandra Moretti

Motion for a resolution
Paragraph 99

Amendment 1328
Nicolás González Casares, María Arena, Romana Jerković, Čyrs Engerer, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis
Motion for a resolution
Paragraph 99

99. Reiterates its call for sustainable and adequate funding for competitive European research on cancer; calls for at least a 20% increase in the mobilisation of public and private research on therapeutic and diagnostic cancer innovations;

Amendment

99. Reiterates its call for sustainable and adequate funding for competitive European research on cancer; calls for at least a 20% increase in the mobilisation of public and private research on therapeutic and diagnostic cancer innovations; considers that conditions for access to public funding should be revised, ensuring an adequate reflection of that funding with conditionalities as regards the accessibility and affordability of new innovations when projects are successful;

Or. en

Amendment 1329
Bartosz Arłukowicz

Motion for a resolution
Paragraph 99

99. Reiterates its call for sustainable and adequate funding for competitive European research on cancer; calls for at least a 20% increase in the mobilisation of public and private research on therapeutic and diagnostic cancer innovations;

Amendment

99. Reiterates its call for sustainable and adequate funding for competitive European research on cancer; supports the implementation of the results of this research in healthcare systems by allowing universal access to solutions based on it; calls for at least a 20% increase in the mobilisation of public and private research on therapeutic and diagnostic cancer innovations;

Or. pl

Amendment 1330
Cindy Franssen, Dolors Montserrat, Aldo Patriciello, Deirdre Clune, Liudas Mažylis
Motion for a resolution
Paragraph 99

99. Reiterates its call for sustainable and adequate funding for competitive European research on cancer; calls for at least a 20% increase in the mobilisation of public and private research on therapeutic and diagnostic cancer innovations;

Amendment

99. Reiterates its call for sustainable and adequate funding for competitive European research on cancer; calls for at least a 20% increase in the mobilisation of public and private research on therapeutic and diagnostic cancer innovations, especially in the field of nuclear medicine where the use of radiopharmaceuticals promises advances in the treatment of cancer;

Or. en

Amendment 1331
Hilde Vautmans, Irena Joveva

Motion for a resolution
Paragraph 99

99. Reiterates its call for sustainable and adequate funding for competitive European research on cancer; calls for at least a 20% increase in the mobilisation of public and private research on therapeutic and diagnostic cancer innovations;

Amendment

99. Reiterates its call for sustainable and adequate funding for competitive European research on cancer; calls for at least a 20% increase in the mobilisation of public and private research on therapeutic and diagnostic cancer innovations, covering all concerned patient populations;

Or. en

Amendment 1332
Loucas Fourlas

Motion for a resolution
Paragraph 99
99. Reiterates its call for sustainable and adequate funding for competitive European research on cancer; calls for at least a 20% increase in the mobilisation of public and private research on therapeutic and diagnostic cancer innovations;

Amendment 1333
Bronis Ropé

Motion for a resolution
Paragraph 99 a (new)

99a. Calls for measures to attract foreign direct investment to be reviewed and extended, with Member States being encouraged to attract life sciences companies to the EU market, thus consolidating the creation of a European market for medicines; considers that, in order to ensure the most effective access to treatments and medicines for patients, all possibilities should be explored to attract life sciences companies to EU Member States, particularly the Central and Eastern European Member States, where the availability of effective, innovative oncology medicines remains several times lower than in Western European countries; considers that, in order to encourage such companies to relocate their operations to the EU, Member States should be able to create additional state aid schemes and grant more state aid to companies in the life sciences and oncology sector and to pharmaceutical companies producing cancer drugs; considers that increased production of medicines in EU countries
will not only ensure that the medicines supply chain runs more smoothly, but will also contribute to the advancement, development and promotion of research in oncology;

Amendment 1334
Alexis Georgoulis

Motion for a resolution
Paragraph 99 b (new)

Motion for a resolution
Amendment

99b. Considers that research in cancer care should address questions relevant and meaningful for patients and public health and that such research should follow an independent process to support optimal access for patients to evidence-based multidisciplinary cancer treatment; highlights therefore the need for a reorientation of health systems and research approaches in cancer, in order to address gaps in clinical and health services research applied to cancer through a reverse engineering approach, starting with better definition of the important clinical and public health questions; underlines that the EU should lead this approach in health systems and treatment optimization taking under thorough consideration possible suggestions from the Civic Society;

Amendment 1335
Michèle Rivasi

Motion for a resolution
Paragraph 99 c (new)
99c. Considers that research in cancer care should address questions relevant and meaningful for patients and public health and that such research should follow an independent process to support optimal access for patients to evidence-based multidisciplinary cancer treatment; considers therefore that a reorientation of health systems and research approaches in cancer is needed, addressing gaps in clinical and health services research applied to cancer through a reverse engineering approach, starting with better definition of the important clinical and public health questions; calls on the Commission and Member States to lead this approach in health systems and treatment optimisation;

Amendment 1336
Peter Liese
on behalf of the EPP Group
Tomislav Sokol, Nathalie Colin-Oesterlé, Liudas Mažylis, Marian-Jean Marinescu, Maria Spyraki, Dolors Montserrat, Cindy Franssen, Adam Jarubas, Deirdre Clune, Sunčana Glavak, Bartosz Arłukowicz

Motion for a resolution
Paragraph 99 d (new)

99d. Recalls that researchers have to work together to find the best possible treatment especially for patients suffering from rare cancer, but that they are facing serious obstacles; calls therefore on the Commission to systematically look at all the obstacles in cross border research on cancer and to appoint a cross-border cancer research special envoy, directly reporting to the Commission President, who should also look at regulation
hindering cross-border cancer research and cooperation and actively apply the 'one in, one out' approach to remove obstacles and red tape that slow down cross border cancer research;

Amendment 1337
Nicolás González Casares, Maria Arena, Romana Jerković, Sara Cerdas, Patrizia Toia, Marc Angel, Johan Danielsson, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 99 e (new)

Motion for a resolution
Amendment

99e. Supports the recommendation by the Conquering Cancer Mission Board to establish a research programme tasked with identifying effective cancer prevention strategies and methods with regard to commercial determinants of health and exposure to occupational carcinogens\(^1\); supports the recommendation for the creation of a Policy Support Facility to enhance knowledge sharing and support the implementation of cancer-related prevention policies on EU, national and local level;

\(^1\) https://op.europa.eu/en/publication-detail/-/publication/b389aad3-fd56-11ea-b44f-01aa75ed71a1/

Amendment 1338
Peter Liese
on behalf of the EPP Group
Tomislav Sokol, Nathalie Colin-Oesterlé, Liudas Mažylis, Marian-Jean Marinescu, Maria Spyraki, Dolors Montserrat, Cindy Franssen, Adam Jarubas, Deirdre Clune, Sunčana Glavak, Bartosz Arłukowicz
Motion for a resolution
Paragraph 99 f (new)

Motion for a resolution  Amendment

99f. Calls for providing structural funding under Horizon Europe for the research agenda of the LifeTime project to develop a cell-based medicine approach to cancer prevention, early detection and treatment in order to understand why cancer is developing in cells and tissues and to treat it before the patient gets symptoms;

Or. en

Amendment 1339
Peter Liese
on behalf of the EPP Group
Tomislav Sokol, Nathalie Colin-Oesterlé, Liudas Mažylis, Marian-Jean Marinescu, Maria Spyraki, Dolors Montserrat, Cindy Franssen, Adam Jarubas, Deirdre Clune, Sunčana Glavak, Bartosz Arłukowicz

Motion for a resolution
Paragraph 99 g (new)

Motion for a resolution  Amendment

99g. Calls on Member States and the Commission to establish programmes to provide the necessary support for the recently consolidated European cell-based interceptive medicine community that will create and integrate breakthrough cellular and AI technologies to understand early events in cancer and therapy response and use this knowledge to improve patient outcomes; supports the creation of a platform for cell-based interceptive medicine to coordinate and establish synergies between research, innovation and multi-sectorial activities; stresses the need for investment in research and innovation approaches to create innovative cell-based early
detection and personalised treatment strategies for cancer;

Amendment 1340
Joëlle Mélin

Motion for a resolution
Paragraph 100

100. Stresses the need for independent and multidisciplinary research on cancer ‘from bench to bedside’, that is from the laboratory to applied studies in patients; **urges the establishment of measures to limit misinformation, especially on social media**;

Or. en

Amendment 1341
Margarita de la Pisa Carrión

Motion for a resolution
Paragraph 100

100. Stresses the need for independent and multidisciplinary research on cancer ‘from bench to bedside’, that is from the laboratory to applied studies in patients; **urges the establishment of measures to foster scientific information about cancer research**, especially on social media;

Or. en

Amendment 1342
Michèle Rivasi
Motion for a resolution  
Paragraph 100

100. Stresses the need for independent and multidisciplinary research on cancer ‘from bench to bedside’, that is from the laboratory to applied studies in patients; urges the establishment of measures to limit misinformation, especially on social media;

Amendment

100. Stresses the need for independent and multidisciplinary research on cancer ‘from bench to bedside’, that is from the laboratory to applied studies in patients; calls for the development of conditionalities related to affordability and accessibility of products resulting from publicly funded research; urges the establishment of measures to limit misinformation, especially on social media;

Or. en

Amendment 1343
Tudor Ciuhodaru

Motion for a resolution  
Paragraph 100

100. Stresses the need for independent and multidisciplinary research on cancer ‘from bench to bedside’, that is from the laboratory to applied studies in patients; urges the establishment of measures to limit misinformation, especially on social media;

Amendment

100. Stresses the need for independent and multidisciplinary research on cancer ‘from bench to bedside’, that is from the laboratory to applied studies in patients, but also for the rapid and regular re-evaluation of the efficacy of medicines already on the market and their adaptation to fresh innovations that occur after their market authorisation; urges the establishment of measures to limit misinformation, especially on social media;

Or. ro

Amendment 1344
Nicolás González Casares, María Arena, Romana Jerković, Čyrus Engerer, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis
Motion for a resolution
Paragraph 100

Motion for a resolution

100. Stresses the need for independent and multidisciplinary research on cancer ‘from bench to bedside’, that is from the laboratory to applied studies in patients; urges the establishment of measures to limit misinformation, especially on social media;

Amendment

100. Stresses the need for independent and multidisciplinary research on cancer ‘from bench to bedside’, that is from the laboratory to applied studies in patients; urges the establishment of measures to limit misinformation, especially on social media, with special attention to measures protecting children and young people, and to support science dissemination initiatives;

Or. en

Amendment 1345
Bartosz Arłukowicz

Motion for a resolution
Paragraph 100

Motion for a resolution

100. Stresses the need for independent and multidisciplinary research on cancer ‘from bench to bedside’, that is from the laboratory to applied studies in patients; urges the establishment of measures to limit misinformation, especially on social media;

Amendment

100. Stresses the need for independent and multidisciplinary research on cancer ‘from bench to bedside’, that is from the laboratory to applied studies in patients; urges the establishment of measures to limit misinformation, especially on social media; stresses the need for the results of this research to be made public in a transparent and simple way;

Or. pl

Amendment 1346
Hilde Vautmans, Irena Joveva

Motion for a resolution
Paragraph 100
100. Stresses the need for independent and multidisciplinary research on cancer ‘from bench to bedside’, that is from the laboratory to applied studies in patients; urges the establishment of measures to limit misinformation, especially on social media;

Amendment
100. Stresses the need for independent and multidisciplinary research on cancer ‘from bench to bedside’, that is from the laboratory to applied studies in patients; urges the establishment of measures to limit misinformation, especially on social media; requests specific measures to protect children and young people from disinformation;

Or. en

Amendment 1347
Pietro Fiocchi

Motion for a resolution
Paragraph 100

Motion for a resolution
100. Stresses the need for independent and multidisciplinary research on cancer ‘from bench to bedside’, that is from the laboratory to applied studies in patients; urges the establishment of measures to limit misinformation, especially on social media;

Amendment
100. Stresses the need for independent and multidisciplinary research on cancer ‘from bench to bedside’, that is from the laboratory to applied studies in patients; urges the establishment of measures to limit the health risks posed by disinformation and misinformation, especially on social media;

Or. en

Amendment 1348
Antoni Comín i Oliveres

Motion for a resolution
Paragraph 100

Motion for a resolution
100. Stresses the need for independent and multidisciplinary research on cancer ‘from bench to bedside’, that is from the laboratory to applied studies in patients; urges the establishment of measures to limit misinformation, especially on social media;

Amendment
100. Stresses the need for independent and multidisciplinary anticipatory and responsive research on cancer ‘from bench
laboratory to applied studies in patients; urges the establishment of measures to limit misinformation, especially on social media; to bedside’, that is from the laboratory to applied studies in patients; urges the establishment of measures to limit misinformation, especially on social media;

Amendment 1349
Michèle Rivasi

Motion for a resolution
Paragraph 100 a (new)

Motion for a resolution

Amendment

100a. Stresses the importance of investment into the development of non-animal new research methodologies, such as in silico and organoids, to shorten pre-clinical observation periods, increase efficiency in research and reduce unnecessary and often less reliable experiments on animals; underlines that non-animal methods for testing the carcinogenicity of environmental chemicals, such as testing strategies focused on the underlying biological mechanisms that lead to cancer, should provide more relevant information than the animal-based methods currently in use for chemical safety assessment thus enabling authorities to take swifter measures to limit exposure to harmful chemicals that could lead to cancer;

Amendment 1350
Alexis Georgoulis, João Pimenta Lopes, Giorgos Georgiou

Motion for a resolution
Paragraph 100 b (new)
Motion for a resolution

100b. Regrets that there are persons/agents monetizing cancer patients' despair and need for hope by offering them misleading information promising treatment and/or wellbeing with false or medically unapproved methods putting at risk patients' health and income; calls on the Commission and the Member States to strengthen their efforts in order to eliminate misinformation about cancer and especially about cancer treatment, as well as for mechanisms to monitor and control such persons/agents;

Or. en

Amendment 1351
Nicolás González Casares, Maria Arena, Romana Jerković, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 100 c (new)

Motion for a resolution

100c. Considers that adequate communication with patients should be a priority, giving them basic scientific and clinical knowledge so that they can make informed decisions on their treatments; calls on the Commission and the Member States to review the legislation related to homeopathy and other pseudotherapies that offer patients treatment options with no scientific evidence which could damage their health and their finances, and even hinder life-saving medical treatments;

Or. en
Amendment 1352
Bronis Ropė

Motion for a resolution
Paragraph 100 d (new)

Motion for a resolution

Amendment

100d. Believes that early phase clinical trials should be more widespread and accessible to as many patients as possible; calls, furthermore, for the promotion of investigator-initiated clinical trials, as investigators are best placed to help patients with serious cancers;

Or. lt

Amendment 1353
Michèle Rivasi

Motion for a resolution
Paragraph 101

Motion for a resolution

Amendment

101. Calls on Member States to make a strong commitment to encouraging public-private cooperation and breaking down the barriers to competitiveness across the EU;

101. Calls on Member States to make a strong commitment to encouraging public-private cooperation, driven by public health needs, and breaking down the barriers to competitiveness across the EU;

Or. en

Amendment 1354
Nicolás González Casares, María Arena, Romana Jerković, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 102

Motion for a resolution

Amendment

102. Considers the significant potential impact of the use of artificial intelligence

102. Considers the significant potential impact of the use of artificial intelligence
and modern technologies in diagnosis and decision-making for cancers in the coming years; encourages the Commission and the Member States to promote the knowledge of cancer biology through the implementation of genomics and informatics infrastructures;

and modern technologies in diagnosis and decision-making for cancers in the coming years; underlines that the combination of real-world data, mathematical modelling, artificial intelligence and digital tools will significantly help to develop innovative treatments in a more cost-efficient way, and reduce the use of animals in research and the need for patients involved in clinical trials; encourages the Commission and the Member States to promote the knowledge of cancer biology through the implementation of genomics and informatics infrastructures;

Amendment 1355
Adam Jarubas, Ewa Kopacz

Motion for a resolution
Paragraph 102

Motion for a resolution

102. Considers the significant potential impact of the use of artificial intelligence and modern technologies in diagnosis and decision-making for cancers in the coming years; encourages the Commission and the Member States to promote the knowledge of cancer biology through the implementation of genomics and informatics infrastructures;

Amendment

102. Considers the significant potential impact of the use of artificial intelligence, BIG DATA algorithmic analysis and other modern technologies in diagnosis and decision-making for cancers in the coming years and for the optimization of the use of healthcare systems resources, increasing efficiency and thus allowing for wider availability of oncological care services, also in less urbanized and remote areas; encourages the Commission and the Member States to promote the knowledge of cancer biology through the implementation of genomics and informatics infrastructures;

Or. en

Amendment 1356
Alexis Georgoulis
Motion for a resolution
Paragraph 102

102. Considers the significant potential impact of the use of artificial intelligence and modern technologies in diagnosis and decision-making for cancers in the coming years; encourages the Commission and the Member States to promote the knowledge of cancer biology through the implementation of genomics and informatics infrastructures;

Amendment

102. Considers the significant potential impact of the use of artificial intelligence and modern technologies in diagnosis and decision-making for cancers in the coming years; encourages the Commission and the Member States to promote the knowledge of cancer biology through the implementation of genomics and informatics infrastructures; **highlights the importance of certain principles to be safeguarded by all relevant agents including trust, transparency, patient centricity and patient involvement at all times;**

Or. en

Amendment 1357
Hilde Vautmans, Irena Joveva, Alin Mituța

Motion for a resolution
Paragraph 102

102. Considers the significant potential impact of the use of artificial intelligence and modern technologies in diagnosis and decision-making for cancers in the coming years; encourages the Commission and the Member States to promote the knowledge of cancer biology through the implementation of genomics and informatics infrastructures;

Amendment

102. Considers the significant potential impact of the use of artificial intelligence and modern technologies in diagnosis and decision-making for cancers in the coming years; encourages the Commission and the Member States to promote the knowledge of cancer biology through the implementation of genomics and informatics infrastructures; **urges all implementation partners to be ever mindful of the principles of trust, transparency, patient centricity and patient involvement at all times;**

Or. en
Amendment 1358
Tomislav Sokol, Sunčana Glavak, Cindy Franssen

Motion for a resolution
Paragraph 102

Motion for a resolution

102. Considers the significant potential impact of the use of artificial intelligence and modern technologies in diagnosis and decision-making for cancers in the coming years; encourages the Commission and the Member States to promote the knowledge of cancer biology through the implementation of genomics and informatics infrastructures;

Amendment

102. Considers the significant potential impact of the use of artificial intelligence and modern technologies in diagnosis and decision-making for cancers in the coming years; encourages the Commission and the Member States to promote the knowledge of cancer biology through the implementation of genomics and informatics infrastructures; **urges all implementation partners to be ever mindful of the principles of trust, transparency, patient centricity and patient involvement at all times;**

Or. en

Amendment 1359
Bartosz Arłukowicz

Motion for a resolution
Paragraph 102

Motion for a resolution

102. Considers the significant potential impact of the use of artificial intelligence and modern technologies in diagnosis and decision-making for cancers in the coming years; encourages the Commission and the Member States to promote the knowledge of cancer biology through the implementation of genomics and informatics infrastructures;

Amendment

102. Considers the significant potential impact of the use of artificial intelligence and modern technologies in diagnosis and decision-making for cancers in the coming years; encourages the Commission and the Member States to promote the knowledge of cancer biology through the implementation of genomics and informatics infrastructures; **draws attention, furthermore, to the need to increase the use of AI technologies in cancer diagnosis and treatment;**
Amendment 1360
Loucas Fourlas

Motion for a resolution
Paragraph 102

102. Considers the significant potential impact of the use of artificial intelligence and modern technologies in diagnosis and decision-making for cancers in the coming years; encourages the Commission and the Member States to promote the knowledge of cancer biology through the implementation of genomics and informatics infrastructures;

Amendment

102. Considers the significant potential impact of the use of artificial intelligence and modern technologies screening in diagnosis and decision-making for cancers in the coming years; encourages the Commission and the Member States to promote the knowledge of cancer biology through the implementation of radiomics, genomics and informatics infrastructures;

Amendment 1361
Dolors Montserrat, Aldo Patriciello, Juan Ignacio Zoido Álvarez, Herbert Dorfmann, Rosa Estaràs Ferragut, Francisco José Millán Mon, José Manuel García-Margallo y Marfil, Gabriel Mato, Esteban González Pons, Lídia Pereira, Pilar del Castillo Vera, Cindy Franssen, Antonio López-Istúriz White, Adrián Vázquez Lázara, Pablo Arias Echeverría, Javier Zarzalejos, Ewa Kopacz, Isabel Benjumea Benjumea

Motion for a resolution
Paragraph 102 a (new)

102a. Stresses the importance of supporting research in the development of integrative oncology based on scientific evidence in Europe; highlights that integrative oncology based on scientific evidence, by integrating complementary therapies in support of conventional treatments, has a beneficial impact on patients' quality of life, their ability to withstand and sustain long and difficult treatments and their overall survival;
Amendment 1362
Adam Jarubas, Ewa Kopacz

Motion for a resolution
Paragraph 102 b (new)

Motion for a resolution
102b. Supports the need for strong international research and innovation cooperation to share best practice in establishing science-based and risk-proportional regulatory standards and to facilitate knowledge sharing to ensure that the most advanced expertise and solutions are available for the benefit of European citizens;

Amendment

Amendment 1363
Nicolás González Casares, Maria Arena, Romana Jerković, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 102 c (new)

Motion for a resolution
102c. Highlights the crucial importance of clinical research and calls on the Member States to facilitate the conciliation of patient care with research and innovation initiatives, especially in smaller centres, reducing the workload and the ratio of patients per health professional;

Amendment
Amendment 1364
Ivars Ijabs, Alin Mituţa, Irena Joveva, Hilde Vautmans

Motion for a resolution
Paragraph 102 d (new)

102d. Encourages the Commission to conduct a study into the impact of GDPR for cancer research and care, and further efforts to harmonise GDPR implementation across the European Union, including adopting specific codes of conduct and certification schemes;

Amendment 1365
Margarita de la Pisa Carrión, Pietro Fiocchi

Motion for a resolution
Paragraph 102 e (new)

102e. Emphasises that oncological research and the research in, and use of, new oncological treatments should follow ethical principles that guarantee the right to life, dignity and the integrity of the person;

Amendment 1366
Tomislav Sokol, Sunčana Glavak, Deirdre Clune, Cindy Franssen

Motion for a resolution
Paragraph 103

103. Welcomes the launch of the Genomics for Public Health project which

103. Calls for research into the potential positive impact of artificial
will give secure access to large amounts of genomic data to be used in 4P medicine (preventive, predictive, personalised and participatory);
Processing, this methodology would make it possible to design and develop algorithms aimed at identifying different events that may occur throughout the evolution of cancer patients; notes that, through these predictive models, it would be possible to establish for each patient the probability of recurrence or death due to the disease or the probability of presenting serious toxicity secondary to treatment, so that the identification of such events would allow for early action to be taken;

Or. en

Amendment 1369
Joëlle Mélin

Motion for a resolution
Paragraph 104

104. Supports the creation of new digital resources and platforms, such as the European Cancer Imaging Initiative, and the strengthening of the European Cancer Information System, which will enable competent authorities to make good use of artificial intelligence applied to big data in the years to come;

104. Supports the creation of new digital resources and platforms, such as the European Cancer Imaging Initiative, and the strengthening of the European Cancer Information System, which will enable competent authorities to make good use of artificial intelligence applied to big data in the years to come and which should entail the collection of more data on the incidence of comorbidities, as a new indicator providing information on cancer; points out that health data must always be collected in strict compliance with the GDPR;

Or. fr

Amendment 1370
Peter Liese
on behalf of the EPP Group

Tomislav Sokol, Nathalie Colin-Oesterlé, Liudas Mažylis, Maria Spyraki, Dolors
Montserrat, Cindy Franssen, Adam Jarubas, Deirdre Clune, Sunčana Glavak, Bartosz Arłukowicz, Christian Sagartz

Motion for a resolution
Paragraph 104

104. Supports the creation of new digital resources and platforms, such as the European Cancer Imaging Initiative, and the strengthening of the European Cancer Information System, which will enable competent authorities to make good use of artificial intelligence applied to big data in the years to come;

Amendment

104. Supports the creation of new digital resources and platforms, such as the European Cancer Imaging Initiative, and the strengthening of the European Cancer Information System, which will enable competent authorities to make good use of artificial intelligence applied to big data in the years to come; *stresses the need for an equal and transparent access to the information included in these platforms*;

Or. en

Amendment 1371
Bartosz Arłukowicz

Motion for a resolution
Paragraph 104

104. Supports the creation of new digital resources and platforms, such as the European Cancer Imaging Initiative, and the strengthening of the European Cancer Information System, which will enable competent authorities to make good use of artificial intelligence applied to big data in the years to come;

Amendment

104. Supports the creation of new digital resources and platforms, such as the European Cancer Imaging Initiative, and the strengthening of the European Cancer Information System, which will enable competent authorities to make good use of artificial intelligence applied to big data in the years to come; *stresses the need to ensure equal and transparent access to information on these platforms*;

Or. pl

Amendment 1372
Michèle Rivasi
Motion for a resolution
Paragraph 105

Motion for a resolution

105. Welcomes the launch of the ‘Cancer Diagnostic and Treatment for All’ flagship initiative under Europe’s Beating Cancer Plan, whose aim is to improve access to innovative cancer diagnosis and treatment and promote the use of the ‘next generation sequencing’ technology for quick and efficient genetic profiles of tumour cells, allowing researchers and clinicians to share cancer profiles and apply the same or similar diagnostic and therapeutic approaches to patients with comparable cancer profiles;

Amendment

105. Welcomes the launch of the ‘Cancer Diagnostic and Treatment for All’ flagship initiative under Europe’s Beating Cancer Plan, whose aim is to improve access to innovative cancer diagnosis and treatment and promote the use of the ‘next generation sequencing’ technology for quick and efficient genetic profiles of tumour cells, allowing researchers and clinicians to share cancer profiles and apply the same or similar diagnostic and therapeutic approaches to patients with comparable cancer profiles;

stresses the need to consider personalised treatments based on well-designed clinical trials with proven added therapeutic value for patients;

Or. en

Amendment 1373
Margarita de la Pisa Carrión

Motion for a resolution
Paragraph 105

Motion for a resolution

105. Welcomes the launch of the ‘Cancer Diagnostic and Treatment for All’ flagship initiative under Europe’s Beating Cancer Plan, whose aim is to improve access to innovative cancer diagnosis and treatment and promote the use of the ‘next generation sequencing’ technology for quick and efficient genetic profiles of tumour cells, allowing researchers and clinicians to share cancer profiles and apply the same or similar diagnostic and therapeutic approaches to patients with comparable cancer profiles;

Amendment

105. Welcomes the launch of the ‘Cancer Diagnostic and Treatment for All’ flagship initiative under Europe’s Beating Cancer Plan, whose aim is to improve access to innovative cancer diagnosis and treatment, as well as comprehensive professional care for patients and their families, and promote the use of the ‘next generation sequencing’ technology for quick and efficient genetic profiles of tumour cells, allowing researchers and clinicians to share cancer profiles and apply the same or similar diagnostic and therapeutic approaches to patients with comparable cancer profiles;
Welcomes the launch of the ‘Cancer Diagnostic and Treatment for All’ flagship initiative under Europe’s Beating Cancer Plan, whose aim is to improve access to innovative cancer diagnosis and treatment and promote the use of the ‘next generation sequencing’ technology for quick and efficient genetic profiles of tumour cells, allowing researchers and clinicians to share cancer profiles and apply the same or similar diagnostic and therapeutic approaches to patients with comparable cancer profiles;

Or. en

Amendment 1374
Joëlle Mélin

Motion for a resolution
Paragraph 105

105. Welcomes the launch of the ‘Cancer Diagnostic and Treatment for All’ flagship initiative under Europe’s Beating Cancer Plan, whose aim is to improve access to innovative cancer diagnosis and treatment and promote the use of the ‘next generation sequencing’ technology for quick and efficient genetic profiles of tumour cells, allowing researchers and clinicians to share cancer profiles and apply the same or similar diagnostic and therapeutic approaches to patients with comparable cancer profiles;

Or. fr

Amendment 1375
Michèle Rivasi

Motion for a resolution
Paragraph 106

106. Welcomes the planned Partnership for Personalised Medicine, announced in Europe’s Beating Cancer Plan and to be funded under Horizon Europe, which will identify priorities for research and education in personalised medicine, support research projects on cancer prevention, diagnosis and treatment, and make recommendations for the roll-out of comparable cancer profiles;

Or. en

106. Takes note of the launch of the ‘Cancer Diagnostic and Treatment for All’ flagship initiative under Europe’s Beating Cancer Plan, whose aim is to improve access to innovative cancer diagnosis and treatment and promote the use of the ‘next generation sequencing’ technology for quick and efficient genetic profiles of tumour cells, allowing researchers and clinicians to share cancer profiles and apply the same or similar diagnostic and therapeutic approaches to patients with comparable cancer profiles;

Or. fr

106. Welcomes the planned Partnership for Personalised Medicine, announced in Europe’s Beating Cancer Plan and to be funded under Horizon Europe, which will identify priorities for research and education in personalised medicine, support research projects on cancer prevention, diagnosis and treatment, and make recommendations for the roll-out of comparable cancer profiles;
personalised medicine approaches in daily medical practice; supports the establishment of a roadmap for personalised prevention allowing for the identification of gaps in research and innovation and for the mapping of all known biological anomalies leading to cancer susceptibility, including hereditary factors;

personalised medicine approaches in daily medical practice; stresses the need to establish a well-defined, globally consistent terminology for ‘personalised medicines’ that would streamline investment in research and benefit patients’ health literacy; supports the establishment of a roadmap for personalised prevention allowing for the identification of gaps in research and innovation and for the mapping of all known biological anomalies leading to cancer susceptibility, including hereditary factors;

Amendment 1376
Bartosz Arłukowicz

Motion for a resolution
Paragraph 106

Motion for a resolution

106. Welcomes the planned Partnership for Personalised Medicine, announced in Europe’s Beating Cancer Plan and to be funded under Horizon Europe, which will identify priorities for research and education in personalised medicine, support research projects on cancer prevention, diagnosis and treatment, and make recommendations for the roll-out of personalised medicine approaches in daily medical practice; supports the establishment of a roadmap for personalised prevention allowing for the identification of gaps in research and innovation and for the mapping of all known biological anomalies leading to cancer susceptibility, including hereditary factors;

Amendment

106. Welcomes the planned Partnership for Personalised Medicine, announced in Europe’s Beating Cancer Plan and to be funded under Horizon Europe, which will identify priorities for research and education in personalised medicine, support research projects on cancer prevention, diagnosis and treatment, and make recommendations for the roll-out of personalised medicine approaches in daily medical practice; supports the establishment of a roadmap for personalised prevention allowing for the identification of gaps in research and innovation and for the mapping of all known biological anomalies leading to cancer susceptibility, including hereditary factors; supports making these solutions accessible through public healthcare systems;
Amendment 1377
Hilde Vautmans, Irena Joveva

Motion for a resolution
Paragraph 106

106. Welcomes the planned Partnership for Personalised Medicine, announced in Europe’s Beating Cancer Plan and to be funded under Horizon Europe, which will identify priorities for research and education in personalised medicine, support research projects on cancer prevention, diagnosis and treatment, and make recommendations for the roll-out of personalised medicine approaches in daily medical practice; supports the establishment of a roadmap for personalised prevention allowing for the identification of gaps in research and innovation and for the mapping of all known biological anomalies leading to cancer susceptibility, including hereditary factors;

Amendment

106. Welcomes the planned Partnership for Personalised Medicine, announced in Europe’s Beating Cancer Plan and to be funded under Horizon Europe, which will identify priorities for research and education in personalised medicine, support research projects on cancer prevention, diagnosis and treatment, including in paediatrics, and make recommendations for the roll-out of personalised medicine approaches in daily medical practice; supports the establishment of a roadmap for personalised prevention allowing for the identification of gaps in research and innovation and for the mapping of all known biological anomalies leading to cancer susceptibility, including hereditary factors and paediatric issues;

Amendment 1378
Nicolás González Casares, Maria Arena, Romana Jerković, Cyrus Engerer, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 106

106. Welcomes the planned Partnership for Personalised Medicine, announced in Europe’s Beating Cancer Plan and to be funded under Horizon Europe, which will

Amendment

106. Welcomes the planned Partnership for Personalised Medicine, announced in Europe’s Beating Cancer Plan and to be funded under Horizon Europe, which will
identify priorities for research and education in personalised medicine, support research projects on cancer prevention, diagnosis and treatment, and make recommendations for the roll-out of personalised medicine approaches in daily medical practice; supports the establishment of a roadmap for personalised prevention allowing for the identification of gaps in research and innovation and for the mapping of all known biological anomalies leading to cancer susceptibility, including hereditary factors;

identify priorities for research and education in personalised medicine, support research projects on cancer prevention, diagnosis and treatment, also in paediatrics, and make recommendations for the roll-out of personalised medicine approaches in daily medical practice; supports the establishment of a roadmap for personalised prevention allowing for the identification of gaps in research and innovation and for the mapping of all known biological anomalies leading to cancer susceptibility, including hereditary and environmental factors;

Amendment 1379
Joëlle Mélin

Motion for a resolution
Paragraph 106

106. **Welcomes** the planned Partnership for Personalised Medicine, announced in Europe’s Beating Cancer Plan and to be funded under Horizon Europe, which will identify priorities for research and education in personalised medicine, support research projects on cancer prevention, diagnosis and treatment, and make recommendations for the roll-out of personalised medicine approaches in daily medical practice; supports the establishment of a roadmap for personalised prevention allowing for the identification of gaps in research and innovation and for the mapping of all known biological anomalies leading to cancer susceptibility, including hereditary factors;
Amendment 1380
Joëlle Mélin

Motion for a resolution
Paragraph 107

107. Encourages research on non-profit clinical trials to improve treatment strategies, with a focus on the elderly; deleted

Amendment

Amendment 1381
Michèle Rivasi

Motion for a resolution
Paragraph 107

107. Encourages research on non-profit clinical trials to improve treatment strategies, with a focus on the elderly; Calls for enhanced capacity building, infrastructure, collaboration and funding of research on non-profit clinical trials to improve treatment strategies, with a focus on vulnerable and under-represented patient populations, including women, children and the elderly;

Amendment

Amendment 1382
Hilde Vautmans, Irena Joveva

Motion for a resolution
Paragraph 107

107. Encourages research on non-profit clinical trials to improve treatment strategies, with a focus on the elderly; Encourages research on non-profit clinical trials to improve treatment strategies, with a focus on the elderly and children;
Amendment 1383
Alexis Georgoulis

Motion for a resolution
Paragraph 107

Motion for a resolution
Amendment

107. Encourages research on non-profit clinical trials to improve treatment strategies, with a focus on the elderly;

Or. en

Amendment 1384
Peter Liese
on behalf of the EPP Group
Tomislav Sokol, Nathalie Colin-Oesterlé, Liudas Mažylis, Marian-Jean Marinescu, Maria Spyraki, Dolors Montserrat, Cindy Franssen, Adam Jarubas, Deirdre Clune, Sunčana Glavak, Bartosz Arłukowicz

Motion for a resolution
Paragraph 107

Motion for a resolution
Amendment

107. Encourages research on non-profit clinical trials to improve treatment strategies, with a focus on the elderly; urges for EU support for the health system and treatment optimization agenda;

Or. en

Amendment 1385
Loucas Fourlas

AM\1239642EN.docx 111/190
107. Encourages research on non-profit clinical trials to improve treatment strategies, with a focus on the elderly; and long-term survivors after successful cancer treatment;
Amendment 1388
Alessandra Moretti

Motion for a resolution
Paragraph 107 a (new)

Motion for a resolution

107a. Stresses the need to support academic research and non-commercial clinical trials aimed at optimising available cancer treatments through Europe’s Beating Cancer Plan, including those areas where there is a lack of commercial feasibility in supporting research; underlines the need to support clinical studies in the cancer domain through the Horizon Europe Mission on Cancer; supports the European Medicines Agency (EMA) in increasing its collaboration with academia to jointly discuss new scientific advances, knowledge, and potentially create solutions addressing the challenges within the field of innovation;

Or. en

Amendment 1389
Nicolás González Casares, Maria Arena, Romana Jerković, Cyrus Engerer, Sara Cerdas, Patrizia Toia, Marc Angel, Johan Danielsson, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 108

Motion for a resolution

108. Calls on the Commission and the Member States to promote studies dedicated to human and social sciences, in particular those addressing health inequalities at the different stages of cancer diseases;

Amendment

108. Calls on the Commission and the Member States to promote studies dedicated to human and social sciences, in particular those addressing health inequalities at the different stages of cancer diseases, including attention to inequalities in cancer care related to such factors as gender, age and socio-economic status, including marginalised groups in society, as well as studies related to
supportive care, including cancer nutrition, psychological services and social assistance;

Amendment 1390
Alexis Georgoulis, Giorgos Georgiou

Motion for a resolution
Paragraph 108

108. Calls on the Commission and the Member States to promote studies dedicated to human and social sciences, in particular those addressing health inequalities at the different stages of cancer diseases;

Amendment

108. Calls on the Commission and the Member States to promote studies dedicated to human and social sciences, in particular those addressing health inequalities at the different stages of cancer diseases; stresses that this should include attention to inequalities in cancer care related to such factors as gender, age, and socio-economic status, including marginalised and vulnerable groups of society;

Amendment 1391
Hilde Vautmans, Irena Joveva

Motion for a resolution
Paragraph 108

108. Calls on the Commission and the Member States to promote studies dedicated to human and social sciences, in particular those addressing health inequalities at the different stages of cancer diseases;

Amendment

108. Calls on the Commission and the Member States to promote studies dedicated to human and social sciences, in particular those addressing health inequalities at the different stages of cancer diseases; stresses that this should include attention to inequalities in cancer care related to such factors as gender, age, and socio-economic status, including
marginalised groups in society;

Amendment 1392
Tomislav Sokol, Sunčana Glavak, Cindy Franssen

Motion for a resolution
Paragraph 108

Motion for a resolution
Amendment

108. Calls on the Commission and the Member States to promote studies dedicated to human and social sciences, in particular those addressing health inequalities at the different stages of cancer diseases;

108. Calls on the Commission and the Member States to promote studies dedicated to human and social sciences, in particular those addressing health inequalities at the different stages of cancer diseases; stresses that this should include attention to inequalities in cancer care related to such factors as gender, age, and socio-economic status, including marginalised groups in society;

Amendment 1393
Michèle Rivasi

Motion for a resolution
Paragraph 108

Motion for a resolution
Amendment

108. Calls on the Commission and the Member States to promote studies dedicated to human and social sciences, in particular those addressing health inequalities at the different stages of cancer diseases;

108. Calls on the Commission and the Member States to promote studies dedicated to human and social sciences, in particular those addressing health inequalities at the different stages of cancer diseases; calls for attention to inequalities in cancer care related to factors such as gender, age, and socio-economic status, with particular attention to marginalised groups in society;
Amendment 1394
Bartosz Arłukowicz

Motion for a resolution
Paragraph 108

108. Calls on the Commission and the Member States to promote studies dedicated to human and social sciences, in particular those addressing health inequalities at the different stages of cancer diseases; as well as studies on optimising the financing of services and the organisation of their delivery;

Or. pl

Amendment 1395
Nicolás González Casares, Maria Arena, Romana Jerković, Cyrus Engerer, Sara Cerdas, Marc Angel, Johan Danielsson, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 108 a (new)

108a. Notes the lack of reliable and comparable EU-level data on workplace exposure to cancer risk factors and encourages European initiatives, covering all Member States, to systematically collect data on occupational exposure to carcinogens;

Or. en

Amendment 1396
Michèle Rivasi

Motion for a resolution
Paragraph 109
Motion for a resolution

109. **Considers that** the Commission and the Member States ***should*** support the development of European multicentre clinical trials;

Amendment

109. **Calls on** the Commission and the Member States ***to*** support the development of European multicentre clinical trials; **points out that using lessons learnt from the RECOVERY platform trial for COVID-19 vaccine would have made better use of scarce resources in order to enable effective international collaboration on trials;***

Or. en

Amendment 1397
Alexis Georgoulis

**Motion for a resolution**
**Paragraph 109**

Motion for a resolution

109. Considers that the Commission and the Member States ***should*** support the development of European multicentre clinical trials;

Amendment

109. Considers that the Commission and the Member States ***should*** support the development of European multicentre clinical trials; **highlights the need for all EU cancer policy initiatives to be coordinated towards defined and shared aims; recommends that support for multinational translational, clinical and outcomes-based research be considered an important element of the EU Network of Comprehensive Cancer Centres;***

Or. en

Amendment 1398
Peter Liese
on behalf of the EPP Group
Tomislav Sokol, Nathalie Colin-Oesterlé, Liudas Mažylis, Marian-Jean Marinescu, Maria Spyraki, DolorsMontserrat, Cindy Franssen, Adam Jarubas, Deirdre Clune, Sunčana Glavak, Bartosz Arlukowicz
Motion for a resolution
Paragraph 109

109. Considers that the Commission and the Member States should support the development of European multicentre clinical trials;

Amendment

109. Considers that the Commission and the Member States should support the development of European multicentre clinical trials and to strengthen multi-national cooperation and the conduct of cross-border clinical trials, building on existing structures where appropriate such as the European Clinical Research Council in the paediatric cancer sector;

Or. en

Amendment 1399
Nicolás González Casares, Maria Arena, Romana Jerković, Cyrus Engerer, Sara Cerdas, Marc Angel, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 109

109. Considers that the Commission and the Member States should support the development of European multicentre clinical trials;

Amendment

109. Considers that the Commission and the Member States should support the development of European multicentre clinical trials, especially in the case of low incidence cancers and/or cancers with reduced treatment options;

Or. en

Amendment 1400
Loucas Fourlas

Motion for a resolution
Paragraph 109

109. Considers that the Commission and the Member States should support the

Amendment

109. Considers that the Commission and the Member States should support the
development of European multicentre clinical trials; and encourage the engagement of smaller countries;

Amendment 1401
Joëlle Mélin

Motion for a resolution
Paragraph 109

109. Considers that the Commission and the Member States should support the development of European multicentre clinical trials on issues of general scientific interest;

Amendment 1402
Margarita de la Pisa Carrión

Motion for a resolution
Paragraph 110 a (new)

110a. Supports the funding of pre-clinical research, in order to provide a deeper understanding on causes of different types of cancers and with this knowledge to design potential new treatments and/or to find preventive solutions;

Amendment 1403
Hilde Vautmans, Irena Joveva
Motion for a resolution
Paragraph 111

111. Strongly believes that patient associations should be involved in defining research endpoints for clinical trials, in order to ensure that the trials address the unmet needs of European patients; considers that the final results of the trials should be communicated to the participating patients and to the public;

Amendment

111. Strongly believes that patient associations should be involved in defining research endpoints for clinical trials, in order to ensure that the trials address the unmet needs of European patients; considers that the final results of the trials should be communicated to the participating patients and to the public; stresses that paediatric patients should be involved in the definition of unmet needs, and can provide input in the design of the protocol, improve communication with the target population and enhance methods for dissemination of findings;

Amendment 1404
Nicolás González Casares, Maria Arena, Romana Jerković, Cyrus Engerer, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 111

111. Strongly believes that patient associations should be involved in defining research endpoints for clinical trials, in order to ensure that the trials address the unmet needs of European patients; considers that the final results of the trials should be communicated to the participating patients and to the public;

Or. en

111. Strongly believes that patient associations should be involved in defining research endpoints for clinical trials, in order to ensure that the trials address the unmet needs of European patients; considers that the final results of the trials should be communicated to the participating patients and to the public; calls for paediatric patients to be involved in the definition of unmet needs to provide input in the design of the clinical trials protocol and to improve communication with the target population;

Or. en
Amendment 1405
Alexis Georgoulis

Motion for a resolution
Paragraph 111

Motion for a resolution

111. Strongly believes that patient associations should be involved in defining research endpoints for clinical trials, in order to ensure that the trials address the unmet needs of European patients; considers that the final results of the trials should be communicated to the participating patients and to the public;

Amendment

111. Strongly believes that patient associations should be involved in defining research endpoints for clinical trials, in order to ensure that the trials address the unmet needs of European patients; considers that the final results of the trials should be communicated to the participating patients and to the public; stresses that the extent to which transparency provisions within the Clinical Trials Regulation 536/2014 are being met, should be kept under surveillance, and therefore regularly reported on;

Or. en

Amendment 1406
Peter Liese
on behalf of the EPP Group
Tomislav Sokol, Nathalie Colin-Oesterlé, Liudas Mažylis, Marian-Jean Marinescu, Maria Spyraki, Dolors Montserrat, Cindy Franssen, Adam Jarubas, Deirdre Clune, Sunčana Glavak, Bartosz Arłukowicz

Motion for a resolution
Paragraph 111

Motion for a resolution

111. Strongly believes that patient associations should be involved in defining research endpoints for clinical trials, in order to ensure that the trials address the unmet needs of European patients; considers that the final results of the trials should be communicated to the participating patients and to the public;

Amendment

111. Strongly believes that patient associations should be involved in defining research endpoints for clinical trials, in order to ensure that the trials address the unmet and quality of life needs of European patients; calls for increased support for therapy optimization clinical trials with improvement of quality of life
as primary endpoint; considers that the final results of the trials should be communicated to the participating patients and to the public;

Amendment 1407
Michèle Rivasi

Motion for a resolution
Paragraph 111

Motion for a resolution

111. Strongly believes that patient associations should be involved in defining research endpoints for clinical trials, in order to ensure that the trials address the unmet needs of European patients; considers that the final results of the trials should be communicated to the participating patients and to the public;

Amendment

111. **Strongly believes that patients and patient associations, including parents and carers, should be involved in defining research priorities and endpoints for clinical trials, in order to ensure that the trials address the unmet needs of European patients; considers that the final results of the trials should be communicated to the participating patients and to the public;**

Amendment 1408
Bartosz Arłukowicz

Motion for a resolution
Paragraph 112

Motion for a resolution

112. Advocates more transparency in the process of research into and the development of cancer treatments, including the establishment of a portal to allow patients access to information on the available clinical trials in Europe;

Amendment

112. **Advocates more transparency in the process of research into and the development of cancer treatments, including the establishment of a portal to allow patients access to information on the available clinical trials in Europe, and transparency on access to, and the use of, these data at Union level;**
Amendment 1409
Giorgos Georgiou, Kateřina Konečná, Alexis Georgoulis, João Pimenta Lopes

Motion for a resolution
Paragraph 112

112. Advocates more transparency in the process of research into and the development of cancer treatments, including the establishment of a portal to allow patients access to information on the available clinical trials in Europe;

Amendment

112. Advocates more robust scrutiny of clinical trials, more transparency in the process of research into and the development of cancer treatments, including the establishment of a portal to allow patients access to information on the available clinical trials in Europe; calls for transparency on the data of clinical trials, including those that have been discarded;

Or. en

Amendment 1410
Loucas Fourlas

Motion for a resolution
Paragraph 112

112. Advocates more transparency in the process of research into and the development of cancer treatments, including the establishment of a portal to allow patients access to information on the available clinical trials in Europe;

Amendment

112. Advocates more transparency in the process of research into and the development of cancer treatments, including the establishment of a portal to allow patients access to information on the available clinical trials in Europe; calls for transparency on the data of clinical trials, including those that have been discarded;

Or. en

Amendment 1411
Michèle Rivasi
Motion for a resolution
Paragraph 112

112. Advocates more transparency in the process of research into and the development of cancer treatments, including the establishment of a portal to allow patients access to information on the available clinical trials in Europe; underlines that this should also include information tailored to children and young patients;

Amendment

Amendment 1412
Hilde Vautmans, Irena Joveva

Motion for a resolution
Paragraph 112

112. Advocates more transparency in the process of research into and the development of cancer treatments, including the establishment of a portal to allow patients access to information on the available clinical trials in Europe; calls for transparency on the data of clinical trials, including those that have been discarded;

Or. en

Amendment 1413
Antoni Comín i Oliveres

Motion for a resolution
Paragraph 112

112. Advocates more transparency in the process of research into and the development of cancer treatments, including the establishment of a portal to allow patients access to information on the available clinical trials in Europe;
process of research into and the development of cancer treatments, including the establishment of a portal to allow patients access to information on the available clinical trials in Europe; process of *anticipatory and responsive* research into and the development of cancer treatments, including the establishment of a portal to allow patients access to information on the available clinical trials in Europe;

Amendment 1414
Pietro Fiocchi

**Motion for a resolution**
**Paragraph 112**

112. Advocates more transparency in the **process of research into and the** development of cancer treatments, including the establishment of a portal to allow patients access to information on the available clinical trials in Europe;

Amendment

112. Advocates more transparency in the research and development of cancer treatments, including the establishment of a portal to allow patients access to information on the available clinical trials in Europe;

Amendment 1415
Alexis Georgoulis

**Motion for a resolution**
**Paragraph 112 a (new)**

112a. **Recommends that research be a parameter of the Cancer Inequalities Registry in order to measure and monitor inequalities in respect to access to clinical trials as well as to better understand and respond to regional and national disparities in trial activity, and to track improvement from initiatives to be taken up via Europe’s Beating Cancer Plan, such as the EU Network of Comprehensive Cancer Centres; strongly**
suggests that research should be considered as an indispensable part of the axes of prevention, early detection and diagnosis, treatment and care, survivorship and follow up;

Or. en

Amendment 1416
Kateřina Konečná, Alexis Georgoulis

Motion for a resolution
Paragraph 112 b (new)

112b. Recommends that research be a parameter of the Cancer Inequalities Registry in order to measure and monitor inequalities in respect to access to clinical trials as well as to better understand and respond to regional and national disparities in trial activity, and to track improvement from initiatives to be taken up via Europe’s Beating Cancer Plan such as the EU Network of Comprehensive Cancer Centres;

Or. en

Amendment 1417
Hilde Vautmans, Irena Joveva

Motion for a resolution
Paragraph 112 b (new)

112b. Recommends that research be a parameter of the Cancer Inequalities Registry in order to measure and monitor inequalities in respect to access to clinical trials as well as to better understand and respond to regional and national disparities in trial activity, and to track improvement from initiatives to be taken up via Europe’s Beating Cancer Plan such as the EU Network of Comprehensive Cancer Centres;
improvement from initiatives to be taken up via Europe’s Beating Cancer Plan, such as the EU Network of Comprehensive Cancer Centres;

Amendment 1418
Hilde Vautmans, Irena Joveva

Motion for a resolution
Paragraph 112 c (new)

Motion for a resolution
Amendment

112c. Underscores that all the actions listed in the present section B.I. of this resolution should consider children, their best interests and variability, guaranteeing that children and young people with cancer are not excluded from major improvements brought by the proposed European plans and actions;

Amendment 1419
Nicolás González Casares, Alessandra Moretti, Maria Arena, Romana Jerković, Cyrus Engerer, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 112 d (new)

Motion for a resolution
Amendment

112d. Highlights that gender-associated differences in cancer research should be taken into consideration, both at preclinical and clinical stages, to describe differences in the physiopathology of the disease and related comorbidities and in drug pharmacokinetics/pharmacodynamics, among others;
Amendment 1420
Alexis Georgoulis

Motion for a resolution
Paragraph 112 e (new)

112e. Applauds the 2021 Porto Declaration on Cancer Research that highlights opportunities for a comprehensive translational cancer research approach with the potential to achieve a 10 year cancer specific survival for 75% of patients diagnosed in 2030 in the EU Member States with a well-developed healthcare system; urges the Commission for active involvement and a leading role towards the achievement of this goal;

Amendment 1421
Peter Liese
on behalf of the EPP Group
Tomislav Sokol, Nathalie Colin-Oesterlé, Liudas Mažylis, Marian-Jean Marinescu, Maria Spyraki, Dolors Montserrat, Cindy Franssen, Adam Jarubas, Deirdre Clune, Sunčana Glavak, Bartosz Arlukowicz

Motion for a resolution
Paragraph 113

113. Considers that the sharing of expertise, data, training programmes and communication tools is needed to improve the knowledge of cancer among both health professionals and patients; stresses the sensitive nature of health data and calls for *full compliance with* Regulation (EU) 2016/679 of 27 April 2016 on the
learning tools to research, and to enabling the digital transformation of healthcare, to tackle disparities in cancer prevention, diagnosis, and treatment around Europe; calls for a prudent implementation of Regulation (EU) 2016/679 of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data (General Data Protection Regulation)\(^ {36} \) to avoid unnecessary restrictions for cross-border healthcare; calls therefore on the Commission to make concrete proposals by the end of the year to address this problem through appropriate guidelines or other non-legislative measures, and should these fail to be effective, to propose a revision of the GDPR;

\(^ {36} \) OJ L 119, 4.5.2016, p. 1.

Or. en

Amendment 1422
Tomislav Sokol, Sunčana Glavak

Motion for a resolution
Paragraph 113

113. Considers that the sharing of expertise, data, training programmes and communication tools is needed to improve the knowledge of cancer among both health professionals and patients; stresses the sensitive nature of health data and calls for full compliance with Regulation (EU) 2016/679 of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data (General Data Protection Regulation)\(^ {36} \);
113. Considers that the sharing of expertise, data, training programmes and communication tools is needed to improve the knowledge of cancer among both health professionals and patients; stresses the sensitive nature of health data and calls for full compliance with Regulation (EU) 2016/679 of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data (General Data Protection Regulation36); calls for a harmonised approach to the collection of data on the incidence of cancer-related comorbidities and for this collection to be systematic;

113. Considers that the sharing of expertise, data, training programmes and communication tools is needed to improve the knowledge of cancer among both health professionals and patients; stresses the sensitive nature of health data and calls for full compliance with Regulation (EU) 2016/679 of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data (General Data Protection Regulation)\(^\text{36}\);
Amendment 1426
Margarita de la Pisa Carrión

Motion for a resolution
Paragraph 113 b (new)

Motion for a resolution

113b. Underlines the need for better communication among the interested parties: health professionals, patients and their families, government bodies, research groups and industry; calls for cooperation and communication among health professionals, patients and their families, experts, scientists, associations, industry and all interested parties with a view to exchanging views and information in order to achieve the objectives laid down in Europe's Beating Cancer Plan;

Or. en

Amendment 1427
Adam Jarubas, Ewa Kopacz

Motion for a resolution
Paragraph 113 c (new)

Motion for a resolution

113c. Calls on the Commission and Member States to boost education of coding and other relevant competences, especially in the underdeveloped regions of Member States, to prepare the workforce to future challenges connected with AI sector in biomedicine and especially cancer treatments; calls on the Member States to align education of health professionals to developments in AI, and to raise awareness of the potential, risks and ethical challenges associated with AI;

Or. en
Amendment 1428
Michèle Rivasi

Motion for a resolution
Paragraph 114

Motion for a resolution

114. Asks the Commission to assess the functioning of the European Reference Networks (ERNs), especially their role in gathering and sharing expertise and best practices, thus rationalising patient referral in the management of rare cancers, which affect an estimated 5.1 million patients across Europe and require cooperation on a large scale;

Amendment

deleted

Or. en

Amendment 1429
Giorgos Georgiou, Kateřina Konečná, Alexis Georgoulis

Motion for a resolution
Paragraph 114

Motion for a resolution

114. Asks the Commission to assess the functioning of the European Reference Networks (ERNs), especially their role in gathering and sharing expertise and best practices, thus rationalising patient referral in the management of rare cancers, which affect an estimated 5.1 million patients across Europe and require cooperation on a large scale;

Amendment

emphasises the importance of the ERNs with regard to overcoming health inequalities and ensuring safer and high-quality treatment across EU borders;

Or. en
Amendment 1430
Peter Liese
on behalf of the EPP Group
Tomislav Sokol, Nathalie Colin-Oesterlé, Liudas Mažylis, Marian-Jean Marinescu, Maria Spyrraki, Dolors Montserrat, Cindy Franssen, Adam Jarubas, Deirdre Clune, Sunčana Glavak, Bartosz Arłukowicz

Motion for a resolution
Paragraph 114

114. Asks the Commission to assess the functioning of the European Reference Networks (ERNs), especially their role in gathering and sharing expertise and best practices, thus rationalising patient referral in the management of rare cancers, which affect an estimated 5.1 million patients across Europe and require cooperation on a large scale; emphasizes the importance of the ERNs with regard to overcoming health inequalities and ensuring safer and high-quality treatment across EU borders;

Amendment 1431
Nicolae Ștefănuță, Alin Mituța, Ivars Ijabs, Vlad Gheorghe

Motion for a resolution
Paragraph 114

114. Asks the Commission to assess the functioning of the European Reference Networks (ERNs), especially their role in gathering and sharing expertise and best practices, thus rationalising patient referral in the management of rare cancers, which affect an estimated 5.1 million patients across Europe and require cooperation on a large scale; emphasizes the importance of the ERNs with regard to overcoming health inequalities and ensuring safer and high-quality treatment across EU borders;
114. Asks the Commission to assess the functioning of the European Reference Networks (ERNs), especially their role in gathering and sharing expertise and best practices, thus rationalising patient referral in the management of rare cancers, which affect an estimated 5.1 million patients across Europe and require cooperation on a large scale; encourages support for digital infrastructure that simplifies and facilitates access to the European Reference Networks (ERNs);
cybersecurity system;

Amendment 1434
Bronis Ropė

Motion for a resolution
Paragraph 114 a (new)

114a. Considers that, by promoting the initiative to develop a European Reference Network (ERN) and seeking to improve their performance, with a particular focus on rare cancers, national centres of excellence for rare cancers could become part of a unified EU structure – a European reference centre for rare tumours – that would allow for the free movement of patients, medicines and professionals, and the sharing of clinical data and expertise;

Amendment 1435
Kateřina Konečná, Alexis Georgoulis

Motion for a resolution
Paragraph 114 a (new)

114a. Stresses the need to guarantee funding for the continued functioning of European Reference Networks (ERNs), through the EU4Health Programme, the European Semester programme, Structural Funds, and through Article 195 of the Financial Regulation;
Amendment 1436
Kateřina Konečná, Alexis Georgoulis, João Pimenta Lopes, Giorgos Georgiou

Motion for a resolution
Paragraph 114 b (new)

Motion for a resolution
Amendment

114b. Calls for the consolidation and expansion to rare and complex cancers, of the four existing ERNs relevant to rare cancers, PaedCan (paediatric cancers), EURACAN (rare adult solid cancers), EuroBloodNet (rare haematological diseases including rare haematological malignancies) and GENTURIS (genetic tumour risk syndromes) in conjunction with the rare cancer patient organisations;

Or. en

Amendment 1437
Peter Liese
on behalf of the EPP Group
Tomislav Sokol, Nathalie Colin-Oesterlé, Liudas Mažylis, Marian-Jean Marinescu, Maria Spyraki, Dolors Montserrat, Cindy Franssen, Adam Jarubas, Deirdre Clune, Sunčana Glavak, Bartosz Arłukowicz

Motion for a resolution
Paragraph 115

Motion for a resolution
Amendment

115. **Emphasises the need to secure sustained long-term funding for the ERNs**; supports the expansion of the ERNs to specific types of cancer (rare, complex, poorly curable) and paediatric cancers;

115. Supports the expansion of the ERNs to specific types of cancer (rare, complex, poorly curable); **calls on the Commission and the Member States to ensure that the European Reference Networks receive appropriate support including sustainable funding and integration into national health systems so as to be able to fulfil their important potential for patients with rare and complex diseases including paediatric
Amendment 1438
Michèle Rivasi

Motion for a resolution
Paragraph 115

115. Emphasises the need to secure sustained long-term funding for the ERNs; supports the expansion of the ERNs to specific types of cancer (rare, complex, poorly curable) and paediatric cancers;

115. Recognises that the rare adult and paediatric cancer sector is based on long-term cooperation and established cross-border structures uniting national haematology units and clinical trial groups; emphasises the need to secure sustained long-term funding for the four existing ERNs relevant to rare cancers, PaedCan (paediatric cancers), EURACAN (rare adult solid cancers), EuroBloodNet (rare haematological diseases including rare haematological malignancies) and GENTURIS (genetic tumour risk syndromes); supports ERNs consolidation and expansion to rare and complex cancers, in conjunction with the rare and paediatric cancer patient and parent organisations;

Amendment 1439
Giorgos Georgiou, Kateřina Konečná, Alexis Georgoulis, João Pimenta Lopes

Motion for a resolution
Paragraph 115

115. Emphasises the need to secure sustained long-term funding for the ERNs; supports the expansion of the ERNs to specific types of cancer (rare, complex, poorly curable) and paediatric cancers;

115. Calls on the Commission and the Member States to secure appropriate and sustained long-term funding for the ERNs, including the ERN PaedCan that covers...
poorly curable) and paediatric cancers; all paediatric cancers, such as towards compensation of virtual consultations, resourcing twinning and education programmes, and effective reimbursement of patient travel when this is required, in order to foster improved standards of care and equal access to the best possible interventions to all patients who require them across Europe; supports the expansion of the ERNs to specific types of cancer (rare, complex, poorly curable) and paediatric cancers;

Amendment 1440
Nicolae Ştefănuţă, Alin Mituţa, Ivars Ijabs, Vlad Gheorghe

Motion for a resolution
Paragraph 115

115. **Emphasises the need** to secure **sustained** long-term funding for the ERNs; supports the expansion of the ERNs to specific types of cancer (rare, complex, poorly curable) **and paediatric cancers**;

Amendment
115. **Calls on the Commission and the Member States** to secure appropriate and long-term funding for the ERNs **and to ensure effective reimbursement of patient travel costs** when this is required, in order to foster improved standards of care and equal access to the best possible interventions to all patients who require them across Europe; supports the expansion of the ERNs to specific types of cancer (rare, complex, poorly curable);

Amendment 1441
Nicolás González Casares, Maria Arena, Romana Jerković, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 115
Motion for a resolution

115. Emphasises the need to secure sustained long-term funding for the ERNs; supports the expansion of the ERNs to specific types of cancer (rare, complex, poorly curable) and paediatric cancers;

Amendment

115. Calls on the Commission and the Member States to secure appropriate and sustained long-term funding for the ERNs; supports the expansion of the ERNs to specific types of cancer (rare, complex, poorly curable) and paediatric cancers;

Or. en

Amendment 1442
Maria Arena

Motion for a resolution
Paragraph 115

Motion for a resolution

115. Emphasises the need to secure sustained long-term funding for the ERNs; supports the expansion of the ERNs to specific types of cancer (rare, complex, poorly curable) and paediatric cancers;

Amendment

115. Emphasises the need to secure sustained long-term funding for the ERNs; supports the expansion of the ERNs to specific types of cancer (rare, complex, endocrine, poorly curable) and paediatric cancers to improve their functionality and to improve health outcomes in rare disease patient populations; calls on the Commission to expand funding for ERNs through Horizon Europe to allow ERNs to expand their activities and create a pan-EU data acquisition strategy to improve current rare disease registries in a common and uniform data space, better coordinate the projects and their infrastructure, and compensate patients and the medical/academic communities for giving their valuable time to the study of these diseases;

Or. en

Amendment 1443
Ondřej Knotek, Irena Joveva
Motion for a resolution
Paragraph 115

115. Emphasises the need to secure sustained long-term funding for the ERNs; supports the expansion of the ERNs to specific types of cancer (rare, complex, poorly curable) and paediatric cancers; as it could facilitate equal access of patients, including children and AYA, to the best available care across Europe;

Amendment 1444
Joëlle Mélin

Motion for a resolution
Paragraph 115

115. Emphasises the need to secure sustained long-term funding for the ERNs; supports the expansion of the ERNs to specific types of cancer (rare, complex, poorly curable), cancer-related comorbidities and paediatric cancers;

Amendment 1445
Kateřina Konečná, Alexis Georgoulis, Giorgos Georgiou

Motion for a resolution
Paragraph 116

116. Believes that the revamping of ERNs will necessarily involve the participation of all Member States in existing ERNs, with each Member State
having at least one ‘full’ or ‘affiliate’ member in each ERN, the facilitation of the individual patient journey through the effective collaboration of national contact points with ERNs, the evaluation of the functioning of the ERNs by sharing data on their performance and networking in the field of rare cancers, the deployment of telemedicine tools allowing for the sharing of case records and imaging results, and the allocation of adequate and long-term funding, both at Union (EU4Health) and national level; having at least one ‘full’ or ‘affiliate’ member in each ERN and in each sub-clinical domain/thematic network of ERNs; stresses the need to facilitate patient access through the effective collaboration of national contact points with ERNs, encourage the deployment of efficient telemedicine tools allowing for the sharing of case records and imaging results in a secured fashion to discuss complex rare cancer cases, foster networking in the field of rare cancer, and allocate adequate and long-term funding, both at Union and national level;

Amendment 1446
Michèle Rivasi

Motion for a resolution
Paragraph 116

116. Believes that the revamping of ERNs will necessarily involve the participation of all Member States in existing ERNs, with each Member State having at least one ‘full’ or ‘affiliate’ member in each ERN, the facilitation of the individual patient journey through the effective collaboration of national contact points with ERNs, the evaluation of the functioning of the ERNs by sharing data on their performance and networking in the field of rare cancers, the deployment of telemedicine tools allowing for the sharing of case records and imaging results, and the allocation of adequate and long-term funding, both at Union (EU4Health) and national level;

Amendment

116. Believes that the consolidation of ERNs will necessarily involve the participation of all Member States in existing ERNs, with each Member State having at least one ‘full’ or ‘affiliate’ member in each ERN and in each sub-clinical domain/thematic network of ERNs, facilitate patient access through the effective collaboration of national contact points with ERNs, encourage the deployment of efficient telemedicine tools allowing for the sharing of case records and imaging results in a secured fashion to discuss complex rare cancer cases, foster networking in the field of rare cancer, and allocate adequate and long-term funding, both at Union (EU4Health) and national level;

Or. en
Amendment 1447
Tomislav Sokol

Motion for a resolution
Paragraph 116

Motion for a resolution

116. Believes that the **revamping** of ERNs will necessarily involve the participation of all Member States in existing ERNs, with each Member State having at least one ‘full’ or ‘affiliate’ member in each ERN, the facilitation of the individual patient journey through the effective collaboration of national contact points with ERNs, the evaluation of the functioning of the ERNs by sharing data on their performance and networking in the field of rare cancers, the deployment of telemedicine tools allowing for the sharing of case records and imaging results, and the allocation of adequate and long-term funding, both at Union (EU4Health) and national level;

Amendment

116. Believes that the **further development and optimisation** of ERNs will necessarily involve the participation of all Member States in existing ERNs, with each Member State having at least one ‘full’ or ‘affiliate’ member in each ERN **and in each sub-clinical domain/thematic network of ERNs**, the facilitation of the individual patient journey through the effective collaboration of national contact points with ERNs, the evaluation of the functioning of the ERNs by sharing data on their performance and networking in the field of rare cancers, the deployment of **efficient** telemedicine tools allowing for the sharing of case records and imaging results **in a secured fashion to discuss complex rare cancer cases**, and the allocation of adequate and long-term funding, both at Union (EU4Health) and national level.

Or. en

Amendment 1448
Nicolae Ștefanuță, Alin Mituța, Ivars Ijabs, Vlad Gheorghe

Motion for a resolution
Paragraph 116

Motion for a resolution

116. Believes that the **revamping of** ERNs will necessarily involve the participation of all Member States in existing ERNs, with each Member State having at least one ‘full’ or ‘affiliate’ member in each ERN, the facilitation of the individual patient journey through the

Amendment

116. Believes that the **consolidation and further development of the** ERNs will necessarily involve the participation of all Member States in existing ERNs, with each Member State having at least one ‘full’ or ‘affiliate’ member in each ERN, the facilitation of the individual patient journey
effective collaboration of national contact points with ERNs, the evaluation of the functioning of the ERNs by sharing data on their performance and networking in the field of rare cancers, the deployment of telemedicine tools allowing for the sharing of case records and imaging results, and the allocation of adequate and long-term funding, both at Union (EU4Health) and national level; through the effective collaboration of national contact points with ERNs, the evaluation of the functioning of the ERNs by sharing data on their performance and networking in the field of rare cancers, the deployment of telemedicine tools allowing for the sharing of case records and imaging results, and the allocation of adequate and long-term funding, both at Union (EU4Health) and national level;

Or. en

Amendment 1449
Peter Liese
on behalf of the EPP Group
Tomislav Sokol, Nathalie Colin-Oesterlé, Liudas Mažylis, Marian-Jean Marinescu, Maria Spyraki, Dolors Montserrat, Cindy Franssen, Adam Jarubas, Deirdre Clune, Sunčana Glavak, Bartosz Arłukowicz

Motion for a resolution
Paragraph 116

116. Believes that the **revamping** of ERNs will necessarily involve the participation of all Member States in existing ERNs, with each Member State having at least one ‘full’ or ‘affiliate’ member in each ERN, the facilitation of the individual patient journey through the effective collaboration of national contact points with ERNs, the evaluation of the functioning of the ERNs by sharing data on their performance and networking in the field of rare cancers, the deployment of telemedicine tools allowing for the sharing of case records and imaging results, and the allocation of adequate and long-term funding, both at Union (EU4Health) and national level;

116. Believes that the **further development and optimisation** of ERNs will necessarily involve the participation of all Member States in existing ERNs, with each Member State having at least one ‘full’ or ‘affiliate’ member in each ERN, the facilitation of the individual patient journey through the effective collaboration of national contact points with ERNs, the evaluation of the functioning of the ERNs by sharing data on their performance and networking in the field of rare cancers, the deployment of telemedicine tools allowing for the sharing of case records and imaging results, and the allocation of adequate and long-term funding, both at Union (EU4Health) and national level;

Or. en
Amendment 1450  
Nicolás González Casares, Maria Arena, Romana Jerković, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis

Motion for a resolution  
Paragraph 116

116. Believes that the revamping of ERNs will necessarily involve the participation of all Member States in existing ERNs, with each Member State having at least one ‘full’ or ‘affiliate’ member in each ERN, the facilitation of the individual patient journey through the effective collaboration of national contact points with ERNs, the evaluation of the functioning of the ERNs by sharing data on their performance and networking in the field of rare cancers, the deployment of telemedicine tools allowing for the sharing of case records and imaging results, and the allocation of adequate and long-term funding, both at Union (EU4Health) and national level;

[Amendment]

116. Believes that further development and optimisation of the ERNs will necessarily involve the participation of all Member States in existing ERNs, with each Member State having at least one ‘full’ or ‘affiliate’ member in each ERN, the facilitation of the individual patient journey through the effective collaboration of national contact points with ERNs, the evaluation of the functioning of the ERNs by sharing data on their performance and networking in the field of rare cancers, the deployment of telemedicine tools allowing for the sharing of case records and imaging results, and the allocation of adequate and long-term funding, both at Union (EU4Health) and national level;

Amendment 1451  
Bronis Ropė

Motion for a resolution  
Paragraph 116 a (new)

116a. Calls on the Member States to give due consideration to the importance of non-governmental local, regional and national organisations uniting cancer patients, survivors and their relatives, in terms of their participation in the knowledge-sharing process, in the fight against cancer, in terms of legislative support, and in terms of the provision of separate funding for these organisations,
especially those involved in programmes to combat cancer;

Amendment 1452
Joëlle Mélin

Motion for a resolution
Paragraph 117

117. Encourages Member States to support a dedicated and tailored approach to rare cancers in adults and paediatric cancers, taking stock of EU initiatives, and to fully integrate ERNs into their national healthcare systems;

Amendment

117. Encourages Member States to support a dedicated and tailored approach to rare cancers in adults and paediatric cancers, taking stock of EU initiatives;

calls for the creation of common and consistent protocols governing the collection of data so that they are available in the same format to all parties, and for the creation of a single set of definitions explaining the data collected;

Amendment 1453
Bartosz Arłukowicz

Motion for a resolution
Paragraph 117

117. Encourages Member States to support a dedicated and tailored approach to rare cancers in adults and paediatric cancers, taking stock of EU initiatives, and to fully integrate ERNs into their national healthcare systems;

Amendment

117. Encourages Member States to support a dedicated and tailored approach to rare cancers in adults and paediatric cancers, taking stock of EU initiatives, and to fully integrate ERNs into their national healthcare systems; calls for the creation of common and consistent protocols governing the collection of data so that they are available in the same format to all parties, and for the creation of a single set of definitions explaining the data collected;
Amendment 1454  
Nicolae Ștefănutea, Alin Mituța, Ivars Ijabs, Vlad Gheorghe

Motion for a resolution
Paragraph 117

**Motion for a resolution**

117. Encourages Member States to support a dedicated and tailored approach to rare cancers in adults and paediatric cancers, taking stock of EU initiatives, and to fully integrate ERNs into their national healthcare systems;

**Amendment**

117. Encourages Member States to support a dedicated and tailored approach to rare cancers in adults and paediatric cancers, taking stock of EU initiatives, and to fully integrate ERNs into their national healthcare systems; **recommends that Member States establish national networks for rare adult cancers in order to optimise the referral of patients to specialised centres in a timely fashion and facilitate interaction with ERNs;**

Or. en

Amendment 1455  
Tomislav Sokol

Motion for a resolution
Paragraph 117

**Motion for a resolution**

117. Encourages Member States to support a dedicated and tailored approach to rare cancers in adults and paediatric cancers, taking stock of EU initiatives, and to fully integrate ERNs into their national healthcare systems;

**Amendment**

117. Encourages Member States to support a dedicated and tailored approach to rare cancers in adults and paediatric cancers, taking stock of EU initiatives, including the recommendations from the EU Joint Action on Rare Cancers set out in the RARECANCER AGENDA 2030, and to fully integrate ERNs into their national healthcare systems;

Or. en
Amendment 1456
Nicolae Ştefănuţă, Alin Mituţa, Ivars Ijabs, Vlad Gheorghe

Motion for a resolution
Paragraph 117 a (new)

Motion for a resolution  

Amendment

117a. Emphasises the need to include rare adult cancers in the "inter-specialty cancer training programme" including specialised nursing training, in conjunction with ERNs for rare adult cancers; additionally, emphasises the need to support educational programmes targeting rare adult cancer patients, carers and patient representatives in conjunction with ERNs, to increase levels of health literacy and ultimately help patients and their families make informed choices about treatment options and follow-up care;

Or. en

Amendment 1457
Tomislav Sokol, Cindy Franssen

Motion for a resolution
Paragraph 117 b (new)

Motion for a resolution  

Amendment

117b. Calls on the Commission to further support the Member States to implement the recommendations of the European Parliament's resolution of 12 February 2019 on the implementation of the Cross-Border Healthcare Directive to ensure that the ERNs fulfil their scope to improve the circulation of information on rare diseases and rare cancers across the EU;

Or. en
Amendment 1458
Ondřej Knotek, Irena Joveva

Motion for a resolution
Paragraph 117 c (new)

Motion for a resolution

Amendment

117c. Encourages Member States to give better recognition to haematological cancer and to increase research and innovation for early diagnosis and treatment;

Or. en

Amendment 1459
Michèle Rivasi

Motion for a resolution
Paragraph 118

Motion for a resolution

Amendment

118. Recalls that the Joint Research Centre has taken an active role in supporting the activities and harnessing the data of cancer registries; considers that the mandate, funding and political support for the Joint Research Centre to continue and accelerate its coordinating work with cancer registries should be strengthened,

particularly in terms of collection of patient outcomes, real world evidence and the identification of cancer clusters, and their integration in existing cancer registries;

Or. en

Amendment 1460
Nicolás González Casares, Maria Arena, Romana Jerković, Cyrus Engerer, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis
Motion for a resolution
Paragraph 118 a (new)

118a. Welcomes the development of a European Research Infrastructure entirely dedicated to paediatric research, also covering the oncology field, that will facilitate basic, preclinical and transnational paediatric research that underpins clinical trials and medicines’ availability for children;

Amendment

Or. en

Amendment 1461
Hilde Vautmans, Irena Joveva

Motion for a resolution
Paragraph 118 a (new)

18a. Welcomes the development of a European Research Infrastructure entirely dedicated to paediatric research, including oncology, that will facilitate basic, preclinical and translational paediatric research, underpinning clinical trials and the availability of medicines for children;

Amendment

Or. en

Amendment 1462
Joëlle Mélin

Motion for a resolution
Paragraph 119

119. Welcomes the launch of a Knowledge Centre on Cancer in 2021,

Amendment

119. Looks forward to the launch, by the Joint Research Centre, of a Knowledge
announced in Europe’s Beating Cancer Plan, in order to contribute to the exchanges and coordination of scientific and technical initiatives related to cancer at EU level; believes that this knowledge centre should be based on data screening, ERN reports and cancer registries, and be part of a European Cancer Institute;

Centre on Cancer in 2021, announced in Europe’s Beating Cancer Plan, in order to contribute to the exchanges and coordination of scientific and technical initiatives related to cancer at EU level; believes that this knowledge centre should be based on data screening, ERN reports and cancer registries, and be part of a European Cancer Institute;

Amendment 1463
Pietro Fiocchi

Motion for a resolution
Paragraph 119

Motion for a resolution

119. Welcomes the launch of a Knowledge Centre on Cancer in 2021, announced in Europe’s Beating Cancer Plan, in order to contribute to the exchanges and coordination of scientific and technical initiatives related to cancer at EU level; believes that this knowledge centre should be based on data screening, ERN reports and cancer registries, and be part of a European Cancer Institute;

Amendment

119. Welcomes the launch of a Knowledge Centre on Cancer in 2021, announced in Europe’s Beating Cancer Plan, in order to contribute to the exchanges and coordination of scientific and technical initiatives related to cancer at EU level; believes that this knowledge centre should be based on data screening, ERN reports and cancer registries, and be part of an Association of European Cancer Institutes;

Amendment 1464
Bronis Ropé

Motion for a resolution
Paragraph 120

Motion for a resolution

120. Recommends the creation of at least one cancer registry in each EU region, including remote and outermost regions;

Amendment

120. Recommends the creation of at least one cancer registry in each EU region, including remote and outermost regions;
supports the strengthening of the capacity of national cancer registries to collect data (including lifestyle and socio-economic information) to better identify the causes of inequalities in cancer incidence, prevalence and survival; asks Member States to ensure the comparability of data sources and the interoperability of regional and national cancer registries;

supports the strengthening of the capacity of national cancer registries to collect data (including lifestyle and socio-economic information) to better identify the causes of inequalities in cancer incidence, prevalence and survival; asks Member States to harmonise the information collected and its quality for full, high-quality data comparability and interoperability across the EU, and calls for national cancer registries to be mandated to carry out analyses of regional disparities in morbidity and to make recommendations to national cancer councils and the Joint Research Centre on the need for interventions; calls for the use of modern epidemiological and molecular genetics methods to analyse the prevalence of cancer and to identify its causes; calls for the comparability of data sources and the interoperability of regional and national cancer registries;

Or. It

Amendment 1465
Giorgos Georgiou, Alexis Georgoulis, João Pimenta Lopes

Motion for a resolution
Paragraph 120

120. Recommends the creation of at least one cancer registry in each EU region, including remote and outermost regions; supports the strengthening of the capacity of national cancer registries to collect data (including lifestyle and socio-economic information) to better identify the causes of inequalities in cancer incidence, prevalence and survival; asks Member States to ensure the comparability of data sources and the interoperability of regional and national cancer registries;

Amendment

120. Recommends the creation of at least one cancer registry in each EU region, including remote and outermost regions; supports the strengthening of the capacity of national cancer registries to collect standardised patient-reported outcomes, real-world data and real world evidence as well as results of anonymised surveys regularly formulated and conducted by trained professionals to better map lifestyle and socio-economic conditions of EU citizens and data to identify the causes of inequalities in cancer incidence, prevalence and survival; asks Member
States to ensure the comparability of data sources and the interoperability of regional and national cancer registries; calls for the implementation of specific cancer registries for paediatric malignancies in line with International Classification of Childhood Cancer (ICCC);

Amendment 1466
Nicolae Ștefănuță, Alin Mituța, Ivars Ijabs, Vlad Gheorghe

Motion for a resolution
Paragraph 120

120. Recommends the creation of at least one cancer registry in each EU region, including remote and outermost regions; supports the strengthening of the capacity of national cancer registries to collect data (including lifestyle and socio-economic information) to better identify the causes of inequalities in cancer incidence, prevalence and survival; asks Member States to ensure the comparability of data sources and the interoperability of regional and national cancer registries;

calls for the implementation of specific cancer registries for paediatric malignancies in line with International Classification of Childhood Cancer (ICCC);

Amendment 1467
Pietro Fiocchi

Motion for a resolution
Paragraph 120

120. Recommends the creation of at least one cancer registry in each EU region, including remote and outermost regions; supports the strengthening of the capacity of national cancer registries to collect data (including lifestyle and socio-economic information) to better identify the causes of inequalities in cancer incidence, prevalence and survival; asks Member States to ensure the comparability of data sources and the interoperability of regional and national cancer registries;

calls for the implementation of specific cancer registries for paediatric malignancies in line with the International Classification of Childhood Cancer (ICCC);
120. Recommends the creation of at least one cancer registry in each EU region, including remote and outermost regions; supports the strengthening of the capacity of national cancer registries to collect data (including lifestyle and socio-economic information) to better identify the causes of inequalities in cancer incidence, prevalence and survival; asks Member States to ensure the comparability of data sources and the interoperability of regional and national cancer registries; stresses the essential need to collect data collaboratively across all Member States;

Amendment 1468
Bartosz Arłukowicz

Motion for a resolution
Paragraph 120

120. Recommends the creation of at least one cancer registry in each EU region, including remote and outermost regions; supports the strengthening of the capacity of national cancer registries to collect data (including lifestyle and socio-economic information) to better identify the causes of inequalities in cancer incidence, prevalence and survival; asks Member States to ensure the comparability of data sources and the interoperability of regional and national cancer registries, as well as secure access to such data;

Or. pl
Amendment 1469
Margarita de la Pisa Carrión, Pietro Fiocchi

Motion for a resolution
Paragraph 120

120. Recommends the creation of at least one cancer registry in each EU region, including remote and outermost regions; supports the strengthening of the capacity of national cancer registries to collect data (including lifestyle and socio-economic information) to better identify the causes of inequalities in cancer incidence, prevalence and survival; asks Member States to ensure the comparability of data sources and the interoperability of regional and national cancer registries;

Amendment

120. Recommends the creation of at least one cancer registry in each EU region, as well as within each Member State, including remote and outermost regions; supports the strengthening of the capacity of national cancer registries to collect data (including lifestyle and socio-economic information) to better identify the causes of inequalities in cancer incidence, prevalence and survival; asks Member States to ensure the comparability of data sources and the interoperability of regional and national cancer registries;

Or. en

Amendment 1470
Michèle Rivasi

Motion for a resolution
Paragraph 120

120. Recommends the creation of at least one cancer registry in each EU region, including remote and outermost regions; supports the strengthening of the capacity of national cancer registries to collect data (including lifestyle and socio-economic information) to better identify the causes of inequalities in cancer incidence, prevalence and survival; asks Member States to ensure the comparability of data sources and the interoperability of regional and national cancer registries;

Amendment

120. Recommends the creation of at least one cancer registry in each EU region, including remote and outermost regions; supports the strengthening of the capacity of national cancer registries to collect data (including lifestyle and environmental factors, and socio-economic information) to better identify the causes of inequalities in cancer incidence, prevalence and survival; asks Member States to ensure the comparability of data sources and the interoperability of regional and national cancer registries;

Or. en
Amendment 1471
Joëlle Mélin

Motion for a resolution
Paragraph 120

Motion for a resolution

120. Recommends the creation of at least one cancer registry in each EU region, including remote and outermost regions; supports the strengthening of the capacity of national cancer registries to collect data (including lifestyle and socio-economic information) to better identify the causes of inequalities in cancer incidence, prevalence and survival; asks Member States to ensure the comparability of data sources and the interoperability of regional and national cancer registries;

Amendment

120. Looks forward to the creation of at least one cancer registry in each EU region, including remote and outermost regions supports the strengthening of the capacity of national cancer registries to collect data (including lifestyle and socio-economic information) to better identify the causes of inequalities in cancer incidence, prevalence and survival; asks Member States to ensure the comparability of data sources and the interoperability of regional and national cancer registries;

Or. fr

Amendment 1472
Nicolás González Casares, Maria Arena, Romana Jerković, Sara Cerdas, Patrizia Toia, Marc Angel, Johan Danielsson, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 120

Motion for a resolution

120. Recommends the creation of at least one cancer registry in each EU region, including remote and outermost regions; supports the strengthening of the capacity of national cancer registries to collect data (including lifestyle and socio-economic information) to better identify the causes of inequalities in cancer incidence, prevalence and survival; asks Member States to ensure the comparability of data sources and the interoperability of regional and national cancer registries;

Amendment

120. Recommends the creation of at least one cancer registry in each EU region, including remote and outermost regions; supports the strengthening of the capacity of national cancer registries to collect data (including lifestyle, occupation and socio-economic information) to better identify the causes of inequalities in cancer incidence, prevalence and survival; asks Member States to ensure the comparability of data sources and the interoperability of regional and national cancer registries;
Amendment 1473
Tiemo Wölken, Piernicola Pedicini

Motion for a resolution
Paragraph 120

120. Recommends the creation of at least one cancer registry in each EU region, including remote and outermost regions; supports the strengthening of the capacity of national cancer registries to collect data (including lifestyle and socio-economic information) to better identify the causes of inequalities in cancer incidence, prevalence and survival; asks Member States to ensure the comparability of data sources and the interoperability of regional and national cancer registries;

Amendment

120. Recommends the creation of at least one cancer registry in each EU region, including remote and outermost regions; supports the strengthening of the capacity of national cancer registries to collect data (including lifestyle and socio-economic information) to better identify the causes of inequalities in cancer incidence, mortality, prevalence and survival; asks Member States to ensure the comparability of data sources and the interoperability of regional and national cancer registries;

Amendment 1474
Nicolae Ștefănuță, Alin Mituța, Ivars Ijabs, Vlad Gheorghe

Motion for a resolution
Paragraph 120 a (new)

120a. Calls for the creation of a Rare Cancer Registry at European level, in order to better understand rare cancer pathophysiology and ease enrolment to clinical trials; calls for improving access to clinical trials and Expanded Access Programmes (EAPs) for rare adult cancer patients;

Or. en
Amendment 1475
Joëlle Mélin

Motion for a resolution
Paragraph 121

Amendment

121. **Strongly supports** the creation of a Cancer Inequalities Registry at European level, announced in Europe’s Beating Cancer Plan, in order to identify trends, disparities, inequalities and inequities between and within Member States; believes that this registry will help to identify challenges and specific areas of action so as to guide investment and intervention at EU, national and regional level;

Motion for a resolution

121. **Looks forward to** the creation of a Cancer Inequalities Registry at European level, announced in Europe’s Beating Cancer Plan, in order to identify trends, disparities, inequalities and inequities between and within Member States; believes that this registry will help to identify challenges and specific areas of action so as to guide investment and intervention at EU, national and regional level;

Or. fr

Amendment 1476
Tomislav Sokol, Sunčana Glavak, Cindy Franssen

Motion for a resolution
Paragraph 121

Amendment

121. Strongly supports the creation of a Cancer Inequalities Registry at European level, announced in Europe’s Beating Cancer Plan, in order to identify trends, disparities, inequalities and inequities between and within Member States; believes that this registry will help to identify challenges and specific areas of action so as to guide investment and intervention at EU, national and regional level; calls, in this respect, for the necessary measures to develop a robust supply chain for nuclear medicine which goes beyond irradiation and includes the supply of target material and processing capabilities;

Motion for a resolution

121. Strongly supports the creation of a Cancer Inequalities Registry at European level, announced in Europe’s Beating Cancer Plan, in order to identify trends, disparities, inequalities and inequities between and within Member States; believes that this registry will help to identify challenges and specific areas of action so as to guide investment and intervention at EU, national and regional level;
Amendment 1477
Tudor Ciuhodaru

Motion for a resolution
Paragraph 121

Motion for a resolution

121. Strongly supports the creation of a Cancer Inequalities Registry at European level, announced in Europe’s Beating Cancer Plan, in order to identify trends, disparities, inequalities and inequities between and within Member States; believes that this registry will help to identify challenges and specific areas of action so as to guide investment and intervention at EU, national and regional level;

Amendment

121. Strongly supports the creation of a Cancer Inequalities Registry at European level, announced in Europe’s Beating Cancer Plan, in order to identify trends, disparities, inequalities and inequities between and within Member States; believes that this registry will help to identify challenges and specific areas of action so as to guide investment and intervention at EU, national and regional level; calls for the access to nuclear medicine services to be included as a key parameter into this diagnostic and treatment capacity mapping exercise;

Amendment 1478
Michèle Rivasi

Motion for a resolution
Paragraph 121

Motion for a resolution

121. Strongly supports the creation of a Cancer Inequalities Registry at European level, announced in Europe’s Beating Cancer Plan, in order to identify trends, disparities, inequalities and inequities between and within Member States; believes that this registry will help to identify challenges and specific areas of action so as to guide investment and intervention at EU, national and regional

Amendment

121. Strongly supports the creation of a Cancer Inequalities Registry at European level, announced in Europe’s Beating Cancer Plan, in order to identify trends, disparities, inequalities and inequities between and within Member States; believes that this registry will help to identify challenges and specific areas of action so as to guide investment and intervention at EU, national and regional
calls for the inequalities registry to integrate information on rare cancers which amount to about 24% of new cancer cases occurring from birth up to elderly age groups;

Amendment 1479
Loucas Fourlas

Motion for a resolution
Paragraph 121

Motion for a resolution

121. Strongly supports the creation of a Cancer Inequalities Registry at European level, announced in Europe’s Beating Cancer Plan, in order to identify trends, disparities, inequalities and inequities between and within Member States; believes that this registry will help to identify challenges and specific areas of action so as to guide investment and intervention at EU, national and regional level;

Amendment

121. Strongly supports the creation of a Cancer Inequalities Registry at European level, announced in Europe’s Beating Cancer Plan, in order to identify trends, disparities, inequalities and inequities between and within Member States; believes that this registry will help to identify challenges and specific areas of action so as to guide investment and intervention at EU, national and regional level; calls for the implementation of specific cancer registries for paediatric malignancies in line with the International Classification of Childhood Cancer (ICCC);

Amendment 1480
Nicolás González Casares, Maria Arena, Romana Jerković, Cyrus Engerer, Sara Cerdas, Patrizia Toia, Marc Angel, Johan Danielsson, Estrella Durà Ferrandis

Motion for a resolution
Paragraph 121

Motion for a resolution

121. Strongly supports the creation of a Cancer Inequalities Registry at European level;

Amendment

121. Strongly supports the creation of a Cancer Inequalities Registry at European level;
level, announced in Europe’s Beating Cancer Plan, in order to identify trends, disparities, inequalities and inequities between and within Member States; believes that this registry will help to identify challenges and specific areas of action so as to guide investment and intervention at EU, national and regional level; stresses the need for the Cancer Inequalities Registry to also cover social inequalities such as those related to socio-economic status, occupation and gender;

Amendment 1481
Ondřej Knotek

Motion for a resolution
Paragraph 121

121. Strongly supports the creation of a Cancer Inequalities Registry at European level, announced in Europe’s Beating Cancer Plan, in order to identify trends, disparities, inequalities and inequities between and within Member States; believes that this registry will help to identify challenges and specific areas of action so as to guide investment and intervention at EU, national and regional level; calls for making the Registry accessible to the public;

Amendment 1482
Tiemo Wölken, Piernicola Pedicini

Motion for a resolution
Paragraph 121
Motion for a resolution

121. Strongly supports the creation of a Cancer Inequalities Registry at European level, announced in Europe’s Beating Cancer Plan, in order to identify trends, disparities, inequalities and inequities between and within Member States; believes that this registry will help to identify challenges and specific areas of action so as to guide investment and intervention at EU, national and regional level;

Amendment

121. Strongly supports the creation of a Cancer Inequalities Registry at European level, announced in Europe’s Beating Cancer Plan, in order to identify trends, disparities, inequalities and inequities between and within Member States; believes that this registry will help to identify challenges and specific areas of action so as to guide investment and intervention facilitate research into inequalities at EU, national and regional level;

Amendment 1483
Nicolás González Casares, Maria Arena, Romana Jerković, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 121 a (new)

Motion for a resolution

121a. Underlines that electronic health records are set to become crucial tools in cancer prevention and care, as they will ensure that clinical information is shared efficiently between oncologists, radiologists and surgeons, enhancing their patients’ treatment and survival chances;

Amendment

Or. en

Amendment 1484
Nicolás González Casares, Maria Arena, Romana Jerković, Sara Cerdas, Patrizia Toia, Marc Angel, Johan Danielsson, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 121 b (new)
Motion for a resolution  

121b. Calls on the Commission to promote the publication of scientific results in open access, to make them easily available to all health professionals and researchers;

Amendment 1485  
Joëlle Mélin

Motion for a resolution  
Paragraph 122

122. Supports the Commission’s intention to enable cancer patients to securely access and share electronic health records across borders; considers that the Commission could lay the foundation for the European Health Data Space, in association with Digital Health Europe, by collecting and analysing anonymised medical data (from cancer registries, hospitals, academic clinical trials and cohorts) and biological data (from blood and tumour samples) in a European Cancer Cloud hosted by a European Cancer Institute; encourages the use of health data for non-commercial purposes (‘data altruism’); welcomes the planned creation of a virtual European Cancer Patient Digital Centre under Horizon Europe’s Mission on Cancer in order to support a standardised approach to the participation of willing patients in the deposit and exchange of their health data; recommends the inclusion of patients in any actions related to the storage and use of health data for policy-making and research purposes; welcomes the planned expansion of the European Cancer

Amendment 122. Points out that some Member States have already introduced electronic health records and that sharing them is down to the patients alone;
Information System before 2022;

Amendment 1486
Alessandra Moretti

Motion for a resolution
Paragraph 122

122. Supports the Commission’s intention to enable cancer patients to securely access and share electronic health records across borders; considers that the Commission could lay the foundation for the European Health Data Space, in association with Digital Health Europe, by collecting and analysing anonymised medical data (from cancer registries, hospitals, academic clinical trials and cohorts) and biological data (from blood and tumour samples) in a European Cancer Cloud hosted by a European Cancer Institute; underlines that an harmonised interpretation of the General Data Protection Regulation (GDPR) in all EU Member States is the foundation for new data-sharing initiatives such as the European Health Data Space; encourages the use of health data for non-commercial purposes (‘data altruism’); welcomes the planned creation of a virtual European Cancer Patient Digital Centre under Horizon Europe’s Mission on Cancer in order to support a standardised approach to the participation of willing patients in the deposit and exchange of their health data; recommends the inclusion of patients in any actions related to the storage and use of health data for policy-making and research purposes; welcomes the planned expansion of the European Cancer Information System before 2022;
Amendment 1487
Nicolás González Casares, Alessandra Moretti, María Arena, Romana Jerković, Cyrus Engerer, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 122

122. Supports the Commission’s intention to enable cancer patients to securely access and share electronic health records across borders; considers that the Commission could lay the foundation for the European Health Data Space, in association with Digital Health Europe, by collecting and analysing anonymised medical data (from cancer registries, hospitals, academic clinical trials and cohorts) and biological data (from blood and tumour samples) in a European Cancer Cloud hosted by a European Cancer Institute; encourages the use of health data for non-commercial purposes (‘data altruism’); welcomes the planned creation of a virtual European Cancer Patient Digital Centre under Horizon Europe’s Mission on Cancer in order to support a standardised approach to the participation of willing patients in the deposit and exchange of their health data; recommends the inclusion of patients in any actions related to the storage and use of health data for policy-making and research purposes; welcomes the planned expansion of the European Cancer Information System before 2022;
Amendment 1488
Bartosz Arłukowicz

Motion for a resolution
Paragraph 122

122. Supports the Commission’s intention to enable cancer patients to securely access and share electronic health records across borders; considers that the Commission could lay the foundation for the European Health Data Space, in association with Digital Health Europe, by collecting and analysing anonymised medical data (from cancer registries, hospitals, academic clinical trials and cohorts) and biological data (from blood and tumour samples) in a European Cancer Cloud hosted by a European Cancer Institute; encourages the use of health data for non-commercial purposes (‘data altruism’); welcomes the planned creation of a virtual European Cancer Patient Digital Centre under Horizon Europe’s Mission on Cancer in order to support a standardised approach to the participation of willing patients in the deposit and exchange of their health data; recommends the inclusion of patients in any actions related to the storage and use of health data for policy-making and research purposes; welcomes the planned expansion of the European Cancer Information System before 2022;

Amendment

122. Supports the Commission’s intention to enable cancer patients to securely access and share electronic health records across borders; considers that the Commission could lay the foundation for the European Health Data Space, in association with Digital Health Europe, by collecting and analysing anonymised medical data (from cancer registries, hospitals, academic clinical trials and cohorts) and biological data (from blood and tumour samples) in a European Cancer Cloud hosted by a European Cancer Institute; encourages the use of health data for non-commercial purposes (‘data altruism’); welcomes the planned creation of a virtual European Cancer Patient Digital Centre under Horizon Europe’s Mission on Cancer in order to support a standardised approach to the participation of willing patients in the deposit and exchange of their standardised and uniformly defined health data; recommends the inclusion of patients in any actions related to the storage and use of health data for policy-making and research purposes; welcomes the planned expansion of the European Cancer Information System before 2022;

Or. pl

Amendment 1489
Pietro Fiocchi

Motion for a resolution
Paragraph 122

PE697.582v02-00 166/190 AM\1239642EN.docx
122. Supports the Commission’s intention to enable cancer patients to securely access and share electronic health records across borders; considers that the Commission could lay the foundation for the European Health Data Space, in association with Digital Health Europe, by collecting and analysing anonymised medical data (from cancer registries, hospitals, academic clinical trials and cohorts) and biological data (from blood and tumour samples) in a European Cancer Cloud hosted by a European Cancer Institute; encourages the use of health data for non-commercial purposes (‘data altruism’); welcomes the planned creation of a virtual European Cancer Patient Digital Centre under Horizon Europe’s Mission on Cancer in order to support a standardised approach to the participation of willing patients in the deposit and exchange of their health data; recommends the inclusion of patients in any actions related to the storage and use of health data for policy-making and research purposes; welcomes the planned expansion of the European Cancer Information System before 2022;

Amendment

122. Supports the Commission’s intention to enable cancer patients to securely access and share electronic health records across borders; considers that the Commission could lay the foundation for the European Health Data Space, in association with Digital Health Europe, by collecting, analysing and exchanging anonymised medical data (from cancer registries, hospitals, academic clinical trials and cohorts) and biological data (from blood and tumour samples) in a European Cancer Cloud hosted by an Association of European Cancer Institutes; encourages the use of health data for non-commercial purposes (‘data altruism’); welcomes the planned creation of a virtual European Cancer Patient Digital Centre under Horizon Europe’s Mission on Cancer in order to support a standardised approach to the participation of willing patients in the deposit and exchange of their health data; recommends the inclusion of patients in any actions related to the storage and use of health data for policy-making and research purposes; welcomes the planned expansion of the European Cancer Information System before 2022;

Or. en

Amendment 1490
Nicolás González Casares, Maria Arena, Romana Jerković, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 122 a (new)

122a. Deplores that limitations in data sharing hamper the possibility of using real-world data with modelling and artificial intelligence for the development
of methods for prediction, diagnosis and treatments, among others; considers that combining health records, always in compliance with EU data protection rules, with other data sets, such as genomics, can provide even better insights into the efficacy of treatments and their optimization;

Or. en

Amendment 1491
Bronis Ropė
Motion for a resolution
Paragraph 122 b (new)

122b. Calls for current good practices in eHealth in the EU Member States to be reviewed and compiled in order to provide an overview of those functionalities of eHealth that are able to contribute to the fight against, and prevention of, oncological diseases; feels that Member States should be able to obtain and use information from third countries in order to find effective solutions in the fight against cancer;

Or. lt

Amendment 1492
Alexis Georgoulis, Giorgos Georgiou
Motion for a resolution
Paragraph 122 c (new)

122c. Understands the importance of sharing knowledge and patients’ data to promote cancer research, yet strongly argues for the need to ensure that
patients’ data will by no means be used against them in the future by private insurance companies or for other market purposes;

Amendment 1493
Pietro Fiocchi

Motion for a resolution
Paragraph 123

123. Calls for improved standards in the education and training of health professionals; encourages common and multidisciplinary training programmes for health professionals in close collaboration with European learned societies; welcomes the launch of an inter-specialty cancer training programme, which will involve cooperation between Member States via a European Cancer Institute;

Amendment

123. Calls for improved standards in the education and training of health professionals; encourages common and multidisciplinary training programmes for health professionals in close collaboration with European learned societies; welcomes the launch of an inter-specialty cancer training programme, which will involve cooperation between Member States via an Association of European Cancer Institutes;

Amendment 1494
Tomislav Sokol, Sunčana Glavak, Cindy Franssen

Motion for a resolution
Paragraph 123

123. Calls for improved standards in the education and training of health professionals; encourages common and multidisciplinary training programmes for health professionals in close collaboration with European learned societies; welcomes the launch of an inter-specialty cancer training programme, which will involve cooperation between Member States via a European Cancer Institute;

123. Calls for improved standards in the education and training of health professionals; encourages common and multidisciplinary training programmes for health professionals in close collaboration with European learned societies; welcomes the launch of an inter-specialty cancer training programme, which should include elements on the entire disease course
European Cancer Institute; through diagnosis, treatment, complications and co-morbidities, survivorship and end-of-life care, and which will involve cooperation between Member States via a European Cancer Institute; urges for nuclear medicine to be included into the interspecialty training programme, alongside other independent medical specialties involved in cancer diagnosis and treatment;

Amendment 1495
Tudor Ciuhodaru

Motion for a resolution
Paragraph 123

Motion for a resolution

123. Calls for improved standards in the education and training of health professionals; encourages common and multidisciplinary training programmes for health professionals in close collaboration with European learned societies; welcomes the launch of an inter-specialty cancer training programme, which will involve cooperation between Member States via a European Cancer Institute;

Amendment

123. Calls for improved standards in the education and training of health professionals; encourages common and multidisciplinary training programmes for health professionals in close collaboration with European learned societies; welcomes the launch of an inter-specialty cancer training programme, which will involve cooperation between Member States via a European Cancer Institute; urges for nuclear medicine should be included into the interspecialty training programme, alongside other independent medical specialties involved in cancer diagnosis and treatment.

Amendment 1496
Tiemo Wölken, Piernicola Pedicini

Motion for a resolution
Paragraph 123
123. Calls for improved standards in the education and training of health professionals; encourages common and multidisciplinary training programmes for health professionals in close collaboration with European learned societies; welcomes the launch of an inter-specialty cancer training programme, which will involve cooperation between Member States via a European Cancer Institute;

Amendment

123. Calls for improved standards in the education and training of health professionals at every stage of the treatment and care pathway; encourages common and multidisciplinary training programmes for health professionals in close collaboration with European learned societies; welcomes the launch of an inter-specialty cancer training programme, which will involve cooperation between Member States via a European Cancer Institute;

Amendment 1497
Kateřina Konečná, Alexis Georgoulis, Giorgos Georgiou

Motion for a resolution
Paragraph 123 a (new)

123a. Notes that the treatment of rare cancers is dependent upon the education and professional competence of the treating physician and stresses, therefore, that specific educational pathways corresponding to specific medical careers should be linked to the ERNs and done in cooperation with the EU university system and national postgraduate medical educational bodies; stresses that educational programmes targeting patients, carers and patient representatives should also be supported, in conjunction with ERNs, to increase levels of health literacy in these populations, and ultimately help patients and their families make informed choices about treatment options and follow-up care;

Or. en
Amendment 1498
Margarita de la Pisa Carrión

Motion for a resolution
Paragraph 123 b (new)

123b. Highlights the fundamental role that the Union can play in the training of professionals, through exchange programmes between Member States, as the meeting of people allows for the creation of contacts that can speed-up the transmission and homogenisation of knowledge and good practices, in order to ensure their implementation in the European area for a better patient care;

Or. en

Amendment 1499
Tiemo Wölken, Piernicola Pedicini

Motion for a resolution
Paragraph 123 c (new)

123c. Highlights that, to tackle the stigma associated with some cancers, such as prostate cancer, a culture of openness about the side effects of treatment, as well as the importance of early screening, should be promoted at both EU and national level by governments, health authorities and patient organisations;

Or. en

Amendment 1500
Pietro Fiocchi
Motion for a resolution
Subheading III

III. Creation of a European Cancer Institute

Amendment

III. Creation of an Association of European Cancer Institutes

Or. en

Amendment 1501
Pietro Fiocchi

Motion for a resolution
Paragraph 124 – introductory part

124. Calls for the creation of a virtual European Cancer Institute, involving all stakeholders (representatives of each NCCP, patients’ and caregivers’ associations, learned societies etc.), in charge of the following missions:

Amendment

124. Calls for the creation of an Association of European Cancer Institutes, involving all stakeholders (representatives of each NCCP, patients’ and caregivers’ associations, learned societies etc.), in charge of the following missions:

Or. en

Amendment 1502
Adam Jarubas, Ewa Kopacz

Motion for a resolution
Paragraph 124 – introductory part

124. Calls for the creation of a virtual European Cancer Institute, involving all stakeholders (representatives of each NCCP, patients’ and caregivers’ associations, learned societies etc.), in charge of the following missions:

Amendment

124. Calls for the creation of a virtual European Cancer Institute, involving all stakeholders (representatives of each NCCP, patients’ and caregivers’ associations, learned societies and representatives of economic operators’ associations etc.), in charge of the following missions:

Or. en
Amendment 1503
Michèle Rivasi

Motion for a resolution
Paragraph 124 – introductory part

124. Calls for the creation of a virtual European Cancer Institute, involving all stakeholders (representatives of each NCCP, patients’ and caregivers’ associations, learned societies etc.), in charge of the following missions:

Amendment

124. Calls for the creation of a virtual European Cancer Institute, involving all stakeholders (representatives of each NCCP, patients’ and caregivers’ associations, learned societies, relevant EU bodies and agencies, etc.), in charge of the following missions:

Or. en

Amendment 1504
Margarita de la Pisa Carrión, Pietro Fiocchi

Motion for a resolution
Paragraph 124 – introductory part

124. Calls for the creation of a virtual European Cancer Institute, involving all stakeholders (representatives of each NCCP, patients’ and caregivers’ associations, learned societies etc.), in charge of the following missions:

Amendment

124. Calls for the creation of a virtual European Cancer Institute, involving all stakeholders (representatives of each NCCP, patients’ and caregivers’ associations, learned societies, as well as economic operators etc.), in charge of the following missions:

Or. en

Amendment 1505
Kateřina Konečná, Alexis Georgoulis, Giorgos Georgiou

Motion for a resolution
Paragraph 124 – introductory part
Motion for a resolution

124. Calls for the creation of a virtual European Cancer Institute, involving all stakeholders (representatives of each NCCP, patients’ and caregivers’ associations, learned societies etc.), in charge of the following missions:

Amendment

124. Calls for the creation of a virtual European Cancer Institute, involving all stakeholders (representatives of each NCCP, patients’ and caregivers’ associations, learned societies etc.), as well as economic operators, in charge of the following missions:

Or. en

Amendment 1506
Stefania Zambelli, Angelo Ciocca, Joëlle Mélin

Motion for a resolution
Paragraph 124 – introductory part

Motion for a resolution

124. Calls for the creation of a virtual European Cancer Institute, involving all stakeholders (representatives of each NCCP, patients’ and caregivers’ associations, learned societies etc.), in charge of the following missions:

Amendment

124. Calls for the creation of a virtual European Cancer Institute, involving all stakeholders (representatives of each NCCP, patients’ and caregivers’ associations, learned societies etc.), as well as economic operators, in charge of the following missions:

Or. en

Amendment 1507
Tudor Ciuhodaru

Motion for a resolution
Paragraph 124 – introductory part

Motion for a resolution

124. Calls for the creation of a virtual European Cancer Institute, involving all stakeholders (representatives of each NCCP, patients’ and caregivers’ associations, learned societies etc.), in charge of the following missions:

Amendment

124. Calls for the creation of a virtual European Cancer Institute, involving all stakeholders (representatives of each NCCP, patients’ and caregivers’ associations, learned societies etc.), as well as economic operators, in charge of the
following missions:

Amendment 1508
Jens Gieseke, Christine Schneider

Motion for a resolution
Paragraph 124 – introductory part

124. Calls for the creation of a virtual European Cancer Institute, involving all stakeholders (representatives of each NCCP, patients’ and caregivers’ associations, learned societies etc.), in charge of the following missions:

Amendment

124. Calls for the creation of a virtual European Cancer Institute, involving all stakeholders (representatives of each NCCP, patients’ and caregivers’ associations, learned societies and economic operators etc.), in charge of the following missions:

Amendment 1509
Joëlle Mélin

Motion for a resolution
Paragraph 124 – point a

a) coordinating the network of all NCCPs;

Amendment

deleted

Amendment 1510
Joëlle Mélin

Motion for a resolution
Paragraph 124 – point b
Motion for a resolution

b) producing a European roadmap to trigger large-scale prevention campaigns and educational programmes on health promotion;

Amendment 1511
Nicolás González Casares, Maria Arena, Romana Jerković, Cyrus Engerer, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 124 – point b a (new)

Motion for a resolution

ba) coordinating best-treatment guidelines, based on the latest scientific evidence, specially for rare and paediatric cancers;

Amendment 1512
Joëlle Mélin

Motion for a resolution
Paragraph 124 – point c

Motion for a resolution

c) coordinating the establishment of common quality criteria to guide the national accreditation of screening programmes, cancer registries and cancer care centres;

Amendment
Amendment 1513
Bartosz Arłukowicz

Motion for a resolution
Paragraph 124 – point c

Motion for a resolution

c) coordinating the establishment of common quality criteria to guide the national accreditation of screening programmes, cancer registries and cancer care centres;

Amendment

c) coordinating the establishment of common quality criteria to guide the national accreditation of screening programmes, cancer registries and cancer care centres; **regular monitoring of screening results and issuing of screening guidelines**;

Or. pl

Amendment 1514
Bartosz Arłukowicz

Motion for a resolution
Paragraph 124 – point d a (new)

Motion for a resolution

da) coordinating the creation of centres of excellence in the Member States and cooperating with scientific associations on the standardisation of clinical guidelines in the field of cancer;

Amendment

da) coordinating the creation of centres of excellence in the Member States and cooperating with scientific associations on the standardisation of clinical guidelines in the field of cancer;

Or. pl

Amendment 1515
Peter Liese
on behalf of the EPP Group

Tomislav Sokol, Nathalie Colin-Oesterlé, Liudas Mažylis, Marian-Jean Marinescu, Maria Spyraki, Dolors Montserrat, Cindy Franssen, Adam Jarubas, Deirdre Clune, Sunčana Glavak, Bartosz Arłukowicz

Motion for a resolution
Paragraph 124 – point d b (new)
Motion for a resolution

Amendment
da) presenting studies on the impact of prevention and diagnosis, including estimates concerning the reduction of economic costs generated through increased investment in these areas;

Or. en

Amendment 1516
Joëlle Mélin

Motion for a resolution
Paragraph 124 – point e

Motion for a resolution

Amendment
e) coordinating the exchange of best practices and results between the ERNs and the Comprehensive Cancer Centres;

deleted

Or. fr

Amendment 1517
Lídia Pereira, Cindy Franssen, Dolors Montserrat

Motion for a resolution
Paragraph 124 – point e

Motion for a resolution

Amendment
e) developing, together with the Knowledge Centre for Cancer, guidelines and quality assurance schemes to improve the entire care pathway for all cancer types and coordinating the exchange of best practices and results between the ERNs and the Comprehensive Cancer Centres;

Or. en
Amendment 1518
Joëlle Mélin

Motion for a resolution
Paragraph 124 – point f

Motion for a resolution
Amendment

f) generating a comprehensive model based on Europe’s Beating Cancer Plan and Horizon Europe in order to identify research priorities and possibly enable the development of a coordinated and efficient cancer research force in Europe;

Amendment 1519
Nicolae Ştefănăuţă, Alin Mituţa, Ivars Ijabs, Vlad Gheorghe

Motion for a resolution
Paragraph 124 – point f

Motion for a resolution
Amendment

f) generating a comprehensive model based on Europe’s Beating Cancer Plan and Horizon Europe in order to identify research priorities and possibly enable the development of a coordinated and efficient cancer research force in Europe; with the input from patients and carers;

Amendment 1520
Bartosz Arłukowicz

Motion for a resolution
Paragraph 124 – point g

Motion for a resolution
Amendment

g) facilitating the sharing of anonymised data, collected in a European
Cancer Cloud, for clinicians and researchers, as well as for public and private entities developing health services and modern technological solutions for cancer patients;

Amendment 1521
Joëlle Mélin

Motion for a resolution
Paragraph 124 – point i

Motion for a resolution

i) delivering updated, certified and transparent information to citizens and professionals on cancer causes, the most common comorbidities, treatments and EU legislation;

Amendment

i) delivering updated, certified and transparent information to citizens and professionals on cancer causes, the most common comorbidities, treatments and EU legislation;

Or. fr

Amendment 1522
Joëlle Mélin

Motion for a resolution
Paragraph 124 – point j

Motion for a resolution

j) monitoring the level of implementation of relevant recommendations in the Member States’ NCCPs;

Amendment
deleted

Or. fr

Amendment 1523
Giorgos Georgiou, Alexis Georgoulis, João Pimenta Lopes
Motion for a resolution
Paragraph 124 – point j

Amendment

j) monitoring the level of implementation of relevant recommendations in the Member States’ NCCPs;

Or. en

Amendment 1524
Joëlle Mélin

Motion for a resolution
Paragraph 124 – point k

Amendment

k) proposing measurable and reproducible indicators for the main outcomes outlined in Europe’s Beating Cancer Plan;

Deleted

Or. fr

Amendment 1525
Ivars Ijabs, Alin Mituța, Irena Joveva, Hilde Vautmans, Nicolae Ștefănuță

Motion for a resolution
Paragraph 124 – point k a (new)

Amendment

ka) facilitating the mission-oriented approach in designing and implementing NCCPs;

Or. en

Amendment 1526
Nicolae Ștefănuță, Alin Mituța, Ivars Ijabs, Vlad Gheorghe
Motion for a resolution
Paragraph 125

125. Emphasises that Europe’s Beating Cancer Plan should not only be seen as a political commitment to driving change but as a set of concrete and ambitious initiatives that will support, coordinate and complement Member States’ efforts to reduce the suffering caused by cancer; stresses that, in order for the initiatives outlined in the Plan to be translated into concrete actions, these initiatives have to be adequately funded; underlines, however, the differing capacity of Member States to absorb the funds dedicated to healthcare programmes thus far; 

Amendment

125. Emphasises that Europe’s Beating Cancer Plan should not only be seen as a political commitment to driving change but as a set of concrete and ambitious initiatives that will support, coordinate and complement Member States’ efforts to reduce the physical and mental suffering caused by cancer; encourages the Commission to optimise the coherent implementation of the initiatives outlined in the Plan, with clear guidance to Member States regarding concrete actions against unequal access to cancer diagnosis and treatment, as well as adequate funding; underlines, however, the differing capacity of Member States to absorb the funds dedicated to healthcare programmes thus far; calls on the Commission to provide Member States with guidance and a clear overview of the dedicated EU resources, the specifically defined pathways that link the actions outlined in the Plan with the EU funding mechanisms identified in it, as well as the possible synergies and complementarities with other EU financing instruments; 

Or. en

Amendment 1527
Kateřina Konečná, Alexis Georgoulis, Giorgos Georgiou

Motion for a resolution
Paragraph 125

125. Emphasises that Europe’s Beating Cancer Plan should not only be seen as a political commitment to driving change but as a set of concrete and ambitious

Motion for a resolution

125. Emphasises that Europe’s Beating Cancer Plan should not only be seen as a political commitment to driving change but as a set of concrete and ambitious
initiatives that will support, coordinate and complement Member States’ efforts to reduce the suffering caused by cancer; stresses that, in order for the initiatives outlined in the Plan to be translated into concrete actions, these initiatives have to be adequately funded; underlines, however, the differing capacity of Member States to absorb the funds dedicated to healthcare programmes thus far;

Amendment 1528
Tomislav Sokol, Sunčana Glavak, Cindy Franssen

Motion for a resolution
Paragraph 125

125. Emphasises that Europe’s Beating Cancer Plan should not only be seen as a political commitment to driving change but as a set of concrete and ambitious initiatives that will support, coordinate and complement Member States’ efforts to reduce the suffering caused by cancer; stresses that, in order for the initiatives outlined in the Plan to be translated into concrete actions, these initiatives have to be adequately funded; underlines, however, the differing capacity of Member States to absorb the funds dedicated to healthcare programmes thus far;

125. Emphasises that Europe’s Beating Cancer Plan should not only be seen as a political commitment to driving change but as a set of concrete and ambitious initiatives that will support, coordinate and complement Member States’ efforts to reduce the suffering caused by cancer; stresses that, in order for the initiatives outlined in the Plan to be translated into concrete actions, these initiatives have to be adequately funded; underlines, however, the differing capacity of Member States to absorb the funds dedicated to healthcare programmes thus far; calls on the Commission to provide the Member States with a clear overview of the dedicated EU resources, the specifically defined pathways that link the actions outlined in the Plan with the EU funding mechanisms identified in it, as well as the possible synergies and complementarities of EU4Health programme with other ones -such as Digital Europe, Horizon Europe,
Amendment 1529
Nicolás González Casares, Maria Arena, Romana Jerković, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 125

125. Emphasises that Europe’s Beating Cancer Plan should not only be seen as a political commitment to driving change but as a set of concrete and ambitious initiatives that will support, coordinate and complement Member States’ efforts to reduce the suffering caused by cancer; stresses that, in order for the initiatives outlined in the Plan to be translated into concrete actions, these initiatives have to be adequately funded; underlines, however, the differing capacity of Member States to absorb the funds dedicated to healthcare programmes thus far; calls on the Commission to provide the Member States with a clear overview of the dedicated EU resources and possible synergies and complementarities between the main available mechanisms, such as

NextGenerationEU / Recovery and Resilience Facility, Structural and Cohesion Funds- to enhance equitable access to quality diagnosis and care, including radiotherapy, adequate investments in cancer prevention and innovation and improved resilience of health systems; emphasises the importance of Cohesion Funds for achieving equality of access to healthcare especially in less developed parts of the EU, including rural regions, by investing into health infrastructure and workforce;
Amendment 1530
Bartosz Arłukowicz

Motion for a resolution
Paragraph 127

127. **Welcomes** the funding plan of EUR 4 billion and notes the complementarity of the sources of funding as set out in the Plan itself; recalls that the Plan will benefit from different sources of funding, such as the EU4Health, Horizon Europe and Digital Europe programmes, cohesion policy funds, and the Recovery and Resilience Facility; highlights the need to include the fight against cancer across all funding sources in a coherent and transparent manner; stresses, in particular, the importance of enhancing cancer research and cancer prevention and the need to dedicate more funds to them;

Amendment

127. **Takes note of** the funding plan of EUR 4 billion and notes the complementarity of the sources of funding as set out in the Plan itself; **notes that the proposed budget should be seen as a first step towards the realisation of all actions under the Europe’s Beating Cancer Plan;** recalls that the Plan will benefit from different sources of funding, such as the EU4Health, Horizon Europe and Digital Europe programmes, cohesion policy funds, and the Recovery and Resilience Facility; highlights the need to include the fight against cancer across all funding sources in a coherent and transparent manner; stresses, in particular, the importance of enhancing cancer research and cancer prevention and the need to dedicate more funds to them; **stresses the need for regular revision of the proposed budget allocation for the Europe’s Beating Cancer Plan, with a view to potentially increasing it when possible;**

Amendment 1531
Pietro Fiocchi

Motion for a resolution
Paragraph 126
Motion for a resolution

126. Calls on the Member States to ensure that enough funds are allocated for the appropriate implementation of the Plan and of their respective NCCPs; considers that no more than 30% of Europe’s Beating Cancer Plan should be allocated to the implementation of the NCCPs;

Amendment

126. Calls on the Member States to ensure that enough funds are allocated for the appropriate implementation of the Plan and of their respective NCCPs; notes that in view of the different administrative and political systems in Member States, the Europe’s Beating Cancer Plan must take national specificities into account when allocating funding to the implementation of the NCCPs;

Or. en

Amendment 1532
Bronis Ropė

Motion for a resolution
Paragraph 126

Motion for a resolution

126. Calls on the Member States to ensure that enough funds are allocated for the appropriate implementation of the Plan and of their respective NCCPs; considers that no more than 30% of Europe’s Beating Cancer Plan should be allocated to the implementation of the NCCPs;

Amendment

126. Calls on the Member States to ensure that enough funds are allocated for the appropriate implementation of the Plan and of their respective NCCPs; considers that at least 30% of Europe’s Beating Cancer Plan should be allocated to the implementation of the NCCPs, with a particular focus on EU Member States with the worst cancer survival rates;

Or. It

Amendment 1533
Giorgos Georgiou, Alexis Georgoulis, João Pimenta Lopes

Motion for a resolution
Paragraph 126

Motion for a resolution

126. Calls on the Member States to ensure that enough funds are allocated for the appropriate implementation of the Plan and of their respective NCCPs; considers that no more than 30% of Europe’s Beating Cancer Plan should be allocated to the implementation of the NCCPs;

Amendment

126. Calls on the Member States to ensure that enough funds are allocated for the appropriate implementation of the Plan and of their respective NCCPs; considers that at least 30% of Europe’s Beating Cancer Plan should be allocated to the implementation of the NCCPs, with a particular focus on EU Member States with the worst cancer survival rates;
ensure that enough funds are allocated for the appropriate implementation of the Plan and of their respective NCCPs; considers that no more than 30% of Europe’s Beating Cancer Plan should be allocated to the implementation of the NCCPs;

ensure that enough funds and human resources are allocated for the appropriate implementation of the Plan and of their respective NCCPs; considers that no less than 30% of Europe’s Beating Cancer Plan should be allocated to the implementation of the NCCPs;

Amendment 1534
Peter Liese
on behalf of the EPP Group
Tomislav Sokol, Nathalie Colin-Oesterlé, Liudas Mažylis, Marian-Jean Marinescu, Maria Spyraiki, Dolors Montserrat, Cindy Franssen, Adam Jarubas, Deirdre Clune, Sunčana Glavak, Bartosz Arłukowicz

Motion for a resolution
Paragraph 126

Amendment

126. Calls on the Member States to ensure that enough funds are allocated for the appropriate implementation of the Plan and of their respective NCCPs; considers that no more than 30% of Europe’s Beating Cancer Plan should be allocated to the implementation of the NCCPs;

advocates that support for the implementation of the NCCPs should privilege the mitigation of disparities and inequalities identified between and within Member States;

Amendment 1535
João Pimenta Lopes, Giorgos Georgiou, Alexis Georgoulis

Motion for a resolution
Paragraph 127
127. Welcomes the funding plan of EUR 4 billion and notes the complementarity of the sources of funding as set out in the Plan itself; recalls that the Plan will benefit from different sources of funding, such as the EU4Health, Horizon Europe and Digital Europe programmes, cohesion policy funds, and the Recovery and Resilience Facility; highlights the need to include the fight against cancer across all funding sources in a coherent and transparent manner; stresses, in particular, the importance of enhancing cancer research and cancer prevention and the need to dedicate more funds to them; stresses the need for the mobilisation of these funds by the Member States to be free of political or economic conditionalities, in line with the needs identified by each country, and geared towards benefiting the public interest and public health services;

Amendment 1536
Nicolás González Casares, Maria Arena, Romana Jerković, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis

Motion for a resolution
Paragraph 127

127. Welcomes the funding plan of EUR 4 billion and notes the complementarity of the sources of funding as set out in the Plan itself; recalls that the Plan will benefit from different sources of funding, such as the EU4Health, Horizon Europe and Digital Europe programmes, cohesion policy funds, and the Recovery and Resilience Facility; highlights the need to include the fight against cancer across all funding sources in a coherent and transparent manner; stresses, in particular, the importance of enhancing cancer research and cancer prevention and the need to dedicate more funds to them;
sources in a coherent and transparent manner; stresses, in particular, the importance of enhancing cancer research and cancer prevention and the need to dedicate more funds to them; sources in a coherent and transparent manner; stresses, in particular, the importance of enhancing cancer research and innovation and cancer prevention and the need to dedicate more funds to them;

Amendment 1537
Bronis Ropė

Motion for a resolution
Paragraph 127 a (new)

Motion for a resolution

Amendment

127a. Recognises that comprehensive cancer research and the continued translation of scientific advances into practice is the only way to successfully improve cancer control rates; stresses that, in order for Europe’s Beating Cancer Plan to be successfully implemented, the Member States must ensure the adequate, equitable, transparent and nation-wide involvement of each EU Member State in the implementation of Europe’s Beating Cancer Plan and provide adequate funding for these activities; considers that, in order to be successful in the fight against cancer and to transparently allocate resources to address disparities in cancer control, numbers of cases and treatment at European level, a mechanism for accounting for and controlling financial flows is needed, based not only on the resources allocated by the EU, but also on national cancer control resources;

Or. lt